var title_f21_32_22016="Marginal TM perforation";
var content_f21_32_22016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F79099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F79099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    True marginal perforation of the tympanic membrane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Keratinizing squamous epithelium can enter the middle ear from the ear canal through a perforation of the outer edge of the drum from a marginal perforation (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Isaacson G. Diagnosis of pediatric cholesteatoma. Pediatrics 2007; 120:603. Copyright &copy; 2007 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_32_22016=[""].join("\n");
var outline_f21_32_22016=null;
var title_f21_32_22017="Incision sites radic vulvectomy";
var content_f21_32_22017=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radical vulvectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The groin incision is marked on the right side. Note markings for anterior superior iliac spine laterally, pubic tubercle medially, and the femoral artery caudally.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of C. William Helm, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_32_22017=[""].join("\n");
var outline_f21_32_22017=null;
var title_f21_32_22018="Patient information: Anal cancer (The Basics)";
var content_f21_32_22018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16831\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?17/27/17842\">",
"         Patient information: Hair loss from cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/40/1667\">",
"         Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/36/579\">",
"         Patient information: Managing pain when you have cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/57/19346\">",
"         Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Anal cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/anal-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H25433171\">",
"      <span class=\"h1\">",
"       What is anal cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Anal cancer happens when normal cells lining the anus change into abnormal cells and grow out of control. The anus is the last part of the digestive tract (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ), where bowel movements leave the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25433186\">",
"      <span class=\"h1\">",
"       What are the symptoms of anal cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Anal cancer does not always cause symptoms at first. People who do have symptoms can have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bleeding from their anus",
"       </li>",
"       <li>",
"        Pain in or around their anus",
"       </li>",
"       <li>",
"        A growth in their anus",
"       </li>",
"       <li>",
"        Itching in their anus",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      All of these symptoms can also be caused by conditions that are not cancer. But if you have these symptoms, tell your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25433201\">",
"      <span class=\"h1\">",
"       Is there a test for anal cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To check for anal cancer, your doctor or nurse will look at your anus and do a &ldquo;digital rectal exam.&rdquo; During a digital rectal exam, your doctor or nurse will put a gloved finger into your anus and lower rectum to feel for abnormal growths.",
"     </p>",
"     <p>",
"      He or she might do 1 or more of the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Anoscopy &ndash; During an anoscopy, the doctor puts a short tube with a light on the end (called an &ldquo;anoscope&rdquo;) into your anus and rectum. He or she will use the anoscope to look for abnormal areas or growths.",
"       </li>",
"       <li>",
"        Biopsy &ndash; A doctor can remove a small sample of tissue from the anus. Another doctor will look at the sample under a microscope to see if it has cancer.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Doctors sometimes find cells in the anus that are not cancer, but are abnormal and have a high chance of turning into cancer. Your doctor can treat these &ldquo;pre-cancer&rdquo; cells in different ways. He or she might remove them to help keep them from turning into cancer. Or he or she might watch them closely over time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25433216\">",
"      <span class=\"h1\">",
"       What is anal cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out if a cancer has spread past the layer of tissue where it began and, if so, how far.",
"     </p>",
"     <p>",
"      The right treatment for you will depend a lot on the stage and type of your anal cancer, and your other medical problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25433231\">",
"      <span class=\"h1\">",
"       How is anal cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with anal cancer are treated with both:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Radiation therapy &ndash; Radiation kills cancer cells.",
"       </li>",
"       <li>",
"        Chemotherapy &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Anal cancer is sometimes treated with",
"      <strong>",
"      </strong>",
"      surgery to remove the cancer. But most people don&rsquo;t need surgery. People do not need surgery if their cancer gets better with chemotherapy and radiation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25433246\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you will be checked every so often to see if the cancer comes back. Regular follow up tests include exams (including digital rectal exams) and anoscopy. Some people also have follow-up imaging tests. Imaging tests can create pictures of the inside of your body.",
"     </p>",
"     <p>",
"      You should also watch for the symptoms listed above. Having those symptoms could mean the cancer has come back. Tell your doctor or nurse if you have any symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25433261\">",
"      <span class=\"h1\">",
"       What happens if the cancer comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the cancer comes back or spreads, you might need surgery or more chemotherapy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25433276\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to follow all your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for anal cancer involves making many choices, such as what treatment to have.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25433291\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/27/17842?source=see_link\">",
"       Patient information: Hair loss from cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=see_link\">",
"       Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=see_link\">",
"       Patient information: Managing pain when you have cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=see_link\">",
"       Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?21/32/22018?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16831 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-77399545CD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_32_22018=[""].join("\n");
var outline_f21_32_22018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25433171\">",
"      What is anal cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25433186\">",
"      What are the symptoms of anal cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25433201\">",
"      Is there a test for anal cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25433216\">",
"      What is anal cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25433231\">",
"      How is anal cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25433246\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25433261\">",
"      What happens if the cancer comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25433276\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25433291\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16831\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/27/17842?source=related_link\">",
"      Patient information: Hair loss from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_32_22019="PHQ";
var content_f21_32_22019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patient health questionnaire&reg; (PHQ)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"5\">",
"        This questionnaire is an important part of providing you with the best health care possible. Your answers will help in understanding problems that you may have. Please answer every question to the best of your ability unless you are requested to skip over a question.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Name:",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Age:",
"       </td>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Sex: [&nbsp;] Female [&nbsp;] Male",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Date:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        1. During the last 4 weeks, how much have you been bothered by any of the following problems?",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Not bothered at all",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Bothered a little",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Bothered a lot",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        a. Stomach pain",
"       </td>",
"       <td colspan=\"2\">",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        b. Back pain",
"       </td>",
"       <td colspan=\"2\">",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        c. Pain in your arms, legs, or joints (knees, hips, etc.)",
"       </td>",
"       <td colspan=\"2\">",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        d. Menstrual cramps or other problems with your periods",
"       </td>",
"       <td colspan=\"2\">",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        e. Pain or problems during sexual intercourse",
"       </td>",
"       <td colspan=\"2\">",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        f. Headaches",
"       </td>",
"       <td colspan=\"2\">",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        g. Chest pain",
"       </td>",
"       <td colspan=\"2\">",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        h. Dizziness",
"       </td>",
"       <td colspan=\"2\">",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        i. Fainting spells",
"       </td>",
"       <td colspan=\"2\">",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        j. Feeling your heart pound or race",
"       </td>",
"       <td colspan=\"2\">",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        k. Shortness of breath",
"       </td>",
"       <td colspan=\"2\">",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        l. Constipation, loose bowels, or diarrhea",
"       </td>",
"       <td colspan=\"2\">",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        m. Nausea, gas, or indigestion",
"       </td>",
"       <td colspan=\"2\">",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        2. Over the last two weeks, how often have you been bothered by any of the following problems?",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Not at all",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Several days",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        More than half the days",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Nearly every day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        a. Little interest or pleasure in doing things",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        b. Feeling down, depressed, or hopeless",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        c. Trouble falling or staying asleep, or sleeping too much",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        d. Feeling tired or having little energy",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        e. Poor appetite or overeating",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        f. Feeling bad about yourself, or that you are a failure, or have let yourself or your family down",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        g. Trouble concentrating on things, such as reading the newspaper or watching television",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        h. Moving or speaking so slowly that other people could have noticed? Or the opposite - being so fidgety or restless that you have been moving around a lot more than usual?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        i. Thoughts that you would be better off dead or of hurting yourself in some way",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        FOR OFFICE CODING: Som Dis if at least three of #1a-m are \"a lot\" and lack an adequate biol explanation. Maj Dep Syn if answers to #2a or b and five or more of #2a-i are at least \"More than half the days\" (count #2i if present at all). Other Dep Syn if #2a or b and two, three, or four of #2a-i are at least \"More than half the days\" (count #2i if present at all).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        3. Questions about anxiety",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        No",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        a. In the last 4 weeks, have you had an anxiety attack - suddenly feeling fear or panic?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\" colspan=\"5\">",
"        If you checked \"No\", go to question #5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        b. Has this ever happened before?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        c. Do some of these attacks come suddenly out of the blue - that is, in situations where you don't expect to be nervous or uncomfortable?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        d. Do these attacks bother you a lot or are you worried about having another attack?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        4. Think about your last bad anxiety attack",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        No",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        a. Were you short of breath?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        b. Did your heart race, pound, or skip?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        c. Did you have chest pain or pressure?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        d. Did you sweat?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        e. Did you feel as if you were choking?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        f. Did you have hot flashes or chills?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        g. Did you have nausea or an upset stomach, or the feeling that you were going to have diarrhea?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        h. Did you feel dizzy, unsteady, or faint?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        i. Did you have tingling or numbness in parts of your body?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        j. Did you tremble or shake?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        k. Were you afraid you were dying?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        5. Over the last 4 weeks, how often have you been bothered by any of the following problems?",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Not at all",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Several days",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        More than half the days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        a. Feeling nervous, anxious, on edge, or worrying a lot about different things",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\" colspan=\"5\">",
"        If you checked \"Not at all\", go to question #6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        b. Feeling restless so that it is hard to sit still",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        c. Getting tired very easily",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        d. Muscle tension, aches, or soreness",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        e. Trouble falling asleep or staying asleep",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        f. Trouble concentrating on things, such as reading a book, watching TV",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        g. Becoming easily annoyed or irritable",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        FOR OFFICE CODING: Pan Syn if all of #3a-d are 'YES' and four or more of #4a-k are 'YES'. Other Anx Syn if #5a and answers to three or more of #5b-g are \"More than half the days\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        6. Questions about eating",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        No",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        a. Do you often feel that you can't control what or how much you eat?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        b. Do you often eat, within any 2-hour period, what most people would regard as an unusually large amount of food?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\" colspan=\"5\">",
"        If you checked \"NO\" to either #6a or #6b, go to question #9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        c. Has this been as often, on average, as twice a week for the last 3 months?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        7. In the last 3 months have you often done any of the following in order to avoid gaining weight?",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        No",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        a. Made yourself vomit?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        b. Took more than twice the recommended dose of laxatives?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        c. Fasted - not eaten anything at all for at least 24 hours?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        d. Exercised for more than an hour specifically to avoid gaining weight after binge eating?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        8. If you checked \"Yes\" to any of these ways of avoiding gaining weight, were any as often, on average, as twice a week?",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        No [&nbsp;]",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Yes [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        9. Do you ever drink alcohol (including beer or wine)?",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        No [&nbsp;]",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Yes [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\" colspan=\"5\">",
"        If you checked \"No\", go to question #11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        10. Have any of the following happened to you more than once in the last 6 months?",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        No",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        a. You drank alcohol even though a doctor suggested that you stop drinking because of a problem with your health",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        b. You drank alcohol, were high from alcohol, or hung over while you were working, going to school, or taking care of children or other responsibilities",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        c. You missed or were late for work, school, or other activities because you were drinking or hung over",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        d. You had a problem getting along with other people while you were drinking",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        e. You drove a car after having several drinks or after drinking too much",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        11. If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Not difficult at all [&nbsp;]",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Somewhat difficult [&nbsp;]",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Very difficult [&nbsp;]",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Extremely difficult [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        FOR OFFICE CODING: Bul Ner if #6a,b, and -c and #8 are all 'YES'; Bin Eat Dis the same but #8 either 'NO' or left blank. Alc Abu if any of #10a-e is 'YES'.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        12. During the last 4 weeks, how much have you been bothered by any of the following problems?",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Not bothered at all",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Bothered a little",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Bothered a lot",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        a. Worrying about your health",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        b. Your weight or how you look",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        c. Little or no sexual desire or pleasure during sex",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        d. Difficulties with husband/wife, partner/lover or boyfriend/girlfriend",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        e. The stress of taking care of children, parents or other family members",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        f. Stress at work or outside of the home or at school",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        g. Financial problems or worries",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        h. Having no one to turn to when you have a problem",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        i. Something bad that happened recently",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        j. Thinking or dreaming about something terrible that happened to you in the past - like your house being destroyed, a severe accident, being hit or assaulted, or being forced to commit a sexual act",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        13. In the last year, have you been hit, slapped, kicked or otherwise physically hurt by someone, or has anyone forced you to have an unwanted sexual act?",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        No [&nbsp;]",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Yes [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        <p>",
"         14. What is the most stressful thing in your life right now?",
"        </p>",
"        <p>",
"         ____________________________________________________________________________________________________________________",
"        </p>",
"        <p>",
"         ____________________________________________________________________________________________________________________",
"        </p>",
"        <p>",
"         ____________________________________________________________________________________________________________________",
"        </p>",
"        <p>",
"         ____________________________________________________________________________________________________________________",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        15. Are you taking any medicine for anxiety, depression or stress?",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        No [&nbsp;]",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Yes [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        16. FOR WOMEN ONLY: Questions about menstruation, pregnancy and childbirth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"5\">",
"        a. Which best describes your menstrual periods?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\" colspan=\"5\">",
"        ___ Periods are unchanged",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\" colspan=\"5\">",
"        ___ No periods because pregnant or recently gave birth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\" colspan=\"5\">",
"        ___ Periods have become irregular or changed in frequency, duration or amount",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\" colspan=\"5\">",
"        ___ No periods for at least a year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\" colspan=\"5\">",
"        ___ Having periods because taking hormone replacement (estrogen) therapy or oral contraceptive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\" rowspan=\"2\">",
"        b. During the week before your period starts, do you have a serious problem with your mood - like depression, anxiety, irritability, anger or mood swings?",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        No",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\" colspan=\"3\">",
"        - IF Yes: Do these problems go away by the end of your period?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        c. Have you given birth within the last 6 months?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        d. Have you had a miscarriage within the last 6 months?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        e. Are you having difficulty getting pregnant?",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"       <td>",
"        [&nbsp;]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        (DO NOT DISTRIBUTE THIS PAGE TO THE PATIENT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        Quick guide to the patient health questionnaire",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        <strong>",
"         Purpose.",
"        </strong>",
"        The Patient Health Questionnaire (PHQ) is designed to facilitate the recognition and diagnosis of the most common mental disorders in primary care patients. For patients with a depressive disorder, a PHQ Depression Severity Index score can be calculated and repeated over time to monitor change.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        <strong>",
"         Who should take the phq.",
"        </strong>",
"        Ideally, the PHQ should be used with all new patients, all patients who have not completed the questionnaire in the last year, and all patients suspected of having a mental disorder.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        <strong>",
"         Making a diagnosis.",
"        </strong>",
"        Since the questionnaire relies on patient self-report, definitive diagnoses must be verified by the clinician, taking into account how well the patient understood the questions in the questionnaire, as well as other relevant information from the patient, his or her family or other sources.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        <strong>",
"         Interpreting the PHQ.",
"        </strong>",
"        To facilitate interpretation of patient responses, all clinically significant responses are found in the column farthest to the right. (The only exception is for suicidal ideation when diagnosing a depressive syndrome.) In addition, the diagnoses of Major Depressive Disorder (rather than Syndrome) and Other Depressive Disorder requires ruling out normal bereavement (mild symptoms, duration less than 2 months), a history of a manic episode (Bipolar Disorder) and a physical disorder, medication or other drug as the biological cause of the depressive symptoms. Similarly, the diagnoses of Panic Disorder and Other Anxiety Disorder require ruling out a physical disorder, medication or other drug as the biological cause of the anxiety symptoms. Criteria for diagnostic judgments for summarizing responses are located at different points, beginning with \"FOR OFFICE CODING\", in small type. The names of the categories are abbreviated, eg, Major Depressive Syndrome is Maj Dep Syn.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"5\">",
"        <strong>",
"         Page 1",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\" colspan=\"5\">",
"        Somatoform Disorder if at least 3 of #1a-m bother the patient \"a lot\" and lack an adequate biological explanation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\" colspan=\"5\">",
"        Major Depressive Syndrome if #2a or b and 5 or more of #2a-i are at least \"more than half the days\" (count #2i if present at all).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\" colspan=\"5\">",
"        Other Depressive Syndrome if #2a or b and 2, 3 or 4 of #2a-i are at least \"more than half the days\" (count #2i if present at all).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\" colspan=\"5\">",
"        <strong>",
"         Note:",
"        </strong>",
"        the diagnoses of Major Depressive Disorder and Other Depressive Disorder requires ruling out normal",
"        <strong>",
"         bereavement (mild symptoms, duration less than 2 months)",
"        </strong>",
"        , a history of a",
"        <strong>",
"         manic",
"        </strong>",
"        episode (Bipolar Disorder) and a",
"        <strong>",
"         physical disorder, medication or other drug",
"        </strong>",
"        as the biological cause of the depressive symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"5\">",
"        <strong>",
"         Page 2",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\" colspan=\"5\">",
"        Panic Syndrome if #3a-d are all 'Yes' and 4 or more of #4a-k are 'Yes'.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\" colspan=\"5\">",
"        Other Anxiety Syndrome if #5a and answers to 3 or more of #5b-g are \"more than half the days\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\" colspan=\"5\">",
"        <strong>",
"         Note:",
"        </strong>",
"        The diagnoses of Panic Disorder and Other Anxiety Disorder require ruling out a",
"        <strong>",
"         physical disorder, medication or other drug",
"        </strong>",
"        as the biological cause of the anxiety symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"5\">",
"        <strong>",
"         Page 3",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\" colspan=\"5\">",
"        Bulimia Nervosa if #6a,b, and c and #8 are 'Yes'; Binge Eating Disorder the same but #8 is either 'NO' or left blank.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\" colspan=\"5\">",
"        Alcohol abuse if any of #10a-e are 'Yes'.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"5\">",
"        <strong>",
"         Additional clinical considerations.",
"        </strong>",
"        After making a provisional diagnosis with the PHQ, there are additional clinical considerations that may affect decisions about management and treatment:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"5\">",
"        <em>",
"         Have current symptoms been triggered by psychosocial",
"         <strong>",
"          stressor(s)",
"         </strong>",
"         ?",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"5\">",
"        <em>",
"         What is the",
"         <strong>",
"          duration",
"         </strong>",
"         of the current disturbance and has the patient received any",
"         <strong>",
"          treatment",
"         </strong>",
"         for it?",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"5\">",
"        <em>",
"         To what extent are the patient's symptoms",
"         <strong>",
"          impairing",
"         </strong>",
"         his or her usual work and activities?",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"5\">",
"        <em>",
"         Is there a",
"         <strong>",
"          history",
"         </strong>",
"         of similar episodes, and were they",
"         <strong>",
"          treated",
"         </strong>",
"         ?",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"5\">",
"        <em>",
"         Is there a",
"         <strong>",
"          family history",
"         </strong>",
"         of similar conditions?",
"        </em>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Pfizer Inc. All rights reserved. Reproduced with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_32_22019=[""].join("\n");
var outline_f21_32_22019=null;
var title_f21_32_22020="Recombinant human factor VIII: Patient drug information";
var content_f21_32_22020=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Recombinant human factor VIII: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/1/23574?source=see_link\">",
"     see \"Recombinant human factor VIII: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/11/33975?source=see_link\">",
"     see \"Recombinant human factor VIII: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Advate;",
"     </li>",
"     <li>",
"      Helixate&reg; FS;",
"     </li>",
"     <li>",
"      Kogenate&reg; FS;",
"     </li>",
"     <li>",
"      Recombinate;",
"     </li>",
"     <li>",
"      Xyntha&reg;;",
"     </li>",
"     <li>",
"      Xyntha&reg; Solofuse&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Advate;",
"     </li>",
"     <li>",
"      Helixate&reg; FS;",
"     </li>",
"     <li>",
"      Kogenate&reg; FS;",
"     </li>",
"     <li>",
"      Xyntha&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hemophilia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat bleeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701529",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to antihemophilic factor (recombinant), mice, hamsters, pigs, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697906",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be given at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Most of the time, this drug will be given to you in a doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699192",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is given at home, store unopened vials at room temperature or in the refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699200",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If stored at room temperature, throw away any unused Advate vials after 6 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699203",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If stored at room temperature, throw away any unused Helixate&reg; FS or Xyntha&reg; Solufuse&trade; vials after 3 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3432521",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If stored at room temperature, throw away any unused Kogenate&reg; FS vials after 12 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3517424",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If stored at room temperature, after 3 months return Xyntha&reg; vials to the refrigerator or throw away any part unused. You may return vials to the refrigerator only 1 time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11469 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_32_22020=[""].join("\n");
var outline_f21_32_22020=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135784\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135785\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014579\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014578\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014582\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014583\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014585\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014581\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014586\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014587\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/1/23574?source=related_link\">",
"      Recombinant human factor VIII: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/11/33975?source=related_link\">",
"      Recombinant human factor VIII: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_32_22021="Hormonal methods of birth control";
var content_f21_32_22021=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Hormonal methods of birth control (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/32/22021/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/32/22021/contributors\" id=\"au7462\">",
"       Mimi Zieman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/32/22021/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/32/22021/contributors\" id=\"se4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/32/22021/contributors\">",
"       Deputy Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/32/22021/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/32/22021/contributors\" id=\"de5123\">",
"       Kathryn A Martin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?21/32/22021?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Hormonal methods of birth control contain estrogen and progestin, or progestin only, and are a safe and reliable way to prevent pregnancy for most women. There are several ways that the hormone(s) can be delivered:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A daily pill taken by mouth",
"      </li>",
"      <li>",
"       A skin patch that is changed weekly",
"      </li>",
"      <li>",
"       An injection that is given once every three months",
"      </li>",
"      <li>",
"       An implant that is worn under the skin for up to three years",
"      </li>",
"      <li>",
"       A ring worn in the vagina that is changed every month",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     This topic discusses hormonal methods of birth control, including birth control pills, injectable contraception, skin patches, vaginal rings, and contraceptive implants. A discussion of long-term and barrier birth control methods are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"      \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=see_link\">",
"      \"Patient information: Barrier methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .) An overview of all birth control methods is also available. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"      \"Patient information: Birth control; which method is right for me? (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CHOOSING A BIRTH CONTROL METHOD",
"     </span>",
"    </p>",
"    <p>",
"     It can be difficult to decide which birth control method is best due to the variety of options available. The best method is one that will be used consistently, is acceptable to the woman and her partner, and which does not cause bothersome side effects. Other factors to consider include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Efficacy",
"      </li>",
"      <li>",
"       Convenience",
"      </li>",
"      <li>",
"       Duration of action",
"      </li>",
"      <li>",
"       Reversibility and time to return of fertility",
"      </li>",
"      <li>",
"       Effect on uterine bleeding",
"      </li>",
"      <li>",
"       Frequency of side effects and adverse events",
"      </li>",
"      <li>",
"       Affordability",
"      </li>",
"      <li>",
"       Protection against sexually transmitted diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     No method of contraception is perfect. Each woman must balance the advantages of each method against the disadvantages and decide which method she prefers. A list of questions that are useful for defining a person's preferences are provided in the table (",
"     <a class=\"graphic graphic_table graphicRef67965 \" href=\"UTD.htm?13/9/13467\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      BIRTH CONTROL PILLS",
"     </span>",
"    </p>",
"    <p>",
"     Most oral contraceptives, also referred to as \"the pill,\" contain a combination of female hormones, estrogen and progestin (a progesterone-like medication). The combination pill reduces the risk of pregnancy by:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Preventing ovulation",
"      </li>",
"      <li>",
"       Keeping the mucus in the cervix thick and impenetrable to sperm",
"      </li>",
"      <li>",
"       Keeping the lining of the uterus thin",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Other non-contraceptive benefits of the pill include a reduction in:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Menstrual cramps or pain (dysmenorrhea)",
"      </li>",
"      <li>",
"       Ovarian cancer",
"      </li>",
"      <li>",
"       Cancer of the endometrium (uterine lining)",
"      </li>",
"      <li>",
"       Acne",
"      </li>",
"      <li>",
"       Iron-deficiency anemia (a low blood count due to low iron levels)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Efficacy",
"     </span>",
"     &nbsp;&mdash;&nbsp;When taken properly, birth control pills are a very effective form of contraception. Although the failure rate is 0.1 percent when pills are taken perfectly (same time every day, no missed pills), the actual failure rate is 9 percent over the first year, due primarily to missed pills or forgetting to restart the pill after the seven-day pill-free interval.",
"    </p>",
"    <p>",
"     Missed pills are a common cause of pregnancy. In general, an active pill should be taken as soon as possible after a pill has been missed. Backup birth control should be used for seven days if more than two pills are missed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Possible side effects of the pill include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Nausea, breast tenderness, bloating, and mood changes, which typically improve within two to three months without treatment.",
"      </li>",
"      <li>",
"       Breakthrough bleeding or spotting. This is particularly common during the first few months of taking oral contraceptives. This almost always resolves without any treatment within two to three months. Forgetting a pill can also cause breakthrough bleeding.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Women taking the pill should notify their healthcare provider if they experience abdominal pain, chest pain, severe headaches, eye problems, or severe leg pain as these could be symptoms of several serious conditions including heart attack, blood clot, stroke, liver, and gallbladder disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;When the pill was first introduced in the 1960s, the doses of both estrogen and progestin were quite high. Because of this, cardiovascular complications occurred, such as high blood pressure, heart attacks, strokes, and blood clots in the legs and lungs.",
"    </p>",
"    <p>",
"     Reduced doses of progestin and estrogen in the currently available oral contraceptives have decreased these complications. Therefore, birth control pills are now considered a reliable and safe option for most healthy, non-smoking women. Blood clots occur in approximately 4 women per 10,000 using pills over a year's time. This compares to approximately two blood clots per 10,000 women who are not using pills and 6 blood clots per 10,000 women who are pregnant.",
"    </p>",
"    <p>",
"     The majority of studies suggest that taking (or previously taking) the pill does not increase the risk of breast cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Who should not take the pill?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who fall into the following categories should NOT take the pill because of an increased risk of complications:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Aged 35 or over who smoke cigarettes (very high risk for cardiovascular complications)",
"      </li>",
"      <li>",
"       Are pregnant",
"      </li>",
"      <li>",
"       Have had blood clots or a stroke in the past, because these women are more likely to have blood clots while taking the pill",
"      </li>",
"      <li>",
"       Have a history of an estrogen-dependent tumor (eg, breast or uterine cancer)",
"      </li>",
"      <li>",
"       Have abnormal or unexplained menstrual bleeding (the cause of the bleeding should be investigated before starting the pill)",
"      </li>",
"      <li>",
"       Have active liver disease (the pill could worsen the liver disease)",
"      </li>",
"      <li>",
"       Have migraine headaches associated with visual or other neurologic symptoms (eg, aura)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Special concerns",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some women may take the pill under certain circumstances, but need close monitoring:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Women with high blood pressure can experience a further increase in blood pressure and should be monitored more frequently while on the pill.",
"      </li>",
"      <li>",
"       Women who take certain medication for seizures (epilepsy) and take the pill have a slightly higher risk of pill failure (pregnancy) because the seizure medicines change the way the pill is metabolized. (See",
"       <a class=\"local\" href=\"#H9\">",
"        'Medication interactions'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Women with diabetes mellitus who are on the pill may need a slightly higher dose of insulin or oral diabetes medication. Women with diabetes and vascular complications from diabetes should not use the pill.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Medication interactions",
"     </span>",
"     &nbsp;&mdash;&nbsp;The effectiveness of the pill may be reduced in women who take certain medications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Anticonvulsants",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some anticonvulsants, including phenytoin (Dilantin&reg;), carbamazepine (Tegretol&reg;), barbiturates, primidone (Mysoline&reg;), topiramate (Topamax&reg;) and oxcarbazepine (Trileptal&reg;) decrease the effectiveness of hormonal birth control methods (pill, patch, ring). As a result, women who take these anticonvulsants are advised to avoid hormonal birth control methods (with the exception of depo-medroxyprogesterone acetate [Depo-Provera&reg;]). (See",
"     <a class=\"local\" href=\"#H19\">",
"      'Injectable birth control'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Other anticonvulsants do not appear to reduce contraceptive efficacy, including gabapentin (Neurontin&reg;), lamotrigine (Lamictal&reg;), levetiracetam (Keppra&reg;), and tiagabine (Gabitril&reg;). However, there is some concern that oral contraceptives may reduce the effectiveness of lamotrigine, potentially increasing the risk of seizures.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Antibiotics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Rifampin, which is sometimes used to treat tuberculosis, can decrease the efficacy of hormonal birth control. As a result, women who take rifampin should not use any hormonal birth control method (pill, patch, ring, implant, injection). Other methods (condom, diaphragm, IUD, sterilization) are recommended.",
"    </p>",
"    <p>",
"     Other antibiotics (eg, penicillin, tetracycline, cephalexin) do not affect the efficacy of hormonal birth control methods. Back-up contraception is not needed when you take these antibiotics.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      St. John's Wort",
"     </span>",
"     &nbsp;&mdash;&nbsp;St. John's wort, an herbal supplement sometimes taken to treat depression, may reduce the effectiveness of birth control pills. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Starting the pill",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ideally, the pill should be started on the first day of the period to provide maximum contraceptive effect in the first cycle; this provides protection from pregnancy immediately.",
"    </p>",
"    <p>",
"     The pill may also be started on the day it is prescribed (called \"quick start), as long as a urine pregnancy test is negative. A back-up form of birth control (eg, condoms) is needed for the first seven days after the quick start.",
"    </p>",
"    <p>",
"     Many women start their pill on the first Sunday after the period starts (because most pill packs are arranged for a Sunday start). Some form of back-up contraception is needed for the first seven days after the Sunday start.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      When to expect a period",
"     </span>",
"     &nbsp;&mdash;&nbsp;Traditionally, the pill is taken on a 28-day cycle with 21 days of hormone pills followed by 7 days of placebo pills (\"sugar pills\"). Some newer formulations have a longer duration of hormone pills and fewer days of placebo pills (eg,",
"     <span class=\"nowrap\">",
"      24/4).",
"     </span>",
"     It is not necessary to take the placebo pills, but some women find it easier to remember to start their next pill pack if they have taken the placebos. The period should occur during the fourth week of the pill pack, ie, the \"placebo week.\" However, some women have irregular breakthrough bleeding or spotting in the first few months. (See",
"     <a class=\"local\" href=\"#H5\">",
"      'Side effects'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Continuous dosing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some women prefer to take birth control pills continuously. This allows them to have fewer days of menstrual bleeding per year. This regimen is a particularly good treatment for women with painful periods or endometriosis, as well as those who want to avoid a monthly bleed.",
"    </p>",
"    <p>",
"     Traditional birth control pill packs can be used in continuous dosing. In this regimen, the woman takes the first three weeks of a pill pack, then immediately starts a new pack (without a break); the last week of (placebo) pills is not used. This can be continued for as long as desired.",
"    </p>",
"    <p>",
"     Seasonale&reg; is an extended cycle birth control regimen in which an active pill is taken every day for 12 weeks, followed by seven days of inactive (placebo) pills. Seasonique&reg; is another extended cycle pill that contains seven days of a low dose estrogen pills instead of the placebo pills; this is intended to reduce breakthrough bleeding and estrogen withdrawal symptoms.",
"    </p>",
"    <p>",
"     Taking an oral contraceptive for an extended time results in fewer periods per year, although many women experience breakthrough bleeding when starting this regimen. Breakthrough bleeding is inconvenient, but does not indicate an increased risk of pill failure (unless pills are forgotten).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Shorter pill-free interval",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several pill formulations are available with 24 days of hormone pills (rather than 21) and only four days of placebo pills. It is hoped that pill failures and side effects will be minimized with this approach.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Progestin only pills",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some pills contain only progestin (called the mini pill), which is useful for women who cannot or should not take estrogen. This includes women who are breastfeeding and within 4 to 6 weeks of delivery or who have worsened migraines or high blood pressure with combination contraceptive pills. Progestin only pills are as effective as combination pills when taken at the same time every day, but there is a slightly higher failure rate of the mini pill if the woman is more than three hours late in taking it. A back up method of birth control should be used for seven days if a pill is forgotten or taken more than three hours late.",
"    </p>",
"    <p>",
"     Progestin only pills are taken on a 28-day cycle, and all 28 pills contain hormone. One pill should be taken every day at the same time, and there is no placebo pill week. Breakthrough bleeding or spotting can occur with progestin only pills.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Emergency contraception",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have sex and have forgotten to take your pill, patch, or vaginal ring, or you are more than two weeks late for your injection of medroxyprogesterone acetate, you can take a \"morning after\" pill to reduce the risk of pregnancy. This should be taken as soon as possible after sex, ideally within 120 hours. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/32/24068?source=see_link\">",
"      \"Patient information: Emergency contraception (morning after pill) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      INJECTABLE BIRTH CONTROL",
"     </span>",
"    </p>",
"    <p>",
"     The only injectable contraceptive currently available in the United States is depot medroxyprogesterone acetate or DMPA (Depo-Provera&reg;). DMPA is injected deep into a muscle, such as the buttock or upper arm, once every three months. A preparation that is given subcutaneously (under the skin) is also available.",
"    </p>",
"    <p>",
"     DMPA prevents ovulation and thickens the cervical mucus, making the cervix impenetrable to sperm. If the first dose of DMPA is given during the first seven days of the menstrual period, it prevents pregnancy immediately. A woman who receives her first DMPA injection after the seventh day of her period should use a second form of contraception (eg, condoms) for seven days. DMPA is very effective, with a failure (pregnancy) rate of less than one percent when the injection is given on time.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common side effects of DMPA are irregular or prolonged bleeding and spotting, particularly during the first few months of use. Up to 50 percent of women completely stop having menstrual periods (amenorrhea) after one year of DMPA use. Menses generally return within six months of the last DMPA injection. DMPA is associated with weight gain in some women.",
"    </p>",
"    <p>",
"     In women who use injectable progestins, there is no increased risk of cardiovascular complications or cancer. Use of DMPA is associated with decreased bone mineral density in current users. This effect is mostly reversed after DMPA is stopped. Studies have not shown an increased risk of bone fractures in women who have used DMPA in the past.",
"    </p>",
"    <p>",
"     Because DMPA is long-acting, it may not be ideal for women who wish to become pregnant shortly after stopping the medication. Although most women are able to conceive within 10 months, fertility may not return for up to 18 months after the last injection.",
"    </p>",
"    <p>",
"     There are a number of women who prefer DMPA to the pill, including those who:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Have difficulty remembering to take a pill every day",
"      </li>",
"      <li>",
"       Cannot use estrogen",
"      </li>",
"      <li>",
"       Also take seizure medications, which can be less effective with combination hormonal contraceptives.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Additional benefits of DMPA include a decreased risk of uterine cancer and pelvic inflammatory disease (PID).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      BIRTH CONTROL SKIN PATCH",
"     </span>",
"    </p>",
"    <p>",
"     Birth control skin patches contain estrogen and progestin, similar to oral contraceptives. The patch is as effective as oral contraceptives, and may be preferred by some women because it does not require daily dosing. However, the failure rate of the patch is higher for obese women (eg, who weigh more than 198 pounds).",
"    </p>",
"    <p>",
"     Ortho Evra&reg; is the only skin patch contraceptive available in the United States. Effectiveness is similar to that of oral contraceptive pills. However, the patch appears to deliver a higher overall dose of estrogen than the pill. One study found that this was associated with an approximate doubling of the risk of blood clots while another study found no increase in risk. Further study is needed to define this risk.",
"    </p>",
"    <p>",
"     The patch is worn for one week on the upper arm, shoulder, upper back, abdomen, or hip (",
"     <a class=\"graphic graphic_picture graphicRef57796 \" href=\"UTD.htm?37/55/38783\">",
"      picture 1",
"     </a>",
"     ). &nbsp;After one week, the old patch is removed and a new patch is applied; this is done for three weeks. During the fourth week, no patch is worn; the menstrual period occurs during this week.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      VAGINAL RING",
"     </span>",
"    </p>",
"    <p>",
"     Nuvaring&reg; is a flexible plastic vaginal ring that contains estrogen and a progestin, which is slowly absorbed through the vaginal tissues (",
"     <a class=\"graphic graphic_picture graphicRef81410 graphicRef73663 \" href=\"UTD.htm?37/30/38368\">",
"      picture 2A-B",
"     </a>",
"     ). This prevents pregnancy, similar to an oral contraceptive. It is worn in the vagina for three weeks, followed by one week when no ring is used; a menstrual period occurs during this time. The ring's position inside the vagina is not important.",
"    </p>",
"    <p>",
"     Most women cannot feel the ring, and it is easy to insert and remove. It may be removed for up to three hours if desired, such as during intercourse, although it is not usually felt by the sexual partner. If the ring is left out for more than 3 hours, a backup method of birth control (eg, condoms) should be used for the next 7 days.",
"    </p>",
"    <p>",
"     Risks and side effects are similar to those of oral contraceptives.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      BIRTH CONTROL IMPLANT",
"     </span>",
"    </p>",
"    <p>",
"     A single-rod progestin implant, Implanon&reg; or Nexplanon&reg;, has been approved for use in the US and elsewhere. It is inserted under the skin into the upper inner arm by a healthcare provider (",
"     <a class=\"graphic graphic_picture graphicRef82387 \" href=\"UTD.htm?18/25/18847\">",
"      picture 3",
"     </a>",
"     ). It is effective for up to three years, but can be removed if pregnancy is desired sooner. Insertion and removal can be done in an office or clinic.",
"    </p>",
"    <p>",
"     The implant is one of the most effective methods of birth control. It provides three years of protection from pregnancy as progestin is slowly absorbed into the surrounding tissues. It is effective within 24 hours of insertion. Irregular bleeding is the most bothersome side effect. Fertility returns rapidly after removal of the rod.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      IUD WITH PROGESTIN",
"     </span>",
"    </p>",
"    <p>",
"     There are two intrauterine devices (IUDs) that contain a hormone, called levonorgestrel. One is called Mirena (in the United States) and can be left in place for up to five years. The other is called Skyla and can be left in place for up to three years. Both are highly effective in preventing pregnancy. A complete discussion of IUDs is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"      \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      PREGNANCY AFTER HORMONAL BIRTH CONTROL",
"     </span>",
"    </p>",
"    <p>",
"     The length of time it takes to become pregnant after use of a hormonal method of birth control depends upon which method was used, as well as some individual factors.",
"    </p>",
"    <p>",
"     Most women are able to become pregnant immediately. For some, it may take several months before ovulation becomes regular and the woman can become pregnant, especially if the her periods were irregular before she used birth control. However, hormonal birth control does not increase the risk of infertility.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Women who use combination estrogen-progestin methods (eg, birth control pill, skin patch, vaginal ring) usually begin to ovulate regularly one to three months after stopping. In one study, the median time for a woman to have a menstrual period after stopping the continuous pill was 32 days, and 185 of 187 women (98.9 percent) had a menstrual period or became pregnant within 90 days [",
"       <a class=\"abstract\" href=\"UTD.htm?21/32/22021/abstract/1\">",
"        1",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       With injectable depot medroxyprogesterone acetate (DMPA or Depo-Provera&reg;), return of fertility can be delayed. Fifty percent of women will become pregnant within 10 months of the last injection. In a small number of women, however, it may take up to 18 months after the last injection to conceive. Women with lower body weights tend to become pregnant sooner than women with higher body weights after discontinuing DMPA.",
"      </li>",
"      <li>",
"       Women who use contraceptive implants (eg, Implanon) usually begin to ovulate again within one month after the device is removed.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H261\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3051576082\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/17/18707?source=see_link\">",
"      Patient information: Hormonal birth control (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=see_link\">",
"      Patient information: Choosing birth control (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/8/5251?source=see_link\">",
"      Patient information: Endometriosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/27/39346?source=see_link\">",
"      Patient information: Ovarian cysts (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42146?source=see_link\">",
"      Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3051576147\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=see_link\">",
"      Patient information: Barrier methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/32/24068?source=see_link\">",
"      Patient information: Emergency contraception (morning after pill) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42201?source=see_link\">",
"      Contraception: Overview of issues specific to adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=see_link\">",
"      Depot medroxyprogesterone acetate for contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31833?source=see_link\">",
"      Emergency contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5334?source=see_link\">",
"      Female condoms",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/58/37800?source=see_link\">",
"      Fertility awareness-based methods of pregnancy prevention",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3832?source=see_link\">",
"      Hormonal contraception for suppression of menstruation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/38/20070?source=see_link\">",
"      Barrier contraception: Diaphragm",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30696?source=see_link\">",
"      Male condoms",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"      Overview of contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=see_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9031?source=see_link\">",
"      Progestin-only pills (minipills) for contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Child Health and Human Development (NICHD)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 370-2943",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nichd.nih.gov/\">",
"      www.nichd.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Women's Health Resource Center (NWHRC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (877) 986-9472",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.healthywomen.org/\">",
"      www.healthywomen.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Planned Parenthood Federation of America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Phone: (212) 541-7800",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.plannedparenthood.org/\">",
"      www.plannedparenthood.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.hormone.org/\">",
"      www.hormone.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?21/32/22021/abstract/2-6\">",
"      2-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?21/32/22021?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22021/abstract/1\">",
"      Davis AR, Kroll R, Soltes B, et al. Occurrence of menses or pregnancy after cessation of a continuous oral contraceptive. Fertil Steril 2008; 89:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22021/abstract/2\">",
"      Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003; 349:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22021/abstract/3\">",
"      Baerwald AR, Olatunbosun OA, Pierson RA. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. Contraception 2004; 70:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22021/abstract/4\">",
"      van Vliet HA, Grimes DA, Lopez LM, et al. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2006; :CD003553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22021/abstract/5\">",
"      Edelman AB, Gallo MF, Jensen JT, et al. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; :CD004695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22021/abstract/6\">",
"      Gallo MF, Grimes DA, Schulz KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev 2003; :CD003552.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f21_32_22021=[""].join("\n");
var outline_f21_32_22021=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CHOOSING A BIRTH CONTROL METHOD",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           BIRTH CONTROL PILLS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           INJECTABLE BIRTH CONTROL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           BIRTH CONTROL SKIN PATCH",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           VAGINAL RING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           BIRTH CONTROL IMPLANT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           IUD WITH PROGESTIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           PREGNANCY AFTER HORMONAL BIRTH CONTROL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/55/38783\" title=\"picture 1\">",
"           Ortho Evra PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/43/22206\" title=\"picture 2A\">",
"           NuvaRing PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/16/43278\" title=\"picture 2B\">",
"           NuvaRing hand squeezing PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/25/18847\" title=\"picture 3\">",
"           Etonogestrel implant PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?13/9/13467\" title=\"table 1\">",
"           Contraception guide PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f21_32_22022="Overview of snoring in adults";
var content_f21_32_22022=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of snoring in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/32/22022/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/32/22022/contributors\">",
"     William Beninati, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/32/22022/contributors\">",
"     William C Frey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/32/22022/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/32/22022/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/32/22022/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/32/22022/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/32/22022/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Snoring is a sound produced by vibration of the soft tissues of the upper airway during sleep. It usually occurs during inspiration, but can also occur during expiration. Habitual snoring is common, occurring in 44 percent of males and 28 percent of females who are between 30 and 60 years of age in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/1\">",
"     1",
"    </a>",
"    ]. Occasional snoring is almost universal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Snoring is indicative of increased upper airway resistance. It can be a sign of obstructive sleep apnea (OSA), a sleep disorder characterized by obstructive apneas and hypopneas that occurs when upper airway resistance is sufficient to disrupt sleep. Snoring can also be associated with conditions that narrow the upper airway, including obesity, nasal congestion, craniofacial abnormalities, hypothyroidism, acromegaly, and adenotonsillar hypertrophy. These conditions, in turn, may cause snoring without OSA, or snoring that occurs as a symptom of OSA. It is important to recognize the clinical features of conditions associated with snoring so that objective testing can be performed and treatment initiated, if indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link\">",
"     \"Overview of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Snoring can also occur in the absence of any condition known to increase upper airway resistance. Previously called primary snoring, simple snoring, or benign snoring, these terms are no longer used [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/2\">",
"     2",
"    </a>",
"    ]. Treatment of such snoring is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2008?source=see_link\">",
"     \"Treatment of adults with snoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Snoring is associated with increased upper airway resistance, which may range from mildly abnormal to severely elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24454?source=see_link\">",
"     \"Mechanisms and anatomic sites of upper airway obstruction in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At relatively low levels of upper airway resistance, there may be snoring without sleep disruption or symptoms of disturbed sleep.",
"     </li>",
"     <li>",
"      As upper airway resistance increases, there is a compensatory increase in respiratory effort in order to maintain ventilation. The increased effort may be associated with transient arousals from sleep. Patients with these respiratory effort-related arousals were previously diagnosed with upper airways resistance syndrome (UARS) if the respiratory effort-related arousals were accompanied by symptoms of disturbed sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. However, UARS is no longer distinguished from obstructive sleep apnea (OSA) in the most recent classification system endorsed by the American Academy of Sleep Medicine [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/2\">",
"       2",
"      </a>",
"      ]. Such patients are now considered to have OSA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link\">",
"       \"Sleep related breathing disorders in adults: Definitions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As upper airway resistance becomes more severe, obstructive apnea and hypopnea may occur, leading to more fragmented sleep, increased symptoms and signs of disrupted sleep, and oxyhemoglobin desaturation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although snoring is indicative of increased upper airway resistance, its absence does not exclude increased upper airway resistance or OSA. This is especially true among women and patients who have had a uvulopalatopharyngoplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32872033\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether snoring progresses to obstructive sleep apnea (OSA); however, the evidence seems to suggest that it is likely with weight gain. This was demonstrated by a retrospective cohort study of 160 middle-age men with untreated snoring or OSA, who were followed for a mean of five years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/9\">",
"     9",
"    </a>",
"    ]. The apnea-hypopnea index (AHI) increased with both weight gain and time in patients with untreated snoring, mild OSA, or moderate OSA. Weight gain had a seven-time larger effect on the AHI than time. A one point gain in the body mass index over one year corresponded to an increase in the AHI of five events per hour.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     POTENTIAL CONSEQUENCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early large epidemiologic studies suggested that snoring may be related to hypertension, cardiovascular disease, and cerebrovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. However, these studies did not distinguish the effects of snoring from the effects of obstructive sleep apnea (OSA), which often coexists and is known to have cardiovascular and cerebrovascular consequences. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link\">",
"     \"Cardiovascular effects of obstructive sleep apnea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38518?source=see_link\">",
"     \"Sleep related breathing disorders and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This limitation was addressed in subsequent studies, which are described below. It now appears that snoring may be associated with carotid artery atherosclerosis, but there is little evidence to support an independent relationship between snoring and either hypertension or ischemic heart disease. Disruption of the sleep of the bed partner may be a significant problem that can cause the bed partner to have daytime sleepiness and marital dissatisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carotid atherosclerosis &ndash; An observational study categorized 110 patients with non-hypoxemic OSA into three groups according to the proportion of the total sleep time spent snoring: mild snoring (&le;25 percent), moderate snoring (26 to 50 percent), or heavy snoring (&gt;50 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/17\">",
"       17",
"      </a>",
"      ]. Heavy snoring was associated with carotid artery atherosclerosis, even after adjustment for known confounders (odds ratio 10.5, 95% CI 2.1-51.8). In addition, there was a dose-response gradient, with the prevalence of carotid atherosclerosis being 20, 32, and 64 percent among those with mild, moderate, and heavy snoring, respectively. The apnea hypopnea index (AHI) and oxygen desaturation index (ODI) were unrelated to the prevalence of carotid artery atherosclerosis. This study suggests that snoring alone may be associated with carotid atherosclerosis. It is postulated that the endothelial cells in the carotid artery walls are subject to direct vibratory damage from heavy snoring, thereby contributing to plaque formation.",
"     </li>",
"     <li>",
"      Hypertension &ndash; In an observational study, 1415 individuals who were referred to a sleep disorders center underwent polysomnography and blood pressure measurement [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/18\">",
"       18",
"      </a>",
"      ]. Among individuals without OSA, hypertension was equally likely among heavy snorers and non-snorers (20 versus 18 percent for non-snorers) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/18\">",
"       18",
"      </a>",
"      ]. This study suggests that snoring alone is not associated with an increased risk of systemic arterial hypertension.",
"     </li>",
"     <li>",
"      Ischemic heart disease &ndash; In an observational study of 5338 adults without known cardiovascular disease who were followed for 7.5 years, self-reported habitual snorers without a physician diagnosis of sleep apnea had similar incident cardiovascular event and death rates compared with non-snoring participants, and lower incident event rates compared with patients with physician diagnosed sleep apnea [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/19\">",
"       19",
"      </a>",
"      ]. This study, along with smaller observational studies, suggests that snoring alone is not independently associated with ischemic heart disease or all-cause mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary purpose of evaluating patients who snore is to identify potential causes of increased upper airway resistance, so they can be confirmed and treated, if necessary. Snoring is most often associated with obesity or obstructive sleep apnea (OSA). Other potential etiologies that should be considered include nasal congestion and craniofacial abnormalities. Rarely, acromegaly, hypothyroidism, or adenotonsillar hypertrophy can contribute to snoring in adults. Snoring may occur in the absence of a condition known to increase upper airway resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is useful to include the bed partner or a family member when evaluating a patient who snores because they may have greater insight into the problem than the patient. The patient, bed partner,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    family member should be asked about symptoms or signs of OSA, including episodes of breathing cessation, periods of silence terminated by loud resuscitative snoring, restless sleep, and awakening with a sensation of choking, gasping, or smothering. Excessive daytime sleepiness may exist, but it is often unnoticed or underestimated because of its insidious onset and chronicity. Moodiness, poor concentration, morning headaches, hypertension, or nocturnal angina may exist. Patients with OSA may also be asymptomatic. The clinical features of OSA are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms and signs of conditions associated with increased upper airway resistance other than OSA should also be sought. Nasal congestion or a history of allergies, sinusitis, or sinus surgery may warrant further investigation, since inadequately treated nasal or sinus disease is a potential cause of snoring [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/22\">",
"     22",
"    </a>",
"    ]. Frequent sore throats or mouth breathing may indicate adenotonsillar hypertrophy, especially among young patients. Fatigue, weight gain, cold intolerance, and constipation may be due to hypothyroidism. Craniofacial abnormalities and acromegaly are generally suspected on the basis of physical examination findings, rather than symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link\">",
"     \"An overview of rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=see_link\">",
"     \"Causes and clinical manifestations of acromegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The history should also cover habits and medication use that will have a bearing on snoring. Habits associated with snoring include smoking and alcohol use [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/23-28\">",
"     23-28",
"    </a>",
"    ]. Benzodiazepine use has been demonstrated to cause snoring and increased upper airway resistance in experiments using healthy volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22022/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should be examined for physical signs associated with OSA, including truncal obesity (ie, body mass index &gt;30), a large neck circumference, and a crowded oropharynx (",
"    <a class=\"graphic graphic_picture graphicRef55998 graphicRef67818 \" href=\"UTD.htm?32/60/33736\">",
"     picture 1A-B",
"    </a>",
"    ). Additional clues that OSA may be present include systemic arterial hypertension and signs of pulmonary hypertension (eg, increased intensity of the pulmonic component of the second heart sound, splitting of the second heart sound, elevated jugular venous pressure, a right-sided third or fourth heart sound, a tricuspid regurgitant murmur, peripheral edema). Physical findings associated with OSA are described in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\", section on 'Physical examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link\">",
"     \"Cardiovascular effects of obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians should also look for physical findings suggestive of other causes of snoring. Obesity, craniofacial abnormalities, nasoseptal deviation, adenotonsillar hypertrophy, and nasal polyps may be obvious. Patients with nasal congestion may have nasal turbinates that appear boggy and edematous. The mucosal tissue is often erythematous, or may have a pale bluish hue or pallor. The mucosa can also appear relatively normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34584?source=see_link&amp;anchor=H16905688#H16905688\">",
"     \"Clinical presentation, diagnosis, and treatment of nasal obstruction\", section on 'Diagnosis'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Patients with acromegaly may manifest acral, articular, and soft tissue overgrowth, while patients with hypothyroidism may have delayed relaxation of deep tendon reflexes, bradycardia, coarse hair and skin, puffy facies, enlargement of the tongue, and hoarseness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link\">",
"     \"An overview of rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=see_link\">",
"     \"Causes and clinical manifestations of acromegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of diagnostic testing in a patient who snores is to confirm or exclude the presence of a coexisting condition that is associated with increased upper airway resistance. These specific conditions are addressed below. Treatment of those conditions that are confirmed can then be initiated, if indicated.",
"   </p>",
"   <p>",
"    Diagnostic testing for suspected OSA involves polysomnography or portable monitoring. An approach for determining which patients are sufficiently likely to have OSA to warrant such diagnostic testing is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\", section on 'Indications for diagnostic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnostic testing for suspected craniofacial abnormalities or adenotonsillar hypertrophy may include lateral cephalometric radiographs to provide information about the patency of the patient's upper airway. This is generally performed along with otolaryngology consultation. Factors that should prompt referral include a structural abnormality causing obstruction, cranial nerve dysfunction, severe epistaxis, or a mucosal abnormality that has been refractory to a trial of nasal inhaled glucocorticoid medication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34584?source=see_link&amp;anchor=H809634165#H809634165\">",
"     \"Clinical presentation, diagnosis, and treatment of nasal obstruction\", section on 'Referral'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metabolic testing is indicated for suspected acromegaly or hypothyroidism, as described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43076?source=see_link\">",
"     \"Diagnosis of acromegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary reasons to treat snoring in patients who do not have a condition associated with increased upper airway resistance are to minimize disruption of the bed partner's sleep and to relieve the patient of any embarrassment caused by the snoring. Treatment of such snoring is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2008?source=see_link\">",
"     \"Treatment of adults with snoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of snoring related to conditions that are associated with increased upper airway resistance generally targets the underlying condition (eg, obstructive sleep apnea), at least initially. Treatment of such conditions is described in the related topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34584?source=see_link&amp;anchor=H16905695#H16905695\">",
"     \"Clinical presentation, diagnosis, and treatment of nasal obstruction\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Snoring is a sound produced by vibration of the soft tissues of the upper airway during sleep. Habitual snoring is common in adults and occasional snoring is almost universal. Snoring can be a sign of a condition associated with increased upper airway resistance, or it can occur independently. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Snoring has been independently associated with carotid artery atherosclerosis, but there is little evidence to support a relationship between snoring and either hypertension or ischemic heart disease. Disruption of the sleep of the bed partner may be a significant problem. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Potential consequences'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary purpose of evaluating patients who snore is to identify treatable causes of the snoring, including obesity, smoking, use of ethanol or benzodiazepines near bedtime, chronic nocturnal nasal congestion, or craniofacial abnormalities. The clinician must also evaluate for obstructive sleep apnea (OSA), an associated condition that requires treatment. Rarely, acromegaly, hypothyroidism, and adenotonsillar hypertrophy can contribute to snoring in adults. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary reasons to treat snoring in patients who do not have a condition associated with increased upper airway resistance are to minimize disruption of the bed partner's sleep and to relieve the patient of any embarrassment caused by the snoring. Treatment of such snoring is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2008?source=see_link\">",
"       \"Treatment of adults with snoring\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DISCLAIMER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The opinions expressed herein are those of the authors and should not be construed as official or reflecting the policy of either the Department of the Air Force, Department of the Army, Department of Defense, or the United States Government.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/1\">",
"      Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328:1230.",
"     </a>",
"    </li>",
"    <li>",
"     International classification of sleep disorders: Diagnostic and coding manual, 2nd ed, American Academy of Sleep Medicine, Westchester, IL 2005.",
"    </li>",
"    <li>",
"     Lugaresi E, Cirignota F, Montagna P, Sforza E. Snoring: pathogenic, clinical, and therapeutic aspects. In: Principles and Practice of Sleep Medicine, Kryger MH, Roth T, Dement WC (Eds), WB Saunders, Philadelphia 1994. p.621.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/4\">",
"      Guilleminault C, Stoohs R, Duncan S. Snoring (I). Daytime sleepiness in regular heavy snorers. Chest 1991; 99:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/5\">",
"      Guilleminault C, Stoohs R, Clerk A, et al. A cause of excessive daytime sleepiness. The upper airway resistance syndrome. Chest 1993; 104:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/6\">",
"      Guilleminault C, Palombini L, Poyares D, Chowdhuri S. Chronic insomnia, postmenopausal women, and sleep disordered breathing: part 1. Frequency of sleep disordered breathing in a cohort. J Psychosom Res 2002; 53:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/7\">",
"      Kristo DA, Lettieri CJ, Andrada T, et al. Silent upper airway resistance syndrome: prevalence in a mixed military population. Chest 2005; 127:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/8\">",
"      Farmer WC, Giudici SC. Site of airway collapse in obstructive sleep apnea after uvulopalatopharyngoplasty. Ann Otol Rhinol Laryngol 2000; 109:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/9\">",
"      Berger G, Berger R, Oksenberg A. Progression of snoring and obstructive sleep apnoea: the role of increasing weight and time. Eur Respir J 2009; 33:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/10\">",
"      Lugaresi E, Cirignotta F, Coccagna G, Piana C. Some epidemiological data on snoring and cardiocirculatory disturbances. Sleep 1980; 3:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/11\">",
"      Norton PG, Dunn EV. Snoring as a risk factor for disease: an epidemiological survey. Br Med J (Clin Res Ed) 1985; 291:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/12\">",
"      Koskenvuo M, Kaprio J, Telakivi T, et al. Snoring as a risk factor for ischaemic heart disease and stroke in men. Br Med J (Clin Res Ed) 1987; 294:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/13\">",
"      Gislason T, Benediktsd&oacute;ttir B, Bj&ouml;rnsson JK, et al. Snoring, hypertension, and the sleep apnea syndrome. An epidemiologic survey of middle-aged women. Chest 1993; 103:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/14\">",
"      Beninati W, Harris CD, Herold DL, Shepard JW Jr. The effect of snoring and obstructive sleep apnea on the sleep quality of bed partners. Mayo Clin Proc 1999; 74:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/15\">",
"      Parish JM, Lyng PJ. Quality of life in bed partners of patients with obstructive sleep apnea or hypopnea after treatment with continuous positive airway pressure. Chest 2003; 124:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/16\">",
"      Nakano H, Furukawa T, Nishima S. Relationship between snoring sound intensity and sleepiness in patients with obstructive sleep apnea. J Clin Sleep Med 2008; 4:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/17\">",
"      Lee SA, Amis TC, Byth K, et al. Heavy snoring as a cause of carotid artery atherosclerosis. Sleep 2008; 31:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/18\">",
"      Hoffstein V. Blood pressure, snoring, obesity, and nocturnal hypoxaemia. Lancet 1994; 344:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/19\">",
"      Yeboah J, Redline S, Johnson C, et al. Association between sleep apnea, snoring, incident cardiovascular events and all-cause mortality in an adult population: MESA. Atherosclerosis 2011; 219:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/20\">",
"      Marshall NS, Wong KK, Cullen SR, et al. Snoring is not associated with all-cause mortality, incident cardiovascular disease, or stroke in the Busselton Health Study. Sleep 2012; 35:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/21\">",
"      Jennum P, Hein HO, Suadicani P, Gyntelberg F. Risk of ischemic heart disease in self-reported snorers. A prospective study of 2,937 men aged 54 to 74 years: the Copenhagen Male Study. Chest 1995; 108:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/22\">",
"      Young T, Finn L, Palta M. Chronic nasal congestion at night is a risk factor for snoring in a population-based cohort study. Arch Intern Med 2001; 161:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/23\">",
"      Wetter DW, Young TB, Bidwell TR, et al. Smoking as a risk factor for sleep-disordered breathing. Arch Intern Med 1994; 154:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/24\">",
"      Franklin KA, G&iacute;slason T, Omenaas E, et al. The influence of active and passive smoking on habitual snoring. Am J Respir Crit Care Med 2004; 170:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/25\">",
"      Issa FG, Sullivan CE. Alcohol, snoring and sleep apnea. J Neurol Neurosurg Psychiatry 1982; 45:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/26\">",
"      Block AJ, Hellard DW. Ingestion of either scotch or vodka induces equal effects on sleep and breathing of asymptomatic subjects. Arch Intern Med 1987; 147:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/27\">",
"      Bloom JW, Kaltenborn WT, Quan SF. Risk factors in a general population for snoring. Importance of cigarette smoking and obesity. Chest 1988; 93:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/28\">",
"      Mitler MM, Dawson A, Henriksen SJ, et al. Bedtime ethanol increases resistance of upper airways and produces sleep apneas in asymptomatic snorers. Alcohol Clin Exp Res 1988; 12:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/29\">",
"      Schneider H, Grote L, Peter JH, et al. The effect of triazolam and flunitrazepam--two benzodiazepines with different half-lives--on breathing during sleep. Chest 1996; 109:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22022/abstract/30\">",
"      Masuda A, Haji A, Wakasugi M, et al. Differences in midazolam-induced breathing patterns in healthy volunteers. Acta Anaesthesiol Scand 1995; 39:785.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7703 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.32.226.102-7D0333FE40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_32_22022=[""].join("\n");
var outline_f21_32_22022=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32872033\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      POTENTIAL CONSEQUENCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DISCLAIMER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7703\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7703|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/38/15971\" title=\"picture 1A\">",
"      Oropharynx of a snorer I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/52/10052\" title=\"picture 1B\">",
"      Oropharynx of a snorer II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=related_link\">",
"      An overview of rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=related_link\">",
"      Causes and clinical manifestations of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34584?source=related_link\">",
"      Clinical presentation, diagnosis, and treatment of nasal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43076?source=related_link\">",
"      Diagnosis of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24454?source=related_link\">",
"      Mechanisms and anatomic sites of upper airway obstruction in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38518?source=related_link\">",
"      Sleep related breathing disorders and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2008?source=related_link\">",
"      Treatment of adults with snoring",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_32_22023="Clinical manifestations and diagnosis of scleritis";
var content_f21_32_22023=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of scleritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/32/22023/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/32/22023/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/32/22023/contributors\">",
"     Reza Dana, MD, MPH, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/32/22023/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/32/22023/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/32/22023/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/32/22023/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/32/22023/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scleral inflammatory disease consists of episcleritis and scleritis. Episcleritis is typically self-limited or quickly responsive to topical therapies. In contrast, scleritis is a painful, destructive, and potentially blinding disorder that may also involve the cornea, adjacent episclera, and underlying uveal tract. Scleritis has a striking, highly symptomatic clinical presentation (",
"    <a class=\"graphic graphic_picture graphicRef81098 \" href=\"UTD.htm?13/30/13797\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Scleritis sometimes occurs in an isolated fashion, without evidence of inflammation in other organs. However, in up to 50 percent of patients, scleritis is associated with an underlying systemic illness such as rheumatoid arthritis or granulomatosis with polyangiitis (Wegener&rsquo;s) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22023/abstract/1\">",
"     1",
"    </a>",
"    ]. Two-thirds of patients with scleritis require high-dose glucocorticoids or the combination of high-dose glucocorticoids and another immunosuppressive agent to achieve disease control [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22023/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the clinical manifestations and diagnosis of scleritis. The treatment of scleritis and issues related to other inflammatory disorders of the eye are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11511?source=see_link\">",
"     \"Treatment of scleritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/80?source=see_link\">",
"     \"Episcleritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=see_link\">",
"     \"Uveitis: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22903?source=see_link\">",
"     \"Ocular manifestations of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33561?source=see_link\">",
"     \"Retinal vasculitis associated with systemic disorders and infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sclera lies beneath the conjunctiva and episclera but above the choroid (",
"    <a class=\"graphic graphic_figure graphicRef62615 \" href=\"UTD.htm?8/23/8561\">",
"     figure 1",
"    </a>",
"    ). The opaque scleral tissue is composed of collagen fibrils arranged in a precise, interlacing manner that enhances rigidity and stability. Although the sclera itself is avascular, the tissue derives its metabolic requirements by diffusion from the episclera and choroid, both of which are highly vascularized.",
"   </p>",
"   <p>",
"    The sclera comprises 90 percent of the outer coat of the eye. Scleral tissue begins at the limbus (the outer edge of the cornea) and terminates posteriorly at the optic canal. At the posterior pole of the eye, the sclera fuses with the dura mater and arachnoid sheaths of the optic nerve. These anatomic relationships explain why optic nerve edema and visual compromise are common complications of posterior scleritis (",
"    <a class=\"graphic graphic_picture graphicRef65671 \" href=\"UTD.htm?42/8/43150\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Posterior scleritis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The sclera is divided into an anterior portion that is visible to the examiner and a posterior portion that lies behind the globe. Inflammation may occur in either the anterior or the posterior portion; rarely, it affects both, particularly in the setting of systemic inflammation. Anterior scleritis and posterior scleritis have different sets of implications for diagnosis, treatment and prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SCLERITIS SUBTYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 90 percent of scleritis cases involve the anterior portion. Posterior scleritis is defined as involvement of the sclera by inflammation posterior to the insertion of the medial and lateral rectus muscles. Subtypes of both anterior and posterior scleritis are recognized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Anterior scleritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior scleritis is subclassified into several subtypes:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Diffuse anterior scleritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse anterior scleritis is the most common and least severe form of scleritis, accounting for nearly 50 percent of cases (",
"    <a class=\"graphic graphic_picture graphicRef55397 \" href=\"UTD.htm?17/46/18159\">",
"     picture 3",
"    </a>",
"    ). Most cases respond to relatively mild therapies and do not recur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11511?source=see_link\">",
"     \"Treatment of scleritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Nodular anterior scleritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodular anterior scleritis is the second most common form of anterior scleritis, accounting for 20 to 40 percent of cases (",
"    <a class=\"graphic graphic_picture graphicRef55940 \" href=\"UTD.htm?1/58/1967\">",
"     picture 4",
"    </a>",
"    ). Multiple attacks of scleritis occur in approximately 50 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Necrotizing anterior scleritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing anterior scleritis is the least common but most dangerous subtype of anterior scleral inflammation. Compared with diffuse or nodular scleritis, this disorder occurs more frequently in women, has an older mean age of onset (average age 66 years), is more often associated with a systemic inflammatory illness, and is more likely to lead to ocular complications.",
"   </p>",
"   <p>",
"    Necrotizing anterior scleritis is divided into two forms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Necrotizing anterior scleritis \"with inflammation\" &mdash; This form of necrotizing anterior disease is highly symptomatic, with florid inflammatory features (",
"      <a class=\"graphic graphic_picture graphicRef81029 \" href=\"UTD.htm?2/6/2159\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef81136 \" href=\"UTD.htm?27/17/27935\">",
"       picture 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Scleromalacia perforans &mdash; Scleromalacia perforans, also known as necrotizing anterior scleritis \"without inflammation\", is a rare form of severe scleritis (",
"      <a class=\"graphic graphic_picture graphicRef78096 \" href=\"UTD.htm?39/37/40542\">",
"       picture 7",
"      </a>",
"      ). The majority of these patients have longstanding histories of rheumatoid arthritis, granulomatosis with polyangiitis (Wegener&rsquo;s), or some other systemic inflammatory illness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Subtypes of posterior scleritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse, nodular, and necrotizing variants of posterior scleritis have also been identified, but the clinical distinction between these entities is more difficult due to anatomic challenges involved in the assessment of posterior scleritis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22023/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the delays inherent in diagnosing an inflammatory process focused behind the eye and the proximity of posterior scleral inflammation to sensitive ocular tissues (eg, the retina and optic nerve), posterior scleritis usually requires the types of intensive immunosuppressive therapy used in necrotizing anterior scleritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11511?source=see_link\">",
"     \"Treatment of scleritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SYSTEMIC DISEASE ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scleritis is associated with a systemic disease in approximately 50 percent of cases. The most common association is with rheumatoid arthritis (RA). When scleritis complicates RA, it is generally considered to be a manifestation of rheumatoid vasculitis, heralding the need for an intensification of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22903?source=see_link\">",
"     \"Ocular manifestations of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rheumatoid vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of other systemic disorders are associated with scleritis (",
"    <a class=\"graphic graphic_table graphicRef77619 \" href=\"UTD.htm?36/5/36955\">",
"     table 1",
"    </a>",
"    ). Among the primary vasculitides, granulomatosis with polyangiitis (Wegener&rsquo;s) is a much more common cause of scleritis than the other types of vasculitis associated with antineutrophil cytoplasmic antibodies (ANCA) such as microscopic polyangiitis and the Churg-Strauss syndrome.",
"   </p>",
"   <p>",
"    The distribution of causes of scleritis was evaluated in a review of 97 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22023/abstract/2\">",
"     2",
"    </a>",
"    ]. Rheumatic and infectious diseases accounted for all of the underlying systemic diseases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A rheumatic disease was present in 39 percent. These included rheumatoid arthritis (18 percent), vasculitis (7 percent), inflammatory bowel disease (5 percent), systemic lupus erythematosus (4 percent), and relapsing polychondritis (3 percent).",
"     </li>",
"     <li>",
"      An infectious disease was present in 8 percent. These included herpes zoster ophthalmicus (5 percent), herpes simplex (2 percent), human immunodeficiency virus (2 percent), and Lyme disease (1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Scleritis may first occur after ocular surgery, perhaps initiated by trauma to the sclera [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22023/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The risk may be greater in patients with underlying rheumatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22023/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the ocular complaints and findings are the most prominent disease feature for many patients with scleritis, critical clues to the presence of a systemic inflammatory condition may be present on the general history and physical examination.",
"   </p>",
"   <p>",
"    The clinician must question the patient directly through a careful review of systems about constitutional symptoms and other organ system involvement. In addition, the clinician must examine with particular care the skin, joints, ears, nose, mouth, heart, lungs, and peripheral nerves, as these organs are often affected by the types of systemic disorders associated with scleritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise steps in the pathophysiology of most forms of scleritis are not well-defined, largely because most patients do not undergo ocular biopsy or enucleation at a time when active, untreated disease is present.",
"   </p>",
"   <p>",
"    One report evaluated conjunctival and scleral biopsies from 25 patients with necrotizing scleritis and five with recurrent non-necrotizing scleritis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22023/abstract/8\">",
"     8",
"    </a>",
"    ]. The patients with necrotizing scleritis had histopathologic evidence of vasculitis, with fibrinoid necrosis and neutrophil invasion of blood vessel walls and immune complex deposition.",
"   </p>",
"   <p>",
"    In rheumatoid vasculitis, which is often associated with necrotizing scleritis, immune complex deposition within the vessel wall leads to fibrinoid necrosis, thrombotic occlusion of blood vessels, and the generation of a chronic inflammatory response in the sclera [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22023/abstract/9\">",
"     9",
"    </a>",
"    ]. The scleritis is usually characterized by granulomatous inflammation adjacent to or involving the scleral blood vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior scleritis is usually readily apparent to both the patient and clinician and can be diagnosed and classified based upon its clinical features. By comparison, posterior scleritis is often less apparent and has variable clinical manifestations that may overlap with other clinical entities, such as inflammatory orbital \"pseudotumor\" [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22023/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scleritis is usually associated with a severe, constant boring pain that worsens at night or in the early morning hours and radiates to the face and periorbital region. The extraocular muscles insert into the sclera, which explains why ocular movements exacerbate the pain associated with scleral inflammation. The pain generally limits activity and often prevents sleep. Additional symptoms include headache, watering of the eye, ocular redness, and photophobia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ocular examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The essential sign of scleritis is edema, usually accompanied by violaceous discoloration of the globe and tenderness (",
"    <a class=\"graphic graphic_picture graphicRef55397 \" href=\"UTD.htm?17/46/18159\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef55940 \" href=\"UTD.htm?1/58/1967\">",
"     picture 4",
"    </a>",
"    ). All vascular layers of the sclera may be involved, but the maximal involvement is in the deep episcleral vascular plexus, which is displaced outward by the edematous, swollen sclera. On slit-lamp examination, there is profound dilatation of the deep episcleral vascular plexus.",
"   </p>",
"   <p>",
"    The different subtypes of scleritis are associated with variable presentations and distinctive findings on physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Diffuse anterior scleritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse anterior scleritis is associated with widespread ocular erythema and scleral edema but no nodules or areas of necrosis (",
"    <a class=\"graphic graphic_picture graphicRef55397 \" href=\"UTD.htm?17/46/18159\">",
"     picture 3",
"    </a>",
"    ). Only a small number of patients with diffuse anterior scleritis have disease that progresses to more aggressive forms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Nodular anterior scleritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized areas of firm, tender edema associated with intense dilation of the deep episcleral vessels may be found in nodular anterior scleritis (",
"    <a class=\"graphic graphic_picture graphicRef55940 \" href=\"UTD.htm?1/58/1967\">",
"     picture 4",
"    </a>",
"    ). With treatment, the pain and scleral tenderness resolve rapidly; however, the nodules may persist for months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Necrotizing anterior scleritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of necrotizing anterior scleritis with inflammation include severe ocular and periorbital pain that steadily worsens to excruciating levels over days or weeks. The pain is boring in quality, and usually worse in the early morning hours.",
"   </p>",
"   <p>",
"    Physical examination reveals scleral edema with intense vasodilatation of the deep episcleral plexus and superficial vessels (",
"    <a class=\"graphic graphic_picture graphicRef81029 \" href=\"UTD.htm?2/6/2159\">",
"     picture 5",
"    </a>",
"    ). With advanced disease, slit-lamp examination reveals obvious blood vessel closure associated with thinning of the sclera and a bluish discoloration, representing the underlying choroid visible through thinned scleral tissue (",
"    <a class=\"graphic graphic_picture graphicRef81136 \" href=\"UTD.htm?27/17/27935\">",
"     picture 6",
"    </a>",
"    ). Patients with this form of scleritis may also develop concurrent corneal ulceration and inflammation as a manifestation of peripheral ulcerative keratitis (PUK).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Scleromalacia perforans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scleromalacia perforans, commonly bilateral, is characterized by a remarkable lack of symptoms, particularly an absence of pain. The absence of pain results from the necrosis of pain fibers. Patients may notice a change in color of their sclera because of scleral thinning. They may also experience a decrease in vision caused by a change in the shape of the eyeball and an alteration of corneal curvature (an acquired astigmatism).",
"   </p>",
"   <p>",
"    Examination reveals thinning and atrophy of the episclera and loss of the normal episcleral vasculature. The anterior sclera develops localized tissue infarctions that have a yellowish-white color often referred to as \"marbleized\" (",
"    <a class=\"graphic graphic_picture graphicRef78096 \" href=\"UTD.htm?39/37/40542\">",
"     picture 7",
"    </a>",
"    ). Spontaneous perforation of the globe is rare, but reported.",
"   </p>",
"   <p>",
"    Patients with scleromalacia perforans need to be followed closely so that appropriate surgical and medical measures (eg, patch grafting) may be undertaken to maintain globe integrity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11511?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of scleritis\", section on 'Role of surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Posterior scleritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of posterior scleritis may include variable amounts of pain (often severe) that is difficult to localize. Diplopia and pain upon eye movement are common. In addition, these patients may have reduced vision due to compression of the retina or optic nerve.",
"   </p>",
"   <p>",
"    When posterior scleritis occurs in association with anterior scleritis, the eye is red. However, when posterior scleritis occurs in isolation, the eye is white. In this setting, the examiner may observe inflammation of parts of the posterior sclera only at extremes of the patient's gaze.",
"   </p>",
"   <p>",
"    Signs of posterior scleritis include exudative retinal detachment, annular choroidal detachment, optic disc edema, retinal folds, choroidal folds, retinal vasculitis, posterior uveitis, and glaucoma (",
"    <a class=\"graphic graphic_picture graphicRef65671 \" href=\"UTD.htm?42/8/43150\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11511?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of scleritis\", section on 'Course and prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Involvement of other ocular structures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the sclera, other ocular tissues may be involved in scleral inflammatory disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cornea &mdash; Chronic inflammation at the limbus can result in collagenolysis, epithelial ulceration, and the rapid development of peripheral ulcerative keratitis (PUK). In severe cases of PUK, the syndrome of \"corneal melt\" may lead swiftly to irreversible loss of vision in the eye [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22023/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22903?source=see_link&amp;anchor=H7#H7\">",
"       \"Ocular manifestations of rheumatoid arthritis\", section on 'Corneal inflammation and melting'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Uveal tract &mdash; Anterior uveitis occurs in up to 40 percent of eyes involved by scleritis and may lead to additional management considerations, eg, the use of glucocorticoid eyedrops. This is thought to be primarily a form of \"spillover\" inflammation, rather than a primary involvement of the uveal tract.",
"     </li>",
"     <li>",
"      Posterior segment &mdash; Posterior scleritis may be associated with vitritis, cystoid macular edema, and exudative retinal detachment. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11511?source=see_link&amp;anchor=H17#H17\">",
"       \"Treatment of scleritis\", section on 'Course and prognosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lens &mdash; Cataract formation is related to the severity of the scleritis. It primarily occurs in necrotizing scleritis, affecting approximately 20 percent of such patients. The incidence of cataract is much lower (less than 5 percent) with other subtypes of scleritis. Glucocorticoid therapy may be a contributor to cataract formation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=see_link\">",
"       \"Cataract in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     LABORATORY ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selected investigations should be guided by findings from the history and general physical examination (",
"    <a class=\"graphic graphic_table graphicRef69612 \" href=\"UTD.htm?26/57/27547\">",
"     table 2",
"    </a>",
"    ). Both routine and specialized serologic assays are important in the evaluation of patients with scleritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Routine tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following routine tests are useful in excluding systemic disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count &mdash; Patients with systemic inflammatory conditions frequently have abnormalities of the white blood cell count, platelet count, or hematocrit.",
"     </li>",
"     <li>",
"      Serum chemistry profile &mdash; This should include creatinine, blood urea nitrogen, electrolytes, albumin, total protein, and aminotransferases.",
"     </li>",
"     <li>",
"      Urinalysis with microscopy &mdash; Urinalysis with microscopic examination of the urine sediment is essential to excluding glomerulonephritis, a common occurrence in some of the systemic diseases associated with scleritis, particularly granulomatosis with polyangiitis (Wegener&rsquo;s) and systemic lupus erythematosus.",
"     </li>",
"     <li>",
"      Acute phase reactants &mdash; Patients with scleritis associated with a systemic illness are likely to have extremely high acute phase reactants. Both the erythrocyte sedimentation rate and serum C-reactive protein should be checked. These markers may also be useful in following responses to therapy and in detecting disease flares.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Specialized serologic assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific blood tests are important in the evaluation for possible underlying systemic illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22023/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rheumatoid factor &mdash; A positive rheumatoid factor assay is a nonspecific result, but extremely high titers of rheumatoid factor are usually found in the setting of rheumatoid vasculitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rheumatoid vasculitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42648?source=see_link\">",
"       \"Origin and utility of measurement of rheumatoid factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antibodies to cyclic citrullinated peptides &mdash; Antibodies to cyclic citrullinated peptides (anti-CCP antibodies) have a high specificity for rheumatoid arthritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link\">",
"       \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antineutrophil cytoplasmic antibody testing &mdash; Antineutrophil cytoplasmic antibody (ANCA) assays are likely to be positive in patients with granulomatosis with polyangiitis (Wegener&rsquo;s), microscopic polyangiitis, or the Churg-Strauss syndrome, particularly in cases associated with scleritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"       \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If an immunofluorescence assay is positive in either a cytoplasmic or perinuclear pattern (ie, C-ANCA or P-ANCA), then confirmation of the presence of the type of ANCA associated with systemic vasculitis is important, through enzyme immunoassays for antibodies to proteinase-3 or myeloperoxidase.",
"     </li>",
"     <li>",
"      Antinuclear antibody testing &mdash; Antinuclear antibody (ANA) testing is useful for the exclusion of connective tissue diseases related to systemic lupus erythematosus. A strongly positive ANA assay should be followed by additional serological testing to determine the specific disease state responsible for the ANA positivity. This additional testing may include serum complement levels (C3, C4), antibodies to double-stranded DNA, and antibodies to the Ro, La, Sm, or RNP antigens. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=see_link\">",
"       \"Measurement and clinical significance of antinuclear antibodies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     IMAGING STUDIES AND BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of imaging studies may contribute to the assessment of scleritis. Some are important for the diagnosis of systemic diseases associated with scleritis, while others are essential to the full assessment of scleritis itself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Chest imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest x-ray is performed to exclude infiltrates and nodules that might be associated with vasculitis, sarcoidosis, or infections such as tuberculosis. Abnormal findings on chest x-ray should be defined further with a computed tomography (CT) examination of the lungs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Imaging to evaluate scleritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of imaging studies are useful in the evaluation of scleritis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ultrasonography &mdash; B-scan ultrasonography can confirm the scleral thickening that is the hallmark of the disease. Imaging of the posterior pole is a critical aspect in the diagnosis of posterior scleritis.",
"     </li>",
"     <li>",
"      Cross-sectional imaging &mdash; CT and magnetic resonance imaging may be needed to exclude orbital lesions, particularly in cases of granulomatosis with polyangiitis (Wegener&rsquo;s), which may be complicated by orbital pseudotumors [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22023/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;On rare occasions, tissue biopsy is performed for the purpose of diagnosis. The usual indication for episcleral biopsy is for the exclusion of an infiltrative process such as sarcoidosis or a lymphoproliferative disorder. Larger procedures are occasionally required to diagnose the nature of a retrobulbar mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    Scleritis is a painful, destructive disorder that may cause visual loss and may also be associated with inflammation in other parts of the eye, such as the cornea, episclera, and uveal tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sclera is divided into an anterior and posterior portion. Anterior scleritis and posterior scleritis have different sets of implications for diagnosis, treatment, and prognosis. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Scleritis subtypes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior scleritis is subclassified into several subtypes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diffuse anterior scleritis",
"     </li>",
"     <li>",
"      Nodular anterior scleritis",
"     </li>",
"     <li>",
"      Necrotizing anterior scleritis, which has two forms: necrotizing anterior scleritis with inflammation and scleromalacia perforans",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diffuse, nodular, and necrotizing variants of posterior scleritis have also been identified, but the clinical distinction between these entities is more difficult due to anatomic challenges involved in the assessment of posterior scleritis. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Scleritis subtypes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Systemic disease associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scleritis is associated with a systemic disease in approximately 50 percent of cases. Most are rheumatic diseases (particularly rheumatoid arthritis and granulomatosis with polyangiitis (Wegener&rsquo;s)). Most of the remaining cases are due to infection. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Systemic disease associations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, scleritis is a manifestation of necrotizing vasculitis, often associated with immune complex deposition in blood vessel walls, granulomatous inflammation, thrombotic occlusion of blood vessels, and fibrinoid necrosis. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior scleritis (with ocular erythema and other examination features as well as intense pain) is usually obvious to both the patient and clinician. Posterior scleritis is generally more difficult to diagnose since it is often not seen on examination.",
"   </p>",
"   <p>",
"    Diffuse anterior, nodular, and necrotizing scleritis subtypes can be distinguished readily on physical examination, particularly when a slit-lamp is used. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Necrotizing anterior scleritis is particularly likely to involve other ocular structures, such as the cornea (PUK), episclera, and uveal tract. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Involvement of other ocular structures'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Laboratory assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both routine and specialized serologic assays are important in the exclusion of systemic diseases. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Laboratory assessment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Useful routine tests are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Serum chemistry profile",
"     </li>",
"     <li>",
"      Urinalysis with microscopy",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate and C-reactive protein",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Helpful specialized assays are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Rheumatoid factor",
"     </li>",
"     <li>",
"      Anti-cyclic citrullinated peptide antibodies",
"     </li>",
"     <li>",
"      Antineutrophil cytoplasmic antibody testing",
"     </li>",
"     <li>",
"      Antinuclear antibody testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest imaging (x-ray and, if positive, computed tomography of the chest) is helpful in excluding systemic diseases. In addition, both ultrasonography and cross-sectional imaging studies of the orbit are useful in diagnosing posterior scleritis. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Imaging studies and biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue biopsy is seldom required for diagnosis but is occasionally performed to exclude infiltrative or malignant disorders.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22023/abstract/1\">",
"      Okhravi N, Odufuwa B, McCluskey P, Lightman S. Scleritis. Surv Ophthalmol 2005; 50:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22023/abstract/2\">",
"      Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol 2000; 130:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22023/abstract/3\">",
"      McCluskey PJ, Watson PG, Lightman S, et al. Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology 1999; 106:2380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22023/abstract/4\">",
"      Horo S, Sudharshan S, Biswas J. Recurrent posterior scleritis--report of a case. Ocul Immunol Inflamm 2006; 14:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22023/abstract/5\">",
"      Sainz de la Maza M, Foster CS. Necrotizing scleritis after ocular surgery. A clinicopathologic study. Ophthalmology 1991; 98:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22023/abstract/6\">",
"      D&iacute;az-Valle D, Ben&iacute;tez del Castillo JM, Castillo A, et al. Immunologic and clinical evaluation of postsurgical necrotizing sclerocorneal ulceration. Cornea 1998; 17:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22023/abstract/7\">",
"      Scott JA, Clearkin LG. Surgically induced diffuse scleritis following cataract surgery. Eye (Lond) 1994; 8 ( Pt 3):292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22023/abstract/8\">",
"      Fong LP, Sainz de la Maza M, Rice BA, et al. Immunopathology of scleritis. Ophthalmology 1991; 98:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22023/abstract/9\">",
"      Scott DG, Bacon PA, Tribe CR. Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine (Baltimore) 1981; 60:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22023/abstract/10\">",
"      Squirrell DM, Winfield J, Amos RS. Peripheral ulcerative keratitis 'corneal melt' and rheumatoid arthritis: a case series. Rheumatology (Oxford) 1999; 38:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22023/abstract/11\">",
"      Lin P, Bhullar SS, Tessler HH, Goldstein DA. Immunologic markers as potential predictors of systemic autoimmune disease in patients with idiopathic scleritis. Am J Ophthalmol 2008; 145:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22023/abstract/12\">",
"      Hoang LT, Lim LL, Vaillant B, et al. Antineutrophil cytoplasmic antibody-associated active scleritis. Arch Ophthalmol 2008; 126:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22023/abstract/13\">",
"      Pakrou N, Selva D, Leibovitch I. Wegener's granulomatosis: ophthalmic manifestations and management. Semin Arthritis Rheum 2006; 35:284.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5599 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-08BE826B45-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_32_22023=[""].join("\n");
var outline_f21_32_22023=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SCLERITIS SUBTYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Anterior scleritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Diffuse anterior scleritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Nodular anterior scleritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Necrotizing anterior scleritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Subtypes of posterior scleritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SYSTEMIC DISEASE ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ocular examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Diffuse anterior scleritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Nodular anterior scleritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Necrotizing anterior scleritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Scleromalacia perforans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Posterior scleritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Involvement of other ocular structures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      LABORATORY ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Routine tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Specialized serologic assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      IMAGING STUDIES AND BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Chest imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Imaging to evaluate scleritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Systemic disease associations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Laboratory assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5599\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5599|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/23/8561\" title=\"figure 1\">",
"      Eye anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5599|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/30/13797\" title=\"picture 1\">",
"      Bilateral scleritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/8/43150\" title=\"picture 2\">",
"      Posterior scleritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/46/18159\" title=\"picture 3\">",
"      Diffuse anterior scleritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/58/1967\" title=\"picture 4\">",
"      Nodular anterior scleritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/6/2159\" title=\"picture 5\">",
"      Ant scleritis inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/17/27935\" title=\"picture 6\">",
"      Chronic scleritis inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/37/40542\" title=\"picture 7\">",
"      Scleromalacia perforans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5599|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/5/36955\" title=\"table 1\">",
"      Scleritis and systemic diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/57/27547\" title=\"table 2\">",
"      Tests in episcleritis scleritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=related_link\">",
"      Cataract in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=related_link\">",
"      Clinical manifestations and diagnosis of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=related_link\">",
"      Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/80?source=related_link\">",
"      Episcleritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22903?source=related_link\">",
"      Ocular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42648?source=related_link\">",
"      Origin and utility of measurement of rheumatoid factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33561?source=related_link\">",
"      Retinal vasculitis associated with systemic disorders and infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11511?source=related_link\">",
"      Treatment of scleritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=related_link\">",
"      Uveitis: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_32_22024="Perindopril: Drug information";
var content_f21_32_22024=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Perindopril: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/13/17621?source=see_link\">",
"    see \"Perindopril: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aceon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Perindopril&reg;;",
"     </li>",
"     <li>",
"      Coversyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F208463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F208427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Heart failure (Canadian labeling; unlabeled use in U.S.):",
"     </b>",
"     Initial: 2 mg once daily; if necessary, may titrate over 2-4 weeks to 4 mg once daily. The American College of Cardiology/ American Heart Association (ACC/AHA) 2009 Heart Failure Guidelines recommend an initial dose of 2 mg once daily with dose titration at 1- to 2- week intervals to a target dose of 8-16 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 4 mg/day but may be titrated to response; usual range: 4-8 mg/day (may be given in 2 divided doses); increase at 1- to 2-week intervals (maximum: 16 mg/day).",
"     <b>",
"      Note:",
"     </b>",
"     The Canadian labeling recommended maximum dose is 8 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Concomitant therapy with diuretics: To reduce the risk of hypotension, discontinue diuretic, if possible,  2-3 days prior to initiating perindopril. If unable to stop diuretic, initiate perindopril at 2-4 mg/day (given in 1-2 divided doses) and monitor blood pressure closely for the first 2 weeks of therapy, and after any dose adjustment of perindopril or diuretic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Stable coronary artery disease:",
"     </b>",
"     Oral: Initial: 4 mg once daily for 2 weeks; then increase as tolerated to 8 mg once daily.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F208428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     &gt;65 years: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     U.S. labeling: Initial: 4 mg/day; maintenance: 8 mg/day; experience with doses &gt;8 mg/day is limited; may be given in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Canadian labeling: Initial: 2 mg/day; if necessary may increase dose after 4 weeks to 4 mg/day; then to 8 mg/day (based on renal function); may be given in 1 or 2 divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     ACCF/AHA Expert Consensus recommendations: Consider lower initial doses and titrating to response (Aronow, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Stable coronary artery disease:",
"     </b>",
"     &gt;70 years: Oral:  Initial: 2 mg/day for 1 week; then increase as tolerated to 4 mg/day for 1 week; then increase as tolerated to 8 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F208429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: Initial: 2 mg/day; maintenance dosing not to exceed 8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Safety and efficacy not established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hemodialysis: Perindopril and its metabolites are dialyzable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: Initial: 4 mg/day; maintenance dosing not to exceed 8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-60 mL/minute: 2 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-30 mL/minute: 2 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hemodialysis (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute): 2 mg on dialysis days (given after dialysis)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F1076310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F208401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2 mg, 4 mg, 8 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aceon&reg;: 2 mg, 4 mg, 8 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F208387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12806236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer prior to a meal.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F208402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension; reduction of cardiovascular mortality or nonfatal myocardial infarction in patients with stable coronary artery disease",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional use (unlabeled use in U.S.): Treatment of mild-moderate (NYHA I-III) heart failure",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F1044879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To delay the progression of nephropathy and reduce risks of cardiovascular events in hypertensive patients with type 1 or 2 diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F208461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (incidence is higher in women, 3:1) (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (4%), chest pain (2%), ECG abnormal (2%), palpitation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (8%, less than placebo), sleep disorders (3%), depression (2%), fever (2%), nervousness (1%), somnolence (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia (1%, less than placebo), triglycerides increased (1%), menstrual disorder (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (4%), abdominal pain (3%), nausea (2%), vomiting (2%), dyspepsia (2%), flatulence (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (3%), sexual dysfunction (male 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (8%), back pain (6%), lower extremity pain (5%), upper extremity pain (3%), hypertonia (3%), paresthesia (2%), joint pain (1%), myalgia (1%), arthritis (1%), neck pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Proteinuria (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (9%), sinusitis (5%), rhinitis (5%), pharyngitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (2%), ear infection (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (3%), seasonal allergy (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Some reactions occurred at an incidence &gt;1% but &le; placebo.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Amnesia, anaphylaxis, angioedema, anxiety, AST increased, dyspnea, erythema, fluid retention, gout, leukopenia, migraine, MI, nephrolithiasis, neutropenia, orthostatic hypotension, pruritus, psychosocial disorder, pulmonary fibrosis, purpura, stroke, syncope, urinary retention, vertigo, visual hallucinations (Doane, 2013)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Additional adverse effects that have been reported with",
"     <b>",
"      ACE inhibitors",
"     </b>",
"     include agranulocytosis (especially in patients with renal impairment or collagen vascular disease), neutropenia, anemia, bullous pemphigoid, cardiac arrest, eosinophilic pneumonitis, exfoliative dermatitis, falls, hepatic failure, hyponatremia, jaundice, pancreatitis (acute), pancytopenia, pemphigus, psoriasis, thrombocytopenia; decreases in creatinine clearance in some elderly hypertensive patients or those with chronic renal failure, and worsening of renal function in patients with bilateral renal artery stenosis or hypovolemic patients (diuretic therapy). In addition, a syndrome which may include fever, myalgia, arthralgia, interstitial nephritis, vasculitis, rash, eosinophilia and positive ANA, and elevated ESR has been reported with ACE inhibitors.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F208406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to perindopril, any other ACE inhibitor, or any component of the formulation; angioedema related to previous treatment with an ACE inhibitor; concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): History of hereditary/idiopathic angioedema; pregnant women during the second and third trimesters",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F208391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose), angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans and patients with idiopathic or hereditary angioedema may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with previous angioedema associated with ACE inhibitor therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium containing salts.  Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers (ARBs) and renin inhibitors: Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss, or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F208396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F208418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Perindopril active metabolite concentrations may be lowered if taken with food. Potassium supplements and/or potassium-containing salts may cause or worsen hyperkalemia. Management: Consult prescriber before consuming a potassium-rich diet, potassium supplements, or salt substitutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Some herbal medications may worsen hypertension (eg, licorice); others may increase the antihypertensive effect of perindopril (eg, shepherd's purse). Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice, and yohimbe. Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F208397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F208409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Perindopril crosses the placenta; teratogenic effects may occur following maternal use during pregnancy. Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Their use in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant. ACE inhibitors are not recommended during pregnancy to treat maternal hypertension or heart failure. Use of an ACE inhibitor should also be avoided in any woman of reproductive age. Women who are planning a pregnancy should be considered for other medication options if an ACE inhibitor is currently prescribed or the ACE inhibitor should be discontinued as soon as possible once pregnancy is detected. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed to an ACE inhibitor",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F208432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6199085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if perindopril is excreted in human breast milk. The manufacturer recommends that caution be exercised when administering perindopril to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F208408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Aceon Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $293.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (100): $356.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Perindopril Erbumine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $189.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $221.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (100): $268.76",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F208399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; serum creatinine and potassium; if patient has collagen vascular disease and/or renal impairment, periodically monitor CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F208410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acerpril (KP);",
"     </li>",
"     <li>",
"      Acertil (CL, HK, KP, TW);",
"     </li>",
"     <li>",
"      Acertil AR (HK);",
"     </li>",
"     <li>",
"      Bioprexum (ID);",
"     </li>",
"     <li>",
"      Cadoril (PH);",
"     </li>",
"     <li>",
"      Covapril (MY);",
"     </li>",
"     <li>",
"      Coverene (AR);",
"     </li>",
"     <li>",
"      Coverex (BG, CZ, HN, HU, PL, SE);",
"     </li>",
"     <li>",
"      Coversum (AT, CH, DE);",
"     </li>",
"     <li>",
"      Coversyl (AE, BB, BE, BM, BR, BS, BZ, CN, CO, CR, DK, DO, ES, FI, FR, GB, GR, GT, GY, IE, IN, IT, JM, JP, KW, LU, MT, MX, MY, NI, NL, NZ, PA, PE, PH, PK, PR, PT, PY, SA, SG, SR, SV, TH, TR, TT, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Covinace (MY);",
"     </li>",
"     <li>",
"      Covrix (TH);",
"     </li>",
"     <li>",
"      Hypergo (PH);",
"     </li>",
"     <li>",
"      Perigard (MY, PH);",
"     </li>",
"     <li>",
"      Perinace (MY, SG);",
"     </li>",
"     <li>",
"      Perindo (AU);",
"     </li>",
"     <li>",
"      Peryndopryl Anpharm (PL);",
"     </li>",
"     <li>",
"      Prenessa (EE);",
"     </li>",
"     <li>",
"      Prestarium (HR, PL);",
"     </li>",
"     <li>",
"      Prestoril (IL);",
"     </li>",
"     <li>",
"      Prinwin (TW);",
"     </li>",
"     <li>",
"      Provinace (HK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F208390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Perindopril is a prodrug for perindoprilat, which acts as a competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which, in turn, causes an increase in plasma renin activity and a reduction in aldosterone secretion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F208405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Perindopril: 60%; Perindoprilat: 10% to 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatically hydrolyzed to active metabolite, perindoprilat (~17% to 20% of a dose) and other inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Perindopril: 75%; Perindoprilat ~25% (~16% with food)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Parent drug: 1.5-3 hours; Metabolite: Effective: 3-10 hours, Terminal: 30-120 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Chronic therapy: Perindopril: 1 hour; Perindoprilat: 3-7 hours (maximum perindoprilat serum levels are 2-3 times higher and T",
"     <sub>",
"      max",
"     </sub>",
"     is shorter following chronic therapy); CHF: Perindoprilat: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (75%, 4% to 12% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, \"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(23):2981-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/12479763/pubmed\" id=\"12479763\" target=\"_blank\">",
"        12479763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636. Available at: file://www.circulationaha.org/cgi/content/full/110/5/588. Last accessed October 26, 2004.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chase MP, Fiarman GS, Scholz FJ, et al, &ldquo;Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 2000, 31(3):254-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/11034011/pubmed\" id=\"11034011\" target=\"_blank\">",
"        11034011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al, &ldquo;Major Congenital Malformations After First-Trimester Exposure to ACE Inhibitors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(23):2443-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/16760444/pubmed\" id=\"16760444\" target=\"_blank\">",
"        16760444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doane J and Stults B, &ldquo;Visual Hallucinations Related to Angiotensin-Converting Enzyme Inhibitor Use: Case Reports and Review,&rdquo;",
"      <i>",
"       J Clin Hypertens (Greenwich)",
"      </i>",
"      , 2013 [epub ahead pf print].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fox KM and EURopean Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators, \"Efficacy of Perindopril in Reduction of Cardiovascular Events Among Patients With Stable Coronary Artery Disease: Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial (The EUROPA Study),\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):782-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/13678872/pubmed\" id=\"13678872\" target=\"_blank\">",
"        13678872",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mastrobattista JM, &ldquo;Angiotensin Converting Enzyme Inhibitors in Pregnancy,&rdquo;",
"      <i>",
"       Semin Perinatol",
"      </i>",
"      , 1997, 21(2):124-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/9201818/pubmed\" id=\"9201818\" target=\"_blank\">",
"        9201818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer M, Poole-Wilson PA, Armstrong PW, et al, &ldquo;Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 100(23):2312-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/10587334/pubmed\" id=\"10587334\" target=\"_blank\">",
"        10587334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, Greaves SC, Arnold JM, et al, &ldquo;Early Versus Delayed Angiotensin-Converting Enzyme Inhibition Therapy in Acute Myocardial Infarction. The Healing and Early Afterload Reducing Therapy Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1997, 95(12):2643-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/9193433/pubmed\" id=\"9193433\" target=\"_blank\">",
"        9193433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, \"Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(20):1893-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/14610160/pubmed\" id=\"14610160\" target=\"_blank\">",
"        14610160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quan A , &ldquo;Fetopathy Associated With Exposure to Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists,&rdquo;",
"      <i>",
"       Early Hum Dev",
"      </i>",
"      , 2006, 82(1):23-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/16427219/pubmed\" id=\"16427219\" target=\"_blank\">",
"        16427219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smoger SH and Sayed MA, &ldquo;Simultaneous Mucosal and Small Bowel Angioedema Due to Captopril,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1998, 91(11):1060-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/9824192/pubmed\" id=\"9824192\" target=\"_blank\">",
"        9824192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yusuf S, Sleight P, Pogue J, et al, \"Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(3):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22024/abstract-text/10639539/pubmed\" id=\"10639539\" target=\"_blank\">",
"        10639539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9758 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-0869272E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_32_22024=[""].join("\n");
var outline_f21_32_22024=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709206\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208422\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208423\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208463\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208427\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208428\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208429\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1076310\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208401\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208387\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806236\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208402\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044879\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208461\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208406\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208391\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299854\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208396\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208418\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208397\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208409\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208432\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6199085\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208408\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208399\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208410\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208390\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208405\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9758\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9758|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/13/17621?source=related_link\">",
"      Perindopril: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_32_22025="Erythromycin (systemic): Pediatric drug information";
var content_f21_32_22025=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Erythromycin (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?25/6/25705?source=see_link\">",
"    see \"Erythromycin (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/23/22901?source=see_link\">",
"    see \"Erythromycin (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8086256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      E.E.S.&reg;;",
"     </li>",
"     <li>",
"      Ery-Tab&reg;;",
"     </li>",
"     <li>",
"      EryPed&reg;;",
"     </li>",
"     <li>",
"      Erythro-RX;",
"     </li>",
"     <li>",
"      Erythrocin&reg;;",
"     </li>",
"     <li>",
"      Erythrocin&reg; Lactobionate-I.V.;",
"     </li>",
"     <li>",
"      PCE&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8086257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Erythro Base&reg;;",
"     </li>",
"     <li>",
"      Apo-Erythro E-C&reg;;",
"     </li>",
"     <li>",
"      Apo-Erythro-ES&reg;;",
"     </li>",
"     <li>",
"      Apo-Erythro-S&reg;;",
"     </li>",
"     <li>",
"      EES&reg;;",
"     </li>",
"     <li>",
"      Erybid&trade;;",
"     </li>",
"     <li>",
"      Eryc&reg;;",
"     </li>",
"     <li>",
"      Novo-Rythro Estolate;",
"     </li>",
"     <li>",
"      Novo-Rythro Ethylsuccinate;",
"     </li>",
"     <li>",
"      Nu-Erythromycin-S;",
"     </li>",
"     <li>",
"      PCE&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10484225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Macrolide",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      General dosing:",
"     </b>",
"     Oral (ethylsuccinate); I.V. (lactobionate): (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bodyweight &le;2 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA &le;7 days: 10 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA 8-28 days: 10 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bodyweight &gt;2 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA &le;7 days: 10 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA 8-28 days: 10 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chlamydial conjunctivitis or chlamydial pneumonia:",
"     </b>",
"     Oral: Ethylsuccinate or base: Full-term neonates: 50 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours for 14 days; a repeat course may be necessary (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pertussis; treatment or postexposure prophylaxis:",
"     </b>",
"     Oral: Ethylsuccinate: 10 mg/kg/dose 4 times daily for 14 days;",
"     <b>",
"      Note:",
"     </b>",
"     Due to association of erythromycin and infantile hypertrophic pyloric stenosis in neonates, azithromycin is considered first-line agent in infants &lt;1 month of age (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prokinetic (GI motility) agent:",
"     </b>",
"     Limited data available; efficacy results variable; optimal dose not established; further studies are needed: PNA &ge;14 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Low-dose regimen: Oral: 1.5-2.5 mg/kg/dose every 6 hours; therapy started after initiation of enteral feeds; has been studied in GA &lt;32 weeks (Chicella, 2005; Oei, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermediate-dose regimen: Oral: 5 mg/kg/dose every 6 hours; therapy started after initiation of enteral feeds; dosing based on a randomized, double-blind, placebo-controlled trial of 45 VLBW neonates (n=19 treatment group; mean GA: 28.4 weeks); treatment was initiated at a mean PNA: 21.9 + 7.7 days and continued for 14 days (Ng, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     High-dose regimens (antimicrobial doses): 10-12.5 mg/kg/dose every 6 hours orally have been used after initiation of enteral feeds; efficacy has not been demonstrated in the majority of trials. Exposure to these doses in neonates with PNA &le;14 days has been associated with a 10-fold increase in the risk of hypertrophic pyloric stenosis (Chicella, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10485224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/6/25705?source=see_link\">",
"      see \"Erythromycin (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing, susceptible infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Oral: Base, ethylsuccinate, stearate: 30-50 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6-8 hours usually; for severe infection may double dose; maximum daily dose: Mild to moderate infection: 2000 mg/",
"     <b>",
"      day",
"     </b>",
"     ; severe infection: 4000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     I .V.: Lactobionate: 15-20 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours; maximum daily dose: 4000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Alternate dosing (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Mild to moderate infection: Oral: 50 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6-8 hours; maximum daily dose: 2000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Severe infection: I.V.: Lactobionate: 5 mg/kg/dose every 6 hours, maximum daily dose: 4000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Anthrax, cutaneous, community-acquired",
"     </b>",
"     (Stevens, 2005):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: 10 mg/kg/dose every 6 hours; treatment duration of 5-9 days usually adequate in most cases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.:  20-40 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours; maximum daily dose: 4000 mg; treatment duration of 5-9 days usually adequate in most cases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Bartonella",
"      </i>",
"      sp infections [bacillary angiomatosis (BA), peliosis hepatis (PH)]:",
"     </b>",
"     Oral: Ethylsuccinate: 10 mg/kg/ dose 4 times daily ; maximum daily dose: 2000 mg/day; treatment duration: BA: 3 months; PH: 4 months (Rolain, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Chlamydia trachomatis",
"      </i>",
"      infection",
"     </b>",
"     (CDC, 2010;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Conjunctivitis or pneumonia: Oral (base or ethylsuccinate): 50 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours for 14 days; maximum daily dose: 2000 mg/",
"     <b>",
"      day",
"     </b>",
"     ; a repeat course may be necessary; for severe trachoma, longer durations may be necessary (40 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Anogenital tract infection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children and Adolescents &lt;45 kg: Oral (base or ethylsuccinate): 50 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours for 14 days; maximum daily dose: 2000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents &ge;45 kg: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Base: 500 mg 4 times daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Ethylsuccinate: 800 mg 4 times daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Lymphogranuloma venereum (LGV): Adolescents &ge;45 kg: Base: 500 mg 4 times daily for 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Impetigo:",
"     </b>",
"     Oral: 10 mg/kg/dose 4 times daily (Stevens, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Lyme Disease:",
"     </b>",
"     Oral: 50 mg/kg/day divided every 6 hours for 14-21 days; maximum dose: 500 mg (Wormser, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pertussis",
"     </b>",
"     (CDC, 2005;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants 1-5 months: Oral: 10 mg/kg/dose 4 times daily for 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants &ge;6 months and Children: Oral: 10 mg/kg/dose 4 times daily for 7-14 days; maximum daily dose: 2000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents: Oral: 500 mg 4 times daily for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pneumonia, community-acquired (CAP)",
"     </b>",
"     (Bradley, 2011): Infants &gt;3 months, Children, and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     A beta-lactam antibiotic should be added if typical bacterial pneumonia cannot be ruled out.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Presumed atypical (",
"     <i>",
"      M. pneumoniae, C. pneumoniae, C. trachomatis",
"     </i>",
"     ); mild infection or step-down therapy: Oral: 10 mg/kg/dose every 6 hours; maximum daily dose: 2000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Moderate to severe atypical infection: I.V.: Lactobionate: 5 mg/kg/dose every 6 hours; maximum daily dose: 4000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Preoperative bowel preparation:",
"     </b>",
"     Oral: Base:  20 mg/kg administered at 1, 2, and 11 PM on the day before surgery combined with mechanical cleansing of the large intestine and oral neomycin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Prokinetic (GI motility) agent:",
"     </b>",
"     Limited data available:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Diagnosis; gastric emptying study (provocative testing): I.V.: 2.8 mg/kg infused over 20 minutes was reported from one center's experience; maximum dose: 250 mg (Waseem, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment: Oral: 3 mg/kg/dose 4 times daily; may increase as needed to effect; maximum dose: 10 mg/kg or 250 mg (Rodriguez, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pneumococcal, prophylaxis  in penicillin-allergic patients with sickle cell disease (SCD) and functional or anatomic asplenia",
"     </b>",
"     (Knight-Madden, 2001): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants and Children: 4 months to &lt;3 years: 125 mg twice daily; salt not specified",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 3-4 years: 250 mg twice daily; salt not specified",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing: Note:",
"     </b>",
"     Due to differences in absorption, 400 mg erythromycin ethylsuccinate produces the same serum levels as 250 mg erythromycin base or stearate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: Lactobionate: 15-20 mg/kg/day divided every 6 hours or given as a continuous infusion over 24 hours, not to exceed 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Base, delayed release: 333 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Stearate or base: 250-500 mg every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Ethylsuccinate: 400-800 mg every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Chancroid:",
"     </b>",
"     Oral: Base: 500 mg 3 times/day for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Chlamydia trachomatis:",
"      </i>",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Base: 500 mg 4 times/day for 7 days",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Ethylsuccinate: 800 mg 4 times/day for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pertussis:",
"     </b>",
"     Oral: 500 mg every 6 hours for 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Preoperative bowel preparation:",
"     </b>",
"     Oral: 1 g erythromycin base at 1, 2, and 11 PM on the day before surgery combined with mechanical cleansing of the large intestine and oral neomycin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Infants, Children, and Adolescents: The following adjustments have been recommended (Aronoff, 2007).",
"     <b>",
"      Note:",
"     </b>",
"     Renally adjusted dose recommendations are based on oral doses of 30-50 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6-8 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     GFR &ge;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     :  No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     GFR &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ; intermittent hemodialysis, peritoneal dialysis: 10-17 mg/kg/dose every 8 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8086458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed release, enteric coated pellets, oral, as base: 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for suspension, oral, as ethylsuccinate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E.E.S.&reg;: Erythromycin activity 200 mg/5 mL (100 mL, 200 mL) [contains sodium 25.9 mg (1.1 mEq)/5 mL; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as lactobionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Erythrocin&reg; Lactobionate-I.V.: Erythromycin activity 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for prescription compounding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Erythro-RX: USP: 100% (50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as ethylsuccinate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EryPed&reg;: Erythromycin activity 200 mg/5 mL (100 mL) [contains sodium 117.5 mg (5.1 mEq)/5 mL; fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EryPed&reg;: Erythromycin activity 400 mg/5 mL (100 mL) [contains sodium 117.5 mg (5.1 mEq)/5 mL; banana flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as base: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as ethylsuccinate: Erythromycin activity 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E.E.S.&reg;: Erythromycin activity 400 mg [contains potassium 10 mg (0.3 mEq)/tablet, sodium 47 mg (2 mEq)/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as stearate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Erythrocin&reg;: Erythromycin activity 250 mg [contains potassium 5 mg (0.1 mEq)/tablet, sodium 56.7 mg (2.5 mEq)/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Erythrocin&reg;: Erythromycin activity 500 mg [sodium free; contains potassium 7 mg (0.2 mEq)/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, enteric coated, oral, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ery-Tab&reg;: 250 mg [contains sodium 8.3 mg (0.4 mEq)/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ery-Tab&reg;: 333 mg [contains sodium 11.2 mg (0.5 mEq)/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ery-Tab&reg;: 500 mg [contains sodium 16.7 mg (0.7 mEq)/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, polymer coated particles, oral, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PCE&reg;: 333 mg [contains sodium 0.5 mg (0.02mEq)/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PCE&reg;: 500 mg [dye free, sodium free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8086259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule,  tablet (as base, ethylsuccinate, and stearate)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10485264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Avoid milk and acidic beverages 1 hour before or after a dose; administer after food to decrease GI discomfort; ethylsuccinate chewable tablets should not be swallowed whole; do not chew or break delayed release capsule or enteric coated tablets, swallow whole",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Administer by I.V. intermittent or continuous infusion diluted in either dextrose or saline solutions to a concentration of 1-2.5 mg/mL; maximum concentration: 5 mg/mL; I.V. intermittent infusions may be administered over 20-60 minutes; to decrease vein irritation, administer as a continuous infusion at a concentration &le;1 mg/mL; prolonging the infusion duration over 60 minutes or longer has been recommended to decrease the cardiotoxic effects of erythromycin; pH (lactobionate): 6.5-7.5 (reconstituted with SW or D",
"     <sub>",
"      5",
"     </sub>",
"     W to a 50 mg/mL concentration)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8086368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Erythromycin lactobionate:",
"     </b>",
"     Stable in NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      10",
"     </sub>",
"     W;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amiodarone, anidulafungin, bivalirudin, cyclophosphamide, cyclosporine, dexmedetomidine, diltiazem, doxapram, enalaprilat, esmolol, famotidine, fenoldopam, foscarnet, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, idarubicin, labetalol, linezolid, lorazepam, magnesium sulfate, meperidine, midazolam, morphine, multivitamins, nicardipine, oxytocin, tacrolimus, theophylline, vitamin B complex with C, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cefepime, fluconazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftazidime, heparin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ampicillin, cloxacillin, heparin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10485204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Store vial at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); after reconstitution with SWI, solution is stable for 2 weeks under refrigeration or 24 hours at room temperature. Stability of lactobionate is pH-dependent; stable at pH 6-8; longest stability in NS. Stability of parenteral admixture at room temperature and at refrigeration temperature is 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets, capsules, powder for reconstitution, or granules for suspension: Store at &lt;30&deg;C (&lt;86&deg;F); after mixing the powder for suspension, store at &le;25&deg;C (77&deg;F) and use within 35 days; after mixing the granules for suspension, refrigerate and use within 10 days.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10485164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mild to moderately severe infections of the upper and lower respiratory tract and skin infections due to susceptible",
"     <i>",
"      streptococcus",
"     </i>",
"     and",
"     <i>",
"      staphylococcus",
"     </i>",
"     sp. and",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"     ; other susceptible bacterial infections, including",
"     <i>",
"      Mycoplasma pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      Legionella pneumonia",
"     </i>",
"     , nongonococcal urethritis, Lyme disease, diphtheria, pertussis, chancroid,",
"     <i>",
"      Chlamydia",
"     </i>",
"     ,",
"     <i>",
"      Ureaplasma",
"     </i>",
"     , and",
"     <i>",
"      Campylobacter",
"     </i>",
"     gastroenteritis, syphilis, prophylaxis of recurrent rheumatic fever in penicillin- or sulfa-allergic patients (all indications: FDA approved in all ages); has also been used in conjunction with neomycin for decontaminating the bowel for surgery; prophylaxis of pneumococcal infections in children with sickle cell disease (SCD), and functional or anatomic asplenia who are penicillin allergic",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8085309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Erythromycin may be confused with azithromycin, clarithromycin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Eryc&reg; may be confused with Emcyt&reg;, Ery-Tab&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8086286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, torsade de pointes, ventricular arrhythmia, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema multiforme, pruritus, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, infantile hypertrophic pyloric stenosis, nausea, oral candidiasis, pancreatitis, pseudomembranous colitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice (most common with estolate), hepatitis, liver function tests abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis at the injection site, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylaxis, hypersensitivity reactions, interstitial nephritis, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10485165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to erythromycin, other macrolides, or any component; concomitant administration with pimozide, astemizole, terfenadine, cisapride, ergotamine, dihydroergotamine, lovastatin, or simvastatin",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10485167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment. Use with caution in patients with myasthenia gravis; erythromycin has been associated with aggravation of weakness.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10485166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatic impairment with or without jaundice has occurred primarily in older children and adults; reported incidence in children is ~0.1% and in adults is 0.25%; it may be accompanied by malaise, nausea, vomiting, abdominal colic, and fever; discontinue use if these occur. Infantile hypertrophic pyloric stenosis with symptoms of nonbilious vomiting or irritability with feeding has been reported in 5% of infants who received erythromycin for pertussis prophylaxis. Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Risk of serious cardiac arrhythmias exist in patients receiving erythromycin and pimozide, astemizole, terfenadine, or cisapride; do not use concurrently with erythromycin. Erythromycin has been associated with rare QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation and ventricular arrhythmias, including torsade de pointes; avoid use in patients with prolonged QT interval, uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or concurrent use of Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, dofetilide, sotalol) antiarrhythmic agents. Use caution with other medication relying on CYP3A4 metabolism (eg, fluconazole, ketoconazole, itraconazole, diltiazem, verapamil); high potential for drug interactions exists. Avoid concurrent use with strong CYP3A inhibitors due to increased risk of sudden cardiac death (Ray, 2004). Rhabdomyolysis has been reported in seriously ill patients receiving erythromycin and lovastatin or simvastatin concomitantly; concurrent use is contraindicated (per manufacturer labeling of lovastatin and simvastatin.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Erythromycin lactobionate injection may contain benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates; the \"gasping syndrome\" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use erythromycin lactobionate injection products containing benzyl alcohol with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8086288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (moderate), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8086289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Macrolide Antibiotics may decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Macrolide Antibiotics may decrease the metabolism of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Macrolide Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Vinca Alkaloids): Macrolide Antibiotics may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues.  Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Macrolide Antibiotics may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Macrolide Antibiotics may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.  Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Macrolide Antibiotics may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Macrolide Antibiotics may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Macrolide Antibiotics may decrease the metabolism of Cilostazol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Macrolide Antibiotics may decrease the metabolism of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Macrolide Antibiotics may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Macrolide Antibiotics may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Macrolide Antibiotics may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Macrolide Antibiotics may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Disopyramide. Macrolide Antibiotics may decrease the metabolism of Disopyramide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Macrolide Antibiotics may decrease the metabolism of Eletriptan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Macrolide Antibiotics may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Macrolide Antibiotics may enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Macrolide Antibiotics. Clarithromycin AUC is reduced and levels of the active metabolite (14-hydroxy-clarithromycin) are modestly increased. Management: For the treatment of",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex, consider changing to alternative agent, such as azithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Erythromycin (Systemic) may increase the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Macrolide Antibiotics may decrease the metabolism of HMG-CoA Reductase Inhibitors.  Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fluvastatin; Pravastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lincosamide Antibiotics: May diminish the therapeutic effect of Erythromycin (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Erythromycin (Systemic) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Pimozide. Macrolide Antibiotics may decrease the metabolism of Pimozide. This mechanism may not apply to azithromycin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Macrolide Antibiotics may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Macrolide Antibiotics may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Macrolide Antibiotics may increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: Macrolide Antibiotics may decrease the metabolism of Rifamycin Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifapentine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Erythromycin (Systemic) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Macrolide Antibiotics may decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE; PARoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Erythromycin (Systemic) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary artery hypertension, concurrent use with erythromycin is not recommended.  When used for treatment of erectile dysfunction, consider using a lower starting dose of 25 mg in patients who are also taking erythromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Erythromycin (Systemic) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Macrolide Antibiotics may decrease the metabolism of Sirolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Erythromycin (Systemic) may increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Erythromycin (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Macrolide Antibiotics may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terfenadine: Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Macrolide Antibiotics may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Erythromycin (Systemic) may increase the serum concentration of Vardenafil.  Management: Limit dose of vardenafil film-coated tablets (Levitra)  to 5 mg per 24 hours with concomitant use of erythromycin. Concomitant use of vardenafil orally disintegrating tablets (Staxyn) with erythromycin is not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Macrolide Antibiotics may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zafirlukast: Erythromycin (Systemic) may decrease the serum concentration of Zafirlukast.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zopiclone: Macrolide Antibiotics may increase the serum concentration of Zopiclone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F15895130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Erythromycin serum concentrations may be altered if taken with food (formulation-dependent).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8086263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8086264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Erythromycin crosses the placenta and low concentrations are found in the fetal serum. Most reports do not identify an increase in risk for congenital abnormalities due to prenatal exposure to erythromycin. Cardiovascular anomalies following exposure in early pregnancy have been reported in some observational studies. Most studies also do not support a link between prenatal exposure to erythromycin and pyloric stenosis in the neonate. In general, serum concentrations of erythromycin are lower in pregnant women. Erythromycin therapy in patients with preterm, premature rupture of membranes is associated with a range of health benefits to the neonate and no long-term adverse events to the child have been observed. However, maternal use of erythromycin in women with preterm labor, intact membranes, and no documented infection does not improve neonatal health and may have adverse effects in childhood (use is not recommended). In patients with acute infections during pregnancy, erythromycin may be given if an antibiotic is required and appropriate based on bacterial sensitivity.  Erythromycin is the antibiotic of choice for preterm premature rupture of membranes (with membrane rupture prior to 34 weeks gestation), the treatment of granuloma inguinale and lymphogranuloma venereum in pregnancy, and the treatment of or long-term suppression of",
"     <i>",
"      Bartonella",
"     </i>",
"     infection in HIV-infected pregnant patients. Erythromycin may be appropriate as an alternative agent for the treatment of chlamydial infections in pregnant women (consult current guidelines).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10485265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Assess results of culture and sensitivity tests and patient's previous allergy history prior to therapy; liver function tests, observe for changes in bowel frequency; with I.V. use: Blood pressure, heart rate",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10485205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial RNA-dependent protein synthesis at the chain elongation step; binds to the 50S ribosomal subunit resulting in blockage of transpeptidation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10485215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Variable, but better with salt forms than with base; 18% to 45% absorbed orally; ethylsuccinate may be better absorbed with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Poor penetration into the CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.64 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 73% to 81%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: In the liver by demethylation via CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neonates (&le;15 days of age): 2.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 1.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     ESRD: 5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Base: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Stearate: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ethylsuccinate: 0.5-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: 2% to 5% unchanged drug excreted in urine, major excretion in feces (via bile)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis: Not removed by peritoneal dialysis or hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10485267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/23/22901?source=see_link\">",
"      see \"Erythromycin (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if prolonged diarrhea, vomiting, or irritability with feeding occurs when administered to infants. Do not crush enteric coated or delayed release drug products.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10485269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of erythromycin-associated cardiac toxicity with prolongation of the QT interval and ventricular tachydysrhythmias includes discontinuing erythromycin and administering magnesium.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chicella MF, Batres LA, Heesters MS, et al, \"Prokinetic Drug Therapy in Children: A Review of Current Options,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(4):706-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/15755792/pubmed\" id=\"15755792\" target=\"_blank\">",
"        15755792",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Costalos C, Gounaris A, Varhalama E, et al, \"Erythromycin as a Prokinetic Agent in Preterm Infants,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2002, 34(1):23-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/11753159/pubmed\" id=\"11753159\" target=\"_blank\">",
"        11753159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Curry JI, Lander TD, and Stringer MD, \"Review Article: Erythromycin as a Prokinetic Agent in Infants and Children,\"",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2001, 15(5):595-603.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/11328252/pubmed\" id=\"11328252\" target=\"_blank\">",
"        11328252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Di Lorenzo C, Lachman R, and Hyman PE, &ldquo;Intravenous Erythromycin for Postpyloric Intubation,&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 1990, 11(1):45-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/2136585/pubmed\" id=\"2136585\" target=\"_blank\">",
"        2136585",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jadcherla SR and Berseth CL, \"Effect of Erythromycin on Gastroduodenal Contractile Activity in Developing Neonates,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2002, 34(1):16-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/11753158/pubmed\" id=\"11753158\" target=\"_blank\">",
"        11753158",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knight-Madden J and Serjeant GR, \"Invasive Pneumococcal Disease in Homozygous Sickle Cell Disease: Jamaican Experience 1973-1997,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(1):65-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/11148514/pubmed\" id=\"11148514\" target=\"_blank\">",
"        11148514",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ng YY, Su PH, Chen JY, et al, \"Efficacy of Intermediate-Dose Oral Erythromycin on Very Low Birth Weight Infants With Feeding Intolerance,\"",
"      <i>",
"       Pediatr Neonatol",
"      </i>",
"      , 2012, 53(1):34-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/22348492/pubmed\" id=\"22348492\" target=\"_blank\">",
"        22348492",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oei J and Lui K, \"A Placebo-Controlled Trial of Low-Dose Erythromycin to Promote Feed Tolerance in Preterm Infants,\"",
"      <i>",
"       Acta Paediatr",
"      </i>",
"      , 2001, 90(8):904-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/11529540/pubmed\" id=\"11529540\" target=\"_blank\">",
"        11529540",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patole S, Rao S, and Doherty D, \"Erythromycin as a Prokinetic Agent in Preterm Neonates: A Systematic Review,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 2005, 90(4):F301-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/15899929/pubmed\" id=\"15899929\" target=\"_blank\">",
"        15899929",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ray WA, Murray KT, Meredith S, et al, \"Oral Erythromycin and the Risk of Sudden Death From Cardiac Causes,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(11):1089-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/15356306/pubmed\" id=\"15356306\" target=\"_blank\">",
"        15356306",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2012 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 29th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reid B, DiLorenzo C, Travis L, et al, &ldquo;Diabetic Gastroparesis Due to Postprandial Antral Hypomotility in Childhood,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 90(1 Pt 1):43-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/1614777/pubmed\" id=\"1614777\" target=\"_blank\">",
"        1614777",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodriguez L, Irani K, Jiang H, et al, \"Clinical presentation, Response to Therapy, and outcome of Gastroparesis in Children,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2012, 55(2):185-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/22228004/pubmed\" id=\"22228004\" target=\"_blank\">",
"        22228004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rolain JM, Brouqui P, Koehler JE, et al, &ldquo;Recommendations for Treatment of Human Infections Caused by Bartonella Species,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2004, 48(6):1921-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/15155180/pubmed\" id=\"15155180\" target=\"_blank\">",
"        15155180",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DL, Bisno AL, Chambers HF, et al, \"Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(10):1373-406.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/16231249/pubmed\" id=\"16231249\" target=\"_blank\">",
"        16231249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tiwari T, Murphy TV, Moran J, et al, \"Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis: 2005 CDC Guidelines,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 54(RR-14):1-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/16340941/pubmed\" id=\"16340941\" target=\"_blank\">",
"        16340941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vanderhoof JA, Young R, Kaufman SS, et al, \"Treatment of cyclic vomiting in childhood with erythromycin,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 1995, 21(Suppl 1):S60-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/8708873/pubmed\" id=\"8708873\" target=\"_blank\">",
"        8708873",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waites KB, Sims PJ, Crouse DT, et al, &ldquo;Serum Concentrations of Erythromycin After Intravenous Infusion in Preterm Neonates Treated for",
"      <i>",
"       Ureaplasma urealyticum",
"      </i>",
"      Infection,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1994, 13(4):287-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/8036045/pubmed\" id=\"8036045\" target=\"_blank\">",
"        8036045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waseem S, Islam S, Kahn G, et al, \"Spectrum of Gastroparesis in Children,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2012, 55(2):166-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/22314391/pubmed\" id=\"22314391\" target=\"_blank\">",
"        22314391",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wormser GP, Dattwyler RJ, Shapiro ED, et al, &ldquo;The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2006, 43(9):1089-134.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/32/22025/abstract-text/17029130/pubmed\" id=\"17029130\" target=\"_blank\">",
"        17029130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15977 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-D91D1357DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_32_22025=[""].join("\n");
var outline_f21_32_22025=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086256\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086257\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484225\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442462\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485224\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086458\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086259\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485264\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086368\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485204\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485164\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085309\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086286\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485165\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485167\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485166\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086288\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086289\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15895130\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086263\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086264\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485265\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485205\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485215\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485267\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485269\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15977\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15977|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26419?source=related_link\">",
"      Erythromycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/61/4052?source=related_link\">",
"      Erythromycin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/41/42642?source=related_link\">",
"      Erythromycin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/6/25705?source=related_link\">",
"      Erythromycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/23/22901?source=related_link\">",
"      Erythromycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/28/31171?source=related_link\">",
"      Erythromycin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/47/756?source=related_link\">",
"      Erythromycin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/6/30818?source=related_link\">",
"      Erythromycin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_32_22026="Overview of pharmacogenomics";
var content_f21_32_22026=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of pharmacogenomics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/32/22026/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/32/22026/contributors\">",
"     Kelan Tantisira, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/32/22026/contributors\">",
"     Scott T Weiss, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/32/22026/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/32/22026/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/32/22026/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/32/22026/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/32/22026/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/32/22026/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is tremendous interindividual variability in the response to pharmacologic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/1\">",
"     1",
"    </a>",
"    ]. Plasma drug levels can vary more than 1000-fold when the same drug dose is administered to two individuals having approximately the same weight [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/2\">",
"     2",
"    </a>",
"    ]. Drug-drug interactions, drug-food interactions, sex, age, disease state (ie, renal and hepatic function) and pregnancy can all influence variability in drug responses between patients. However, genetic factors are also likely to play a major role, since the individual response to a given therapeutic agent is highly reproducible [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacogenomics is the study of the role of inherited and acquired genetic variation on drug response. It is distinguished from pharmacogenetics, which focuses on individual candidate genes (identified by approaches such as genome-wide association studies (GWAS), genome-wide expression profiling, or methylation studies) to identify markers across the genome that affect drug metabolism, distribution, receptor targets, and biologic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the two terms are frequently used interchangeably.",
"   </p>",
"   <p>",
"    In theory, the identification of genetic factors that influence drug absorption, metabolism, and action at the receptor level should allow for individualized therapy; this could optimize drug efficacy and minimize toxicity profiles in a given population [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/1,5-8\">",
"     1,5-8",
"    </a>",
"    ]. The potential for cost savings (through increased drug efficacy) and for decreased morbidity and mortality (through increased drug safety and fewer adverse drug reactions [ADRs]) is immense [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. Although many ADRs are preventable and attributed in many cases to human error, others appear idiosyncratic, and potentially influenced by genetic factors. In one study of 2227 ADRs identified in a large teaching hospital, fewer than 50 percent had readily identified causes, and thus, might have been due to pharmacogenetic variability [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic provides a practical overview of the field of pharmacogenomics, including the historical context, the different ways in which pharmacogenomic differences can affect the response to drug therapy, an overview of US Food and Drug Administration (FDA) approved labeling of medications for which genetic testing is recommended, and the challenges that must be overcome before routine pharmacogenetic testing (genotyping) is fully integrated into mainstream clinical medicine. Throughout, examples of relevant pharmacogenetic associations will be cited.",
"   </p>",
"   <p>",
"    While the details of all known specific drug-gene interactions are beyond the scope of this overview, current information regarding most of the known associations can be obtained through the National Institute of Health Pharmacogenetics Research Network's PharmGKB: The Pharmacogenetics and the Pharmacogenomics Knowledge Base [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL CONTEXT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The roots of pharmacogenomics may date back as early as the 6th century BC, when Pythagoras was said to have recognized that eating fava beans caused illness in some, but not all, individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/16\">",
"     16",
"    </a>",
"    ]. In the 1940s, the immunochemist William Boyd noted that in contrast to Mediterranean populations, native Britons almost never developed hemolytic anemia after ingestion of fava beans; he suggested a genetic difference as the probable explanation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/16\">",
"     16",
"    </a>",
"    ]. It is now known that the hemolytic anemia associated with ingestion of fava beans, which may also occur with a variety of pharmacologic agents, is due to X-linked glucose-6-phosphate dehydrogenase deficiency (G6PD) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=see_link\">",
"     \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following pioneering discoveries ushered in the modern field of pharmacogenetics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the early 1900s, Garrod recognized a subset of psychiatric patients who developed porphyria upon administration of sulphonal [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 1932, Snyder attributed the 'phenylthiourea non-taster' phenotype to an autosomal recessive trait whose inheritance varied according to ethnicity [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the 1950s, patients with an inherited deficiency of plasma cholinesterase were noted to have a prolonged paralytic response to suxamethonium [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 1957, Motulsky first suggested that interindividual differences in drug efficacy as well as ADRs were at least partially attributable to genetic differences [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/20\">",
"       20",
"      </a>",
"      ]. The term \"pharmacogenetics\" was first coined by Frederich Vogel, a German geneticist, in 1959 [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The role of genetics in the interindividual variation in drug response was reinforced by a series of twin studies conducted in the early 1960s [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/22-26\">",
"       22-26",
"      </a>",
"      ]. Plasma half-lives of many drugs, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , were found to be similar in monozygotic twins, but varied significantly among dizygotic twins, siblings, and the general population.",
"     </li>",
"     <li>",
"      In the late 1970s, two independent groups associated a deficiency in drug metabolism that was inherited in an autosomal recessive pattern with a markedly higher frequency of side effects in certain volunteers taking the antihypertensive debrisoquine [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/27\">",
"       27",
"      </a>",
"      ] and the antiarrhythmic sparteine [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/28\">",
"       28",
"      </a>",
"      ]. Approximately ten years later, the metabolism of both drugs was shown to result from allelic variation at the cytochrome P450 2D6 (CYP2D6) locus [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/29\">",
"       29",
"      </a>",
"      ]. This was the first example of applied genotyping in the field of pharmacogenetics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since then, advances in human genetic technology and an increased understanding of the molecular basis of drug metabolism, transport, and action at the level of its target (often a receptor) has led to the characterization of dozens of mutations and functional pharmacogenetic polymorphisms that influence the response to drug therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     WAYS IN WHICH GENETIC FACTORS INFLUENCE DRUG RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The heritability of some drug responses was formally established via genetic studies, including the twin studies of Vessel and Page described above [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/22-26\">",
"     22-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, most drugs have not been formally studied to assess heritable properties, primarily because it is neither safe nor ethical to administer most medications to individuals in whom they are not indicated. Barring formal genetic studies, the distribution of responses to a certain drug in populations can strongly suggest a genetic component.",
"   </p>",
"   <p>",
"    The interindividual response distribution to a drug may be either multimodal or unimodal. A multimodal distribution suggests distinct population subgroups of responders, and therefore plausibility of a pharmacogenetic basis for response heterogeneity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/3\">",
"     3",
"    </a>",
"    ]. A unimodal drug response distribution also supports the possibility of pharmacogenetic variation in response, with subjects demonstrating either a \"good\" or a \"poor\" response.",
"   </p>",
"   <p>",
"    In particular, the combination of significant interindividual variability in level",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    response to a drug combined with high repeatability within individual patients (the likelihood of a subsequent",
"    <span class=\"nowrap\">",
"     beneficial/poor",
"    </span>",
"    response to a drug given a prior response) strongly suggests the potential for pharmacogenetic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacogenomic influences on drug response have traditionally been divided into four categories based upon the impact of genetic variability on the pharmacologic properties of a drug [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Effect on drug pharmacokinetics; an example is a genetic variant that alters drug metabolism, affecting plasma concentration",
"     </li>",
"     <li>",
"      Effects on pharmacodynamics; an example is a genetic variation that reduces binding of the drug to its receptor, thereby decreasing therapeutic efficacy",
"     </li>",
"     <li>",
"      Effects on idiosyncratic reactions, such as the likelihood of a hypersensitivity reaction to a certain drug",
"     </li>",
"     <li>",
"      Effects on disease pathogenesis or severity and response to specific therapies; these include specific molecular defects related to the pathogenesis of certain malignancies for which specific targeted therapies have been developed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific examples of medications and specific genetic variants relevant to each of these pharmacogenetic categories are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef65875 \" href=\"UTD.htm?42/6/43118\">",
"     table 1",
"    </a>",
"    ). The following sections will expand upon these four categories, and provide clinically relevant examples illustrating how pharmacogenetic variability might potentially influence drug response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Altered pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacokinetics refers to the study of the transport and metabolism of administered drugs, including absorption, distribution, tissue localization, biotransformation, and excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/31\">",
"     31",
"    </a>",
"    ]. The vast majority of pharmacogenetic investigations reported in the literature have been in this area, with the major areas of study being genetic differences in drug metabolizing enzymes and drug transporters.",
"   </p>",
"   <p>",
"    In humans, there are two phases of xenobiotic (ie, substances foreign to the body) metabolism that are controlled by several hundred drug metabolizing enzymes (",
"    <a class=\"graphic graphic_figure graphicRef77320 \" href=\"UTD.htm?6/14/6372\">",
"     figure 1",
"    </a>",
"    ), and their corresponding genes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During phase I metabolism, polar groups are added to lipophilic molecules by oxidation, reduction, or hydrolysis to facilitate water-solubility. This group of reactions is catalyzed predominantly by the cytochrome P450 superfamily of mixed function oxidases (CYPs), which represent a classic example of polymorphic (ie, occurring in different types) drug metabolizing enzymes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=see_link&amp;anchor=H4#H4\">",
"       \"Drugs and the liver: Metabolism and mechanisms of injury\", section on 'Phase I reactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Following phase I metabolism, most compounds are still insufficiently hydrophilic for excretion, and require further processing (phase II reactions result) to form readily excretable, nontoxic substances. An example of a polymorphic phase II drug metabolizing enzyme is thiopurine-S-methyltransferase (TPMT), which is involved in the metabolism of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      and 6-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      (6-MP) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=see_link&amp;anchor=H6#H6\">",
"       \"Drugs and the liver: Metabolism and mechanisms of injury\", section on 'Phase II reactions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     CYP isoenzymes and drug metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cytochrome P450s (CYPs) are members of a superfamily of oxidative enzymes, which represent the major system for oxidative metabolism of therapeutic substances. Sequencing of the human genome has revealed 58 different human CYP genes (information on human CYP P450 genes available online at",
"    <a class=\"external\" href=\"file://drnelson.uthsc.edu/cytochromep450.html\">",
"     file://drnelson.uthsc.edu/cytochromeP450.html",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of the CYP genes encoding for enzymes that are active in xenobiotic metabolism are polymorphic, and polymorphisms that affect drug metabolism are seen in a significant portion of the population [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/27,34-36\">",
"     27,34-36",
"    </a>",
"    ]. In many cases, the frequency varies according to ethnic background. As an example, expression of CYP2D6 is functionally absent in 7 percent of Caucasians and African-Americans, while deficiency is rare among Asians [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/37\">",
"     37",
"    </a>",
"    ]. Due to the importance of these genes, a website has been created that is continuously updated for newly identified CYP polymorphisms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polymorphisms in CYP genes may contribute to either diminished or absent metabolism, or excessive metabolism of a compound [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/39\">",
"     39",
"    </a>",
"    ]. In general, genotypic CYP variations result in three metabolic phenotypes: ultra-rapid metabolizers, extensive (normal) metabolizers, and poor metabolizers.",
"   </p>",
"   <p>",
"    The clinically most important polymorphic variations in hepatic CYPs are seen in the CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes, which code for enzymes that are responsible for the phase I metabolism of approximately 60 to 70 percent of all therapeutic medications used in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2216886\">",
"    <span class=\"h4\">",
"     Clopidogrel and CYP2C19 variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse in vivo effects of reduced function CYP2C19 alleles on benefit from the anti-platelet agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    have been demonstrated in a number of studies and a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/40\">",
"     40",
"    </a>",
"    ]. In March 2010, a new black box warning from the US Food and Drug Administration was issued to alert clinicians that genetic testing is available to identify individuals with poor metabolizer variants of CYP2C19 who may not receive the full benefits of clopidogrel and require dose adjustment or use of a different drug. Two subsequent meta-analyses, however, which included more recently published reports and had more stringent definitions of adverse events, did not show a correlation between CYP2C19 genotype and adverse cardiovascular events in patients treated with clopidogrel [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. These data have not led to a change in the FDA recommendation. Although guidelines for CYPC19 genotype-directed antiplatelet therapy are available from the",
"    <a class=\"external\" href=\"file://pharmkgb.org/\">",
"     Clinical Pharmacogenetics implementation Consortium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/43\">",
"     43",
"    </a>",
"    ], many experts do not recommend",
"    <strong>",
"     routine",
"    </strong>",
"    testing of patients for \"clopidogrel resistance\" by genetic testing for CYP2C19 poor metabolizers. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link\">",
"     \"Nonresponse and resistance to clopidogrel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2216941\">",
"    <span class=\"h4\">",
"     CYP2D6 variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic polymorphisms have been particularly well studied in the CYP2D6 subfamily, which is responsible for the metabolism of a wide variety of drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    , the selective serotonin reuptake inhibitors (SSRIs),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CYP2D6 is highly polymorphic, with over 90 known allelic variants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/15\">",
"     15",
"    </a>",
"    ]. The following example illustrates the markedly different impact that the same genetic variant in CYP2D6 can have on the pharmacokinetic profile of two drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    are metabolized by CYP2D6; however, codeine is a prodrug and its analgesic properties are not manifest until it is metabolized by CYP2D6, primarily to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    and codeine-6-glucuronide. In contrast, nortriptyline is the active moiety and its metabolism results in inactivation of the drug to its primary metabolite.",
"    <br/>",
"    <br/>",
"    At conventional doses, subjects who are poor metabolizers based upon CYP2D6 genotype will derive no therapeutic benefit from codeine (because it will not be converted to its active moiety), but they may be \"overdosed\" with nortriptyline, and at increased risk of side effects (",
"    <a class=\"graphic graphic_figure graphicRef55020 \" href=\"UTD.htm?9/24/9615\">",
"     figure 2",
"    </a>",
"    ).",
"    <br/>",
"    <br/>",
"    Conversely, at conventional doses of codeine, subjects who are ultra-rapid metabolizers based upon CYP2D6 genotype have higher than expected morphine levels (an initial \"overdose\"), with more side effects and a shorter than expected duration of pain control [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/46\">",
"     46",
"    </a>",
"    ]. On the other hand, these patients may derive no significant therapeutic benefit from nortriptyline because of excessive metabolism of the drug.",
"   </p>",
"   <p>",
"    Given the evolving knowledge of pharmacogenomics and its impact on pharmacokinetics, preliminary dosing recommendations for several drugs have been made based upon known genetic variations in drug metabolizing enzymes (",
"    <a class=\"graphic graphic_figure graphicRef78144 \" href=\"UTD.htm?0/59/952\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. However, these have not been validated by prospective studies. Although guidelines for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    therapy based upon CYP2D6 phenotype are available from the",
"    <a class=\"external\" href=\"file://www.pharmgkb.org/\">",
"     Clinical Pharmacogenetics Implementation Consortium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/49\">",
"     49",
"    </a>",
"    ], routine assay to identify specific CYP2D6 genotypes as a means of choosing a dose for any of these compounds is not yet considered standard practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Thiopurine methyltransferase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphisms in the CYP isoenzymes represent the most common genetic variant affecting pharmacokinetics, but there are others. As an example, thiopurine s-methyltransferase (TPMT, MIM #187680) is responsible for the metabolism of the class of therapeutic compounds called thiopurines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    [6-MP]). Variation in the TPMT gene can result in functional inactivation of the enzyme, and a markedly increased risk of treatment-related leukopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. For this reason, TPMT testing is recommended by the US Food and Drug Administration prior to treatment with a thiopurine. For individuals with low or absent TPMT activity, dose reductions of up to 90 percent may be needed, based upon experience in pediatric acute lymphocytic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Specific dosing recommendations for thiopurines according to TPMT phenotype are available from the",
"    <a class=\"external\" href=\"file://www.pharmgkb.org/\">",
"     Clinical Pharmacogenetics Implementation Consortium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, TPMT genotyping has not been universally adopted, and the cost effectiveness and optimal clinical circumstances in which to perform routine testing are not well defined [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/58\">",
"     58",
"    </a>",
"    ]. A systematic review of the use of TPMT genotyping in the treatment of patients with chronic inflammatory disease found imprecision in estimates of genotyping sensitivity and insufficient evidence of outcomes effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/59\">",
"     59",
"    </a>",
"    ]. Expert opinions differ regarding the role of TPMT genotyping prior to the administration of thiopurines for treatment of inflammatory and autoimmune disorders; some advocate routine testing while others, citing the low frequency of homozygous variants among Caucasians (only about 1 in 300) and the fact that the majority of patients who develop myelosuppression while taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    do not have detectable TPMT gene mutations, disagree with this approach. Some clinicians, in particular those treating acute leukemia with 6-MP, only perform TPMT genotyping if there is unexpectedly severe or prolonged myelosuppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44566?source=see_link&amp;anchor=H3#H3\">",
"     \"6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine\", section on 'TPMT genotyping'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=see_link\">",
"     \"Chronic immunomodulating therapies for myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link&amp;anchor=H4#H4\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Pharmacogenetics and TPMT testing'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3654047\">",
"     'Study design limitations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Drug transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited variations in drug transport proteins make up the second major area of pharmacogenetic investigation in the area of pharmacokinetics. The potential clinical relevance of inherited differences in membrane drug transport proteins can be illustrated by the following examples.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Efficacy of non-nucleoside reverse transcriptase inhibitors &mdash; Members of the adenosine triphosphate (ATP)-binding cassette (ABC) family of membrane transporters are among the most extensively studied in terms of drug disposition and modulating drug action at the cellular level [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/4\">",
"       4",
"      </a>",
"      ]. One member, the P-glycoprotein, is encoded by the human ABCB1 gene (also called the multidrug resistant 1 or MDR1 gene, MIM 171050). P-glycoprotein enhances the energy-dependent cellular efflux of many substrates, such as bilirubin, and several medications, including many antiretroviral agents [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/4\">",
"       4",
"      </a>",
"      ]. Several studies have examined whether certain single nucleotide polymorphisms (SNPs) within the ABCB1 gene may predict either plasma concentrations of drug, virologic efficacy, or drug toxicity in subsets of HIV-infected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/60-63\">",
"       60-63",
"      </a>",
"      ]. While each of these studies has demonstrated differences related to one particular variant (MDR1 3435C to T), the mechanistic basis for these associations remains to be clarified.",
"      <br/>",
"      <br/>",
"      Some data also suggest that genotypic differences in drug transport may influence the ability to achieve high cerebrospinal fluid (CSF) drug levels, although the clinical significance of this finding (ie, whether rates of HIV-related dementia are lower in patients with these genetic variants) is unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"       \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12249?source=see_link&amp;anchor=H14#H14\">",
"       \"Dementia and delirium in HIV-infected patients\", section on 'Antiretroviral therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       Sunitinib",
"      </a>",
"      -related toxicity &mdash; In a study of 219 patients treated with sunitinib, a multitargeted tyrosine kinase inhibitor used for the treatment of advanced renal cell cancer, the prevalence and severity of several side effects, including mucosal inflammation and hand-foot syndrome, were significantly higher in patients who had inherited specific haplotypes of the ABCB1 and ABCB2 efflux transporter genes [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Solute carrier organic anion transporter family polymorphisms &mdash; Plasma concentrations are quite variable following administration of high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (HD-MTX) for treatment of leukemia, lymphoma, and osteosarcoma. A variety of genetic polymorphisms affect MTX efficacy and toxicity, depending on the specific disease and the dose of MTX [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/65\">",
"       65",
"      </a>",
"      ]. Some data suggest an impact of inherited polymorphisms in the SLCO1B1 (solute carrier organic anion transporter family, member 1B1, MIM 604843) gene, which encodes organic anion transporting polypeptide 1B1 (OATP1B1). This peptide is localized at the membrane of hepatocytes and mediates uptake of substrates from sinusoidal blood, resulting in their net excretion from the blood, likely via biliary excretion. OATP1B1 levels appear to be an important determinant of plasma methotrexate (MTX) levels and toxicity following administration of high-dose MTX [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/66\">",
"       66",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33658?source=see_link\">",
"       \"Therapeutic use and toxicity of high-dose methotrexate\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, variants in SLCO2B1 (solute carrier organic anion transporter family, member 2B1, MIM 604988) have also been associated with variation in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    levels and with asthmatic response to montelukast [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=see_link&amp;anchor=H22#H22\">",
"     \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\", section on 'Heterogeneity of response to controller therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Altered pharmacodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacodynamics is the study of the biochemical and physiologic consequences of drug administration (ie, the effect of a drug at its therapeutic target and at other nontarget sites) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/31\">",
"     31",
"    </a>",
"    ]. Genetic variation may lead to interindividual differences in therapeutic response despite the presence of appropriate concentrations of the drug at its intended target. These variations can modulate drug response by affecting the drug target itself or one of the downstream components in the target's mechanistic pathway.",
"   </p>",
"   <p>",
"    While studies of pharmacogenetic predictors of efficacy at therapeutic target sites may eventually become the primary basis for \"individualized therapy,\" there are relatively few clinical examples of replicable pharmacogenomic associations related to pharmacodynamics, compared to pharmacokinetics [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/68\">",
"     68",
"    </a>",
"    ]. There are at least three reasons for the prominence of pharmacokinetic over pharmacodynamic pharmacogenetic studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The biology of drug metabolism and drug transport is relatively straightforward, and each compound typically has one principal enzyme responsible for its metabolism. In contrast, the physiology of most drug target pathways is fairly complex, providing multiple venues that may require investigation prior to the discovery of an interaction between the drug and genetic differences within the target pathway.",
"     </li>",
"     <li>",
"      Variability in drug metabolism related to genetic factors (eg, the difference in drug levels seen in ultra-rapid versus slow metabolizers because of CYP variants) can be as high as a 10,000-fold difference, whereas differences in target binding related to genetics are generally less than 20-fold [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/69,70\">",
"       69,70",
"      </a>",
"      ]. The resultant ability (power) to detect differences in drug metabolism is clearly far greater than the ability to detect variance in drug targets.",
"     </li>",
"     <li>",
"      The pattern of inheritance permits easier identification of pharmacokinetic variants. Typically, the inheritance pattern underlying the pharmacogenetic effects related to differences in drug metabolism or transport is Mendelian (eg X-linked inheritance underlying G6PD deficiency). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=see_link\">",
"       \"Overview of Mendelian inheritance\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, the inheritance patterns of pharmacodynamic pharmacogenetic relationships usually demonstrate relationships consistent with the complex traits underlying the purpose of the drug. Thus, these target responses tend to be determined by polygenic or gene-environment interactions, which are much more difficult to identify.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2216811\">",
"    <span class=\"h3\">",
"     Warfarin and VKORC1 polymorphisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;An example of a genetic variant that influences pharmacodynamics is the effect of polymorphisms in the gene encoding vitamin K epoxide reductase complex (VKORC1) on response to the anticoagulant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , a drug with a narrow therapeutic index and a wide variability in individual dosing. VKORC1 variants account for approximately 25 percent of the phenotypic variability in warfarin dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3654061\">",
"     'Lack of cost-effectiveness analyses'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    VKORC1 is responsible for the conversion of Vitamin K-epoxide to Vitamin K, which is the rate-limiting step in the physiological process of Vitamin K recycling and the primary therapeutic target for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . Common polymorphisms within the VKORC1 gene appear to modulate the mean daily dose of warfarin required to achieve the targeted intensity of anticoagulation. In a study on the effect of VKORC1 polymorphisms in 297 patients undergoing warfarin anticoagulation, a low-dose haplotype group (group A) and a high-dose haplotype group (non-A or group B) were identified, with the following mean warfarin maintenance doses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/71\">",
"     71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Group",
"      <span class=\"nowrap\">",
"       A/A",
"      </span>",
"      &mdash; 2.7 &plusmn; 0.2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      Group",
"      <span class=\"nowrap\">",
"       A/B",
"      </span>",
"      &mdash; 4.9 &plusmn; 0.2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      Group",
"      <span class=\"nowrap\">",
"       B/B",
"      </span>",
"      &mdash; 6.2 &plusmn; 0.3",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic testing for detecting variants of the VKORC1 genes is available to help clinicians assess whether a patient may be especially sensitive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , and require a lower starting dose; they also test for genetic variants in CYP2C9 that influence warfarin metabolism. However, routine genotyping of patients prior to starting warfarin is not widely accepted (or recommended in guidelines from the American College of Chest Physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/72\">",
"     72",
"    </a>",
"    ]) because of the limited evidence from prospective randomized trials that pharmacogenetic-based individualized dosing improves clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=see_link&amp;anchor=H5#H5\">",
"     \"Vitamin K and the synthesis of gamma carboxyglutamic acid\", section on 'Mutations and polymorphisms of the VKOR complex'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H23#H23\">",
"     \"Therapeutic use of warfarin\", section on 'Initial dose'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H15#H15\">",
"     \"Therapeutic use of warfarin\", section on 'Genotype testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Effect on idiosyncratic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;An idiosyncratic reaction is an adverse drug reaction (ADRs) that cannot be anticipated based upon the known drug target. Three examples in which an idiosyncratic reaction to a drug varies according to genetic factors are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    hypersensitivity and HLA-B*5701, TCL1A variants and musculoskeletal side effects from aromatase inhibitors, and HLA-A*3101 or B*1502 and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    hypersensitivity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       Abacavir",
"      </a>",
"      is a nucleoside analog with potent activity against HIV; however, a proportion of patients develop severe hypersensitivity reactions to this drug. Abacavir hypersensitivity is associated with carriage of the major histocompatibility complex (MHC) class I allele HLA-B*5701. It is theorized that abacavir is metabolized to an aldehyde-reactive metabolite, which undergoes classical MHC class 1 processing. Presentation of the peptide-HLA complex on an antigen-presenting cell to the receptor of an abacavir-specific CD8+ T-cell activates the release inflammatory cytokines, resulting in the clinical syndrome of acute hypersensitivity syndrome.",
"      <br/>",
"      <br/>",
"      Several trials have demonstrated the improved safety of drug administration with prior immunogenetic screening for HLA-B*5701, and guidelines from expert groups (including the",
"      <a class=\"external\" href=\"file://www.pharmgkb.org/\">",
"       Clinical Pharmacogenetics Implementation Consortium, CPIC",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/74\">",
"       74",
"      </a>",
"      ]) endorse the use of abacavir only in patients who have tested negative for HLA-B*5701. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=see_link\">",
"       \"Abacavir hypersensitivity reaction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inherited variants in the T-cell leukemia 1A (TCL1A) gene have been associated with the risk of musculoskeletal side effects in women receiving an aromatase inhibitor (AI) for treatment of breast cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/75\">",
"       75",
"      </a>",
"      ]. However, the magnitude of the excess risk is small, and only a small fraction (approximately 11 percent) of the clinically significant musculoskeletal adverse events from AIs may be attributable to this particular genetic variant [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/76\">",
"       76",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"       \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"      , an anticonvulsant and mood stabilizing drug, causes Stevens-Johnson syndrome and the related toxic epidermal necrolysis, idiosyncratic reactions that may be reduced in frequency by avoiding the drug in patients carrying one of two HLA alleles, B*1502 (in Asian populations), and A*3101 (in Europeans). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H5408138#H5408138\">",
"       \"Pharmacology of antiepileptic drugs\", section on 'Adverse events'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Disease pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final category of drug response that may be influenced by genetics is that certain genetic variations can influence disease pathogenesis, the underlying severity of a disease, and response to specific therapies. As an example, cystic fibrosis (CF) is a multisystem disorder that is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which regulates chloride and water transport in the lungs, digestive tract, and elsewhere. The G551D mutation, which is present in about 5 percent of CF patients, interferes with activation of the CFTR chloride channel.",
"    <br/>",
"    <br/>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/58/22437?source=see_link\">",
"     Ivacaftor",
"    </a>",
"    , an orally available CFTR modulator that is specific for the G551D mutation, restores functioning of the CFTR protein in patients who harbor this mutation. In a clinical trial leading to its approval in the United States, subjects with CF and a G551D mutation in at least one of their CFTR genes experienced improved FEV",
"    <sub>",
"     1",
"    </sub>",
"    , less frequent pulmonary exacerbations, and greater weight gain with ivacaftor compared with those receiving placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/77\">",
"     77",
"    </a>",
"    ]. All individuals with CF should undergo genotyping to determine whether they carry the G551D mutation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link&amp;anchor=H20592751#H20592751\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'CFTR modulators'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3654033\">",
"    <span class=\"h1\">",
"     US FOOD AND DRUG ADMINISTRATION AND USE OF GENOMIC BIOMARKERS TO GUIDE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US Food and Drug Administration (FDA) has had a longstanding interest in the field of pharmacogenomics. In August 2008, as part of its Critical Path Initiative, the scientific process through which a medical product is transformed from discovery to development, the FDA released a table listing genomic biomarkers that have established roles in determining drug response. A full listing of valid genomic biomarkers in the context of drug labeling in the United States is available online [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/78\">",
"     78",
"    </a>",
"    ], and a synopsis of selected drugs is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef65875 \" href=\"UTD.htm?42/6/43118\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pharmacogenomic information is currently contained in about 10 percent of labels for drugs approved by the FDA. Although most of the FDA labeling recommendations have involved variants that influence drug pharmacokinetics, there are examples within each of the pharmacogenetic categories described above of medications for which the FDA recommends testing prior to administration (",
"    <a class=\"graphic graphic_table graphicRef65875 \" href=\"UTD.htm?42/6/43118\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Altered pharmacodynamics'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link&amp;anchor=H22#H22\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Pharmacokinetic variability'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the FDA has officially approved a few tests, the major contribution of the agency in the field of pharmacogenetics has been in the updating of drug labels to contain information on pharmacogenomic issues that are applicable to a given therapeutic agent.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    holds a unique place in the current recommendations, as it is the only therapeutic agent for which testing for two independent genetic variants (in the CYP2C9 and VKORC1 genes) is recommended. CYP2C9 is the primary enzyme involved in the metabolism of warfarin, while polymorphisms within the VKORC1 gene appear to modulate the mean daily dose of warfarin required to acquire target anticoagulation intensity. Thus, the warfarin recommendations incorporate testing of variants involved in both the pharmacokinetics and pharmacodynamics of warfarin. (See",
"    <a class=\"local\" href=\"#H2216811\">",
"     'Warfarin and VKORC1 polymorphisms'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3654040\">",
"    <span class=\"h1\">",
"     CHALLENGES TO WIDESPREAD USE OF GENOTYPING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the labeling changes implemented by the FDA and the increasing number of pharmacogenetic studies in the published literature, integration of pharmacogenetic testing into clinical care has been slow, and many of the tests recommended by the FDA for individual drugs are not in routine use. Among the reasons for lack of implementation are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limitations in the design of published pharmacogenetic studies (in particular, the lack of prospective randomized trials demonstrating improved clinical outcomes when drug therapy or specific dose is selected on the basis of genotype)",
"     </li>",
"     <li>",
"      Regulatory and ethical concerns",
"     </li>",
"     <li>",
"      Lack of cost effectiveness analyses",
"     </li>",
"     <li>",
"      Limitations in the number of available pharmacogenetic tests and lack of guidelines for test implementation",
"     </li>",
"     <li>",
"      A lack of education on the benefits of pharmacogenetic testing, both for patients and providers",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3654047\">",
"    <span class=\"h2\">",
"     Study design limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several problems in study design have limited the translation of pharmacogenetics into the clinical sphere.",
"   </p>",
"   <p>",
"    The initially reported genetic and pharmacogenetic associations often have not been reproducible (ie, many of the initial reports represented \"false-positive\" findings) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. In many cases, the original pharmacogenetic studies were \"spin-offs\" from clinical trials and, thus, were underpowered for genetic association studies given the small sample sizes allocated to a given treatment arm. Replication of results from genome-wide association studies requires identification of a large and appropriate sample, and this can be both difficult and expensive [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another contributor to the failure to replicate initial findings is heterogeneity among studies, which can be phenotypic (ie, the selective use of different endpoints, times of assessment, types of interventions, and genetic groups across studies) or genotypic (ie, evaluation of disparate markers within the same gene or varying genetic allele frequencies due to ethnicity, which may be overt or subtle).",
"   </p>",
"   <p>",
"    The problems of phenotypic and genotypic heterogeneity can be illustrated by an evaluation of the pharmacogenetic associations of the beta2-adrenergic receptor (ADRB2, MIM# 109690) gene with the response to beta2-agonist therapy in asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/81\">",
"     81",
"    </a>",
"    ]. In a review of 21 studies that focused on the two most common ADRB2 coding variants (Arg16Gly and Gln27Glu), the total number of statistically significant probed and reported associations was 487 when the multiple endpoints and types of comparisons presented by the various studies were considered [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/81\">",
"     81",
"    </a>",
"    ]. However, 465 (95 percent) were probed only once; six associations were probed twice, and only two of the associations were probed five times for the same endpoint, time of assessment, type of intervention, and genetic group. When the data were reanalyzed, adjusting for the number of comparisons, only 38 of the original 487 associations (8 percent) were statistically significant for the comparison between all available genetic groups. Heterogeneity in the available data precludes a definitive conclusion regarding the utility of ADRB2 variants to guide asthma therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15239?source=see_link&amp;anchor=H4#H4\">",
"     \"Beta-2 adrenergic receptor dysfunction and polymorphism in asthma\", section on 'Receptor polymorphisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the study design problems of small sample size and",
"    <span class=\"nowrap\">",
"     phenotypic/genotypic",
"    </span>",
"    heterogeneity, the identified variants themselves may not be amenable to clinical application. Most pharmacogenetic variants identified to date are either rare traits with relatively strong phenotypic effects, or common traits that have relatively weak phenotypic effects.",
"   </p>",
"   <p>",
"    Two clinically relevant examples illustrate these issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thiopurine s-methyltransferase (TPMT) is responsible for the metabolism of the thiopurines",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      (6-MP). Genetic variations in the TPMT gene can result in functional inactivation of the enzyme, and a markedly increased risk of life-threatening treatment-associated myelosuppression.",
"      <br/>",
"      <br/>",
"      The role for TPMT genotyping prior to the administration of thiopurines for treatment of inflammatory and autoimmune disorders remains controversial. While some consider testing to be mandatory, the prevalence of homozygous variants among Caucasians is only about 1 in 300; it is even lower in African and Asian populations [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/82\">",
"       82",
"      </a>",
"      ]. Therefore, testing is only applicable to a very small percent of the population. Furthermore, the majority of patients who develop myelosuppression while taking azathioprine do not have detectable TPMT gene mutations. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Thiopurine methyltransferase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A common haplotype in the corticotropin releasing hormone receptor 1 (CRHR1, MIM# 122561) gene has been associated with an improved lung function response to inhaled corticosteroids in patients with asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/83\">",
"       83",
"      </a>",
"      ]. Following eight weeks of inhaled corticosteroid therapy, adults and children who were homozygous for the haplotype (27 percent of the population) demonstrated two to three times the FEV1 improvement that those who were homozygous for other haplotypes (",
"      <a class=\"graphic graphic_figure graphicRef60913 \" href=\"UTD.htm?36/0/36877\">",
"       figure 4",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      However, despite the high frequency of the haplotype, the overall proportion of the variability in FEV1 response that was explained by the haplotype was under 5 percent. Therefore, genotyping of CRHR1 in isolation would be insufficient as a predictor of outcomes with inhaled corticosteroid usage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3654054\">",
"    <span class=\"h2\">",
"     Regulatory and ethical concerns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although pharmacogenetic information is now included on about 10 percent of labels for drugs approved by the FDA, questions remain regarding the regulation of genotyping tests and the extent to which pharmacogenetic analyses should be incorporated into each phase of new drug development [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. From an ethics perspective, a longstanding concern has been whether the identification of pharmacogenetic variants (in particular those associated with a poor treatment response or prognosis) in an individual could result in stigmatization (eg, denial of insurance) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A major step in the protection of individuals' rights came with the passage of H.R. 493, the Genetic Information Nondiscrimination Act of 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/86\">",
"     86",
"    </a>",
"    ]. This law protects Americans against discrimination based on their genetic information in matters related to health insurance and employment and should translate into increased acceptance of pharmacogenetic testing by the public in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3654061\">",
"    <span class=\"h2\">",
"     Lack of cost-effectiveness analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circumstances that favor cost effectiveness of a pharmacogenetic test include a high prevalence of the genetic variant of interest in the target population, a good correlation between phenotype and genotype, satisfactory diagnostic test criteria, a disease that is associated with significant morbidity or mortality if left untreated, and a significant reduction in adverse drug reactions resulting from testing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the multitude of pharmacogenetic association studies in the literature, relatively few cost-effective analyses have been performed. These studies are crucial to determine reimbursement for routine pharmacogenetic testing, but their performance is problematic for two reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/87\">",
"     87",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are only limited data on the rate at which pharmacogenetic testing actually prevents",
"      <strong>",
"       clinically significant",
"      </strong>",
"      adverse drug reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/88-90\">",
"       88-90",
"      </a>",
"      ] .",
"     </li>",
"     <li>",
"      The price of pharmacogenetic tests is likely to drop continuously over the next few years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first issue can be illustrated by pharmacogenetic testing for CYP2C9 and VKORC1 variants in patients being started on the anticoagulant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H2216811\">",
"     'Warfarin and VKORC1 polymorphisms'",
"    </a>",
"    above). VKORC1 variants account for approximately 25 percent of the phenotypic variability in warfarin dosing, with CYP2C9 variants adding an additional 6 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/71\">",
"     71",
"    </a>",
"    ]. The available data suggest that combining knowledge of genetic variants with clinical characteristics can explain between 55 and 71 percent of the variability in warfarin dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2006 working paper from the American Enterprise Institute-Brookings Joint Center for Regulatory Studies (and partially published in 2008) estimated that formally integrating genetic testing into routine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy could allow American warfarin users to avoid 85,000 serious bleeding events and 17,000 strokes annually, resulting in estimated savings of $1.1 billion annually, with a range of about $100 million to $2 billion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Nonetheless, routine genotyping is not widely accepted (or recommended in guidelines from the American College of Chest Physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/72\">",
"     72",
"    </a>",
"    ]) because of the lack of evidence from prospective randomized trials that pharmacogenomic-based individualized dosing actually improves clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/93,94\">",
"     93,94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, a cost-effectiveness study of using pharmacogenomic information for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    dosing concluded that routine genotyping before warfarin dosing was",
"    <strong>",
"     unlikely",
"    </strong>",
"    to be cost-effective for typical patients with nonvalvular atrial fibrillation (ie, with the estimated cost-effectiveness of testing exceeding $170,000 per quality-adjusted life-year gained) (QALY) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/95\">",
"     95",
"    </a>",
"    ]. The authors concluded that on the basis of available data and cost of testing (about $400 in 2007), there was only a 10 percent chance that genotype-guided dosing is likely to be cost-effective (ie, &lt;$50,000 per QALY).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3654068\">",
"    <span class=\"h2\">",
"     Lack of tests and guidelines for test implementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When compared to other clinical tests, pharmacogenetic testing is relatively precise because of the stability of DNA in the laboratory, the fact that germline DNA does not change in an individual's lifetime, and the robust nature of the available genetic tests [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/94\">",
"     94",
"    </a>",
"    ]. Nevertheless, relatively few pharmacogenetic tests are available for use in clinical practice, and even when tests are available, there has been slow adoption of these tests to inform clinical decision making in practice [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limitations cited in the development and implementation of new tests include the difficulty of identifying and incorporating multiple (interacting) variants in the same test, the translation of a test developed based upon average population responses to the case of a specific individual, the need to develop tests that can be interpreted within a clinical context, the need for a test associated with biologically meaningful differences, the need for tests to undergo formal regulatory approval (eg, Clinical Laboratory Improvement Amendment (CLIA) in the United States) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/94\">",
"     94",
"    </a>",
"    ], and the lack of clear, peer-reviewed evidence-based guidelines that translate laboratory test results into actionable prescribing decisions for specific drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3654075\">",
"    <span class=\"h2\">",
"     Need to educate patients and providers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacogenomics and the promise of personalized medicine is frequently mentioned in the popular lay press. It is therefore incumbent upon both the developers of a given pharmacogenetic test as well as the health care professionals responsible for ordering the test to be cognizant of the test characteristics and interpretation, and to be able to effectively disseminate that information to patients. As noted above, a crucial part of testing efforts should be directed toward the meaning of the Genetic Information Nondiscrimination Act of 2008, providing reassurance regarding the safety and privacy of testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8777?source=see_link\">",
"     \"Personalized medicine\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3654054\">",
"     'Regulatory and ethical concerns'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is also a need for educating health care providers in both the broad array of potential predictive tools and the strengths and weaknesses of these tools. An expanding array of markers will be increasingly available, including genetic variants, genomic, proteomic, and other molecular biomarkers. The context for these educational efforts is not yet clear.",
"   </p>",
"   <p>",
"    The use of biomarkers in clinical practice may lead a paradigm shift in patient management. Providers will potentially need to perform a diagnostic test prior to prescribing a drug to determine which drug is best suited to each individual patient. Of paramount importance, providers will need to be reassured and cognizant that performing these tests will not and cannot replace sound clinical judgment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11041771\">",
"    <span class=\"h2\">",
"     Clinical Pharmacogenetics Implementation Consortium",
"    </span>",
"    &nbsp;&mdash;&nbsp;For all of the above stated reasons, pharmacogenomic testing has been slow to be adopted in clinical practice. However, some argue that the available evidence linking routine use of pharmacogenomic analysis to reduced disease risk is sufficient to warrant clinical implementation now [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/96\">",
"     96",
"    </a>",
"    ]. In addition to the enhanced coverage of the FDA in pharmacogenomic labeling of drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/78\">",
"     78",
"    </a>",
"    ], which now includes boxed warnings for several drugs (",
"    <a class=\"graphic graphic_table graphicRef65875 \" href=\"UTD.htm?42/6/43118\">",
"     table 1",
"    </a>",
"    ), several cost-effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/90\">",
"     90",
"    </a>",
"    ] and \"real world\" efficacy studies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/97\">",
"     97",
"    </a>",
"    ] have begun to overcome the limitations cited above and suggest that implementation of pharmacogenomics testing will likely be incorporated into clinical practice in the future.",
"   </p>",
"   <p>",
"    Toward this end, leading pharmacogenetic investigators, from the NIH-sponsored Pharmacogenetics Research Network and elsewhere, have begun to publish a series of articles on&nbsp;clinical implementation (",
"    <a class=\"external\" href=\"file://www.pharmgkb.org/\">",
"     Clinical Pharmacogenetics Implementation Consortium",
"    </a>",
"    (CPIC) Guidelines) of pharmacogenomics testing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/32/22026/abstract/43,49,57,74,98,99\">",
"     43,49,57,74,98,99",
"    </a>",
"    ]. However, clinical guidelines from this group largely focus on HOW pharmacogenomic testing can be integrated into clinical practice rather than WHETHER they should or should not be used to make treatment decisions in individual patients. Recommendations on whether testing is justified in clinical practice still emanate predominantly from subspecialty-based expert clinical groups (eg, the American College of Chest Physicians).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3654082\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic polymorphisms for many drug metabolizing enzymes and drug targets (eg, receptors) have been identified and probably contribute to interpatient variability in drug response. There are four general mechanisms by which genetic factors can influence the response to pharmacologic agents:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Effect on drug pharmacokinetics",
"     </li>",
"     <li>",
"      Effects on pharmacodynamics",
"     </li>",
"     <li>",
"      Effect on idiosyncratic reactions",
"     </li>",
"     <li>",
"      An effect on disease pathogenesis, the underlying severity of a disease, or the ability to respond to a specific therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pharmacogenetic testing is available in some areas in conjunction with certain drug classes, and may enable physicians to understand why patients respond differently to various drugs and to make better decisions about therapy. However, the goal of \"individualized therapy\" based upon pharmacogenetic testing has yet to be realized. Despite the promise of a growing body of research relating to pharmacogenetics and its impact on drug response, and FDA guidelines as to the use of genetic markers to guide therapy for a variety of agents (",
"    <a class=\"graphic graphic_table graphicRef65875 \" href=\"UTD.htm?42/6/43118\">",
"     table 1",
"    </a>",
"    ), use of these tests is not widespread with a few notable exceptions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some molecularly targeted agents used for treatment of specific cancers are restricted to those tumors that display certain genetic features (eg, use of the anti HER2 monoclonal antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      is restricted to breast cancers that overexpress HER2). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Ways in which genetic factors influence drug response'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=see_link\">",
"       \"HER2 and predicting response to therapy in breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some molecularly targeted agents for cystic fibrosis are restricted to patients who harbor specific mutations in the cystic fibrosis transmembrane regulator gene (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/58/22437?source=see_link\">",
"       ivacaftor",
"      </a>",
"      for patients with the G551D mutation). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Disease pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Guidelines from expert groups endorse the use of the anti-HIV drug",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      only in patients who have tested negative for HLA-B*5701 (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Effect on idiosyncratic reactions'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Before starting treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or 6-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      for treatment of an inflammatory or autoimmune disease, many (but not all) clinicians advocate screening patients for mutations in the thiopurine methyltransferase (TPMT) gene that cause TPMT deficiency. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Thiopurine methyltransferase'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44566?source=see_link\">",
"       \"6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In March 2010, a new black box warning from the US Food and Drug Administration for the antiplatelet agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      was issued to alert clinicians that genetic testing (using the Roche AmpliChip Cytochrome P450 Genotyping test) is available to identify individuals with poor metabolizer variants of CYP2C19 who may not receive the full benefits of the drug. However, two separate meta-analyses have come to opposite conclusions regarding the influence of CYP2C19 genotype on adverse cardiovascular events in patients treated with clopidogrel. It remains to be seen whether genetic testing will be implemented in clinical practice. (See",
"      <a class=\"local\" href=\"#H2216886\">",
"       'Clopidogrel and CYP2C19 variants'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link\">",
"       \"Nonresponse and resistance to clopidogrel\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Numerous barriers exist to the direct application of pharmacogenomics advances in knowledge to drug therapy in the context of clinical care, which will need to be overcome before personalized drug therapy becomes a routine component of mainstream medicine.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/1\">",
"      Leufkens HG. The interface between pharmacoepidemiology and pharmacogenetics. Eur J Pharmacol 2000; 410:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/2\">",
"      Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001; 250:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/3\">",
"      Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000; 56:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/4\">",
"      Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med 2003; 348:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/5\">",
"      Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011; 364:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/6\">",
"      Vesell ES. Therapeutic lessons from pharmacogenetics. Ann Intern Med 1997; 126:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/7\">",
"      Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/8\">",
"      Mancinelli L, Cronin M, Sad&eacute;e W. Pharmacogenomics: the promise of personalized medicine. AAPS PharmSci 2000; 2:E4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/9\">",
"      Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/10\">",
"      Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother 2008; 42:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/11\">",
"      Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 2001; 41:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/12\">",
"      Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995; 155:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/13\">",
"      Meisel C, Gerloff T, Kirchheiner J, et al. Implications of pharmacogenetics for individualizing drug treatment and for study design. J Mol Med (Berl) 2003; 81:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/14\">",
"      Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277:301.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute of Health Pharmacogenetics Research Network's PharmGKB: The Pharmacogenetics and the Pharmacogenomics Knowledge Base. www.pharmgkb.org (Accessed on July 13, 2011).",
"    </li>",
"    <li>",
"     Davidson RG. Pharmacogenetics: Pharmacogenomics, PDQ Medical Genetics (Ed), Elsevier, Oxford 2002. p.232.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/17\">",
"      Garrod AE. The incidence of alkaptonuria: a study in chemical individuality. Lancet 1902; 160:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/18\">",
"      Snyder LH. Studies in human inheritance. IX. The inheritance of taste deficiency in man. Ohio J Sci 1932; 32:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/19\">",
"      Kalow W. Familial incidence of low pseudocholinesterase level. Lancet 1956; 271:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/20\">",
"      MOTULSKY AG. Drug reactions enzymes, and biochemical genetics. J Am Med Assoc 1957; 165:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/21\">",
"      Vogel F. Moderne Probleme der Humangenetik. Ergeb Inn Med Kinderheilkd 1959; 12:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/22\">",
"      Vesell ES, Page JG. Genetic control of drug levels in man: phenylbutazone. Science 1968; 159:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/23\">",
"      Vesell ES, Page JG. Genetic control of drug levels in man: antipyrine. Science 1968; 161:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/24\">",
"      Vesell ES, Page JG. Genetic control of dicumarol levels in man. J Clin Invest 1968; 47:2657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/25\">",
"      Vesell ES, Page JG. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. J Clin Invest 1969; 48:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/26\">",
"      Vesell ES, Passananti GT, Greene FE, Page JG. Genetic control of drug levels and of the induction of drug-metabolizing enzymes in man: individual variability in the extent of allopurinol and nortriptyline inhibition of drug metabolism. Ann N Y Acad Sci 1971; 179:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/27\">",
"      Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of Debrisoquine in man. Lancet 1977; 2:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/28\">",
"      Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/29\">",
"      Gonzalez FJ, Skoda RC, Kimura S, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331:442.",
"     </a>",
"    </li>",
"    <li>",
"     Silverman ES, Hjoberg J, Palmer LJ, et al. Application of Pharmacogenetics to the Therapeutics of Asthma. In: Therapeutic Targets of Airway Inflammation, Eissa NT, Huston D (Eds), Marcel Dekker, New York 2003. Vol 177, p.1000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/31\">",
"      Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta 2002; 315:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/32\">",
"      Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/33\">",
"      Nelson DR. The cytochrome p450 homepage. Hum Genomics 2009; 4:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/34\">",
"      Tanaka E. Update: genetic polymorphism of drug metabolizing enzymes in humans. J Clin Pharm Ther 1999; 24:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/35\">",
"      Hasler JA. Pharmacogenetics of cytochromes P450. Mol Aspects Med 1999; 20:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/36\">",
"      Dorne JL, Walton K, Renwick AG. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. Food Chem Toxicol 2005; 43:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/37\">",
"      Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 2003; 35:99.",
"     </a>",
"    </li>",
"    <li>",
"     Website for CYP alleles available online at www.cypalleles.ki.se (Accessed on July 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/39\">",
"      Ueshima Y, Tsutsumi M, Takase S, et al. Acetaminophen metabolism in patients with different cytochrome P-4502E1 genotypes. Alcohol Clin Exp Res 1996; 20:25A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/40\">",
"      Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/41\">",
"      Bauer T, Bouman HJ, van Werkum JW, et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011; 343:d4588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/42\">",
"      Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011; 306:2704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/43\">",
"      Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011; 90:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/44\">",
"      Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/45\">",
"      Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/46\">",
"      Kelly LE, Rieder M, van den Anker J, et al. More codeine fatalities after tonsillectomy in North American children. Pediatrics 2012; 129:e1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/47\">",
"      Brockm&ouml;ller J, Kirchheiner J, Meisel C, Roots I. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 2000; 1:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/48\">",
"      Kirchheiner J, Br&oslash;sen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/49\">",
"      Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 2012; 91:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/50\">",
"      Evans WE, Horner M, Chu YQ, et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991; 119:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/51\">",
"      Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/52\">",
"      Zelinkova Z, Derijks LJ, Stokkers PC, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol 2006; 4:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/53\">",
"      Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/54\">",
"      Andersen JB, Szumlanski C, Weinshilboum RM, Schmiegelow K. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr 1998; 87:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/55\">",
"      Lennard L, Gibson BE, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993; 69:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/56\">",
"      Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001; 2:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/57\">",
"      Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011; 89:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/58\">",
"      Payne K, Newman W, Fargher E, et al. TPMT testing in rheumatology: any better than routine monitoring? Rheumatology (Oxford) 2007; 46:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/59\">",
"      Booth RA, Ansari MT, Loit E, et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med 2011; 154:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/60\">",
"      Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/61\">",
"      Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 2006; 43:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/62\">",
"      Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis 2005; 192:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/63\">",
"      Tozzi V, Libertone R, Liuzzi G. HIV pharmacogenetics in clinical practice: recent achievements and future challenges. Curr HIV Res 2008; 6:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/64\">",
"      van Erp NP, Eechoute K, van der Veldt AA, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009; 27:4406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/65\">",
"      Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 2009; 146:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/66\">",
"      Trevi&ntilde;o LR, Shimasaki N, Yang W, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009; 27:5972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/67\">",
"      Mougey EB, Feng H, Castro M, et al. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 2009; 19:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/68\">",
"      Johnson JA, Lima JJ. Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges. Pharmacogenetics 2003; 13:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/69\">",
"      Meyer UA. Pharmacogenetics: the slow, the rapid, and the ultrarapid. Proc Natl Acad Sci U S A 1994; 91:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/70\">",
"      Nebert DW, Ingelman-Sundberg M, Daly AK. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metab Rev 1999; 31:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/71\">",
"      Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/72\">",
"      Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/73\">",
"      Rosove MH, Grody WW. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. Ann Intern Med 2009; 151:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/74\">",
"      Martin MA, Klein TE, Dong BJ, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther 2012; 91:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/75\">",
"      Ingle JN, Schaid DJ, Goss PE, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010; 28:4674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/76\">",
"      Offit K, Robson ME. New pharmacogenomic paradigm in breast cancer treatment. J Clin Oncol 2010; 28:4665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/77\">",
"      Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365:1663.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services FaDA, Table of valid genomic biomarkers in the context of approved drug labels. Available online at file://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm (Accessed on July 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/79\">",
"      Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002; 4:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/80\">",
"      Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/81\">",
"      Contopoulos-Ioannidis DG, Alexiou GA, Gouvias TC, Ioannidis JP. An empirical evaluation of multifarious outcomes in pharmacogenetics: beta-2 adrenoceptor gene polymorphisms in asthma treatment. Pharmacogenet Genomics 2006; 16:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/82\">",
"      Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999; 9:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/83\">",
"      Tantisira KG, Lake S, Silverman ES, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 2004; 13:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/84\">",
"      Roden DM, Altman RB, Benowitz NL, et al. Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006; 145:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/85\">",
"      Kirchheiner J, Fuhr U, Brockm&ouml;ller J. Pharmacogenetics-based therapeutic recommendations--ready for clinical practice? Nat Rev Drug Discov 2005; 4:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/86\">",
"      Hudson KL, Holohan MK, Collins FS. Keeping pace with the times--the Genetic Information Nondiscrimination Act of 2008. N Engl J Med 2008; 358:2661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/87\">",
"      Swen JJ, Huizinga TW, Gelderblom H, et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med 2007; 4:e209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/88\">",
"      McWilliam A, Lutter R, Nardinelli C. Healthcare impact of personalized medicineusing genetic testing: an exploratory analysis for warfarin. Personalized Medicine 2008; 5:279.",
"     </a>",
"    </li>",
"    <li>",
"     www.healthanddna.com/warfarinsavings.pdf?pid=1127 (Accessed on July 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/90\">",
"      Reese ES, Daniel Mullins C, Beitelshees AL, Onukwugha E. Cost-Effectiveness of Cytochrome P450 2C19 Genotype Screening for Selection of Antiplatelet Therapy with Clopidogrel or Prasugrel. Pharmacotherapy 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/91\">",
"      Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/92\">",
"      Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007; 7:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/93\">",
"      Garcia DA. Warfarin and pharmacogenomic testing: the case for restraint. Clin Pharmacol Ther 2008; 84:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/94\">",
"      Weiss ST, McLeod HL, Flockhart DA, et al. Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov 2008; 7:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/95\">",
"      Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009; 150:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/96\">",
"      Altman RB. Pharmacogenomics: \"noninferiority\" is sufficient for initial implementation. Clin Pharmacol Ther 2011; 89:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/97\">",
"      Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010; 55:2804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/98\">",
"      Wilke RA, Ramsey LB, Johnson SG, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 2012; 92:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/32/22026/abstract/99\">",
"      Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther 2013; 93:153.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2904 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-24A2ECD58B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_32_22026=[""].join("\n");
var outline_f21_32_22026=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3654082\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL CONTEXT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      WAYS IN WHICH GENETIC FACTORS INFLUENCE DRUG RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Altered pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - CYP isoenzymes and drug metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2216886\">",
"      Clopidogrel and CYP2C19 variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2216941\">",
"      CYP2D6 variants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Thiopurine methyltransferase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Drug transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Altered pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2216811\">",
"      - Warfarin and VKORC1 polymorphisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Effect on idiosyncratic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Disease pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3654033\">",
"      US FOOD AND DRUG ADMINISTRATION AND USE OF GENOMIC BIOMARKERS TO GUIDE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3654040\">",
"      CHALLENGES TO WIDESPREAD USE OF GENOTYPING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3654047\">",
"      Study design limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3654054\">",
"      Regulatory and ethical concerns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3654061\">",
"      Lack of cost-effectiveness analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3654068\">",
"      Lack of tests and guidelines for test implementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3654075\">",
"      Need to educate patients and providers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11041771\">",
"      Clinical Pharmacogenetics Implementation Consortium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3654082\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2904\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2904|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/14/6372\" title=\"figure 1\">",
"      Known drug metab enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/24/9615\" title=\"figure 2\">",
"      Variation CYP2D6 metab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/59/952\" title=\"figure 3\">",
"      Dose adj pharmacogenetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/0/36877\" title=\"figure 4\">",
"      Haplotype pair asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2904|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/6/43118\" title=\"table 1\">",
"      FDA label ex pharmacogen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44566?source=related_link\">",
"      6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=related_link\">",
"      Abacavir hypersensitivity reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=related_link\">",
"      Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15239?source=related_link\">",
"      Beta-2 adrenergic receptor dysfunction and polymorphism in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11546?source=related_link\">",
"      Chronic immunomodulating therapies for myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12249?source=related_link\">",
"      Dementia and delirium in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=related_link\">",
"      Drugs and the liver: Metabolism and mechanisms of injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=related_link\">",
"      Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=related_link\">",
"      Overview of Mendelian inheritance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8777?source=related_link\">",
"      Personalized medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=related_link\">",
"      Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33658?source=related_link\">",
"      Therapeutic use and toxicity of high-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=related_link\">",
"      Vitamin K and the synthesis of gamma carboxyglutamic acid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_32_22027="Ddx foodborne disease by food";
var content_f21_32_22027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of foodborne disease by item consumed",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Item",
"       </td>",
"       <td class=\"subtitle1\">",
"        Commonly associated microbes*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Raw seafood",
"       </td>",
"       <td>",
"        Norwalk-like virus, Vibrio spp, hepatitis A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Raw eggs",
"       </td>",
"       <td>",
"        Salmonella spp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Undercooked meat or poultry",
"       </td>",
"       <td>",
"        Salmonella spp, Campylobacter spp, STEC, C. perfringens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unpasteurized milk or juice",
"       </td>",
"       <td>",
"        Salmonella spp, Campylobacter spp, STEC, Y. enterocolitica",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unpasteurized soft-cheeses",
"       </td>",
"       <td>",
"        Salmonella spp, Campylobacter spp, STEC, Y. enterocolitica, L. monocytogenes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Home made canned goods",
"       </td>",
"       <td>",
"        C. botulinum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Raw hot dogs, deli meat",
"       </td>",
"       <td>",
"        L. monocytogenes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     STEC: shiga toxin producing Escherichia coli.",
"     <br>",
"      * This association lists the commonly associated organisms and is not fully comprehensive.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_32_22027=[""].join("\n");
var outline_f21_32_22027=null;
var title_f21_32_22028="Metformin toxicity - Rapid overview";
var content_f21_32_22028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Metformin toxicity: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        General information",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metformin is an antihyperglycemic agent whose major toxicity is lactic acidosis, which can occur with renal insufficiency, liver disease, and hemodynamic instability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metformin may exacerbate hypoglycemia caused by other agents; taken alone it almost never causes hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with metformin-induced lactic acidosis may complain of nausea and abdominal pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Examination findings may include tachycardia, tachypnea, and hyperpnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For all poisoned patients, obtain: fingerstick glucose; ECG; acetaminophen and aspirin blood concentrations; serum pregnancy test in women of childbearing age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For suspected metformin toxicity, obtain: basic serum electrolytes, BUN and creatinine, serum bicarbonate, and serum lactate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secure airway, breathing, and circulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For acute ingestions, give activated charcoal: 1 g/kg (generally 50 g in adults); Do",
"        <strong>",
"         not",
"        </strong>",
"        give activated charcoal to patients with chronic toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For patients with profound acidosis (pH &lt;7.10), consider sodium bicarbonate infusion (eg, give 1 to 2 meq/kg IV push; then put approximately 133 meq NaHCO3 in one liter D5W, run at 250 mL/hour in adults, or twice maintenance fluid infusion rate in children)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For patients with profound acidosis, renal disease, or critical illness, obtain immediate nephrology consultation; hemodialysis will correct metformin-induced acid-base disturbance and slightly increase metformin clearance",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_32_22028=[""].join("\n");
var outline_f21_32_22028=null;
var title_f21_32_22029="Diff dx postop delirium";
var content_f21_32_22029=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of postoperative delirium",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cardiovascular",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myocardial ischemia or infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Arrhythmias",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypertension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypotension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Medications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amantidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amoxapine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anticholinergics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antipsychotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Benzodiazepines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beta-blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cimetadine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Corticosteroids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Digoxin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Insulin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Narcotic analgesics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Endocrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thyrotoxicosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypothyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adrenalcortical dysfunction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypoglycemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diabetic ketoacidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infectious",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Septicemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Meningitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Encephalitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Urinary tract",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Wound",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Metabolic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hyponatremia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypomagnesemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypercalcemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acid-base disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neurologic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Subdural hematoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Subarachnoid hemorrhage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intracranial bleeding",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cerebrovascular accident",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Seizure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Oncologic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neoplasm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paraneoplastic syndromes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Psychiatric",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pain",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sensory deprivation or overload",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Depression",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Pulmonary",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypoxia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypercapnia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chang, PH, Steinberg, MB. Alcohol withdrawal. Med Clin North Am 2001; 85:1191. Copyright &copy; 2001 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_32_22029=[""].join("\n");
var outline_f21_32_22029=null;
var title_f21_32_22030="Nomogram to estimate KtV";
var content_f21_32_22030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F64426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F64426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nomogram to estimate Kt/V",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 292px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nomogram to estimate Kt/V from the ratio (R) of the postdialysis to predialysis BUN and the fraction of body weight removed by ultrafiltration (UF/W), ranging from 0 to 0.09 (0 to 9 percent). Drawing the postdialysis blood sample should be delayed for 30 minutes after short-duration, high-efficiency hemodialysis to permit reequilibration with intracellular stores (see text for details).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Daugirdas, JT, J Am Soc Nephrol 1993; 4:1205.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_32_22030=[""].join("\n");
var outline_f21_32_22030=null;
var title_f21_32_22031="Mediastinal goiter MRI II";
var content_f21_32_22031=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mediastinal goiter on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 242px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAPIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5pToKehKMGUkMDkEdqYg+UU/rigCzd311espvLiWYrwN7E4qvSUtAF3S/luo2cfJnmtvVyz3Mc7whAowpXvUfhqzjuYWkkHKNVzX0fzYYshUC8D1oA7DRtLOseHQ0UgWZjjk1Vl8K6imGvSptk6jufpU/w4llbT5I0uTH5bbj8m7cP7vtXW6ve3C2sskCPbsF3CRhkN7j0oAxfCVq482UJ5qp8ht5Mg7fpWd418LWFgsF5bXRtmuCf9GcYx71S0nxHcW+si8u5nYZw5AwSK0vEck2owTahNKl3DJxbxseU/CgDj/s7WVvM/zzPjOW4AHtWfaWcV6vm3UrZb16CpbyUKF+0SuXXoh6ClXVo2i24j4GBuXHNAGTHG0V28a52qevtXQaYVliOGBI6CsrG0Mdw3v0PrVrR3ChlIy2e1AGhfbvIJUciuet4o5dVT7c5SBj8zYya2tTdEgzk+YP4Qayy3mTxtkeoz0FAHSR6VpNrLIYPPmyuVlZMAVVnhCW+bjcSD8pT096uLrqmyS3mYqV6Z+7WZd3aXl7GkLAdmH8LCgDqPh/b6EuoCHUJ3urqXmFNmQD6E16B4o1M6LYxXEsaBg21bdDyR6muMv4YdAk0fU7KAIvlhnTH8XrXN6jdTX9zJeSTvLJKxwpbge1AHqmkav/AGtE93axKIkX5kfnB9MVm+I760n0i4CRshEZLMflAbP3cVb+HempbaNJ9okCSzDzCp9BWb4w1WG68I3Mf2QwXTS7BIF++ooA8msFjW6QOvmJIxJBpviq1kjdQq7Yh0UdqmsUCzW4VRwcE5roNWjE6NGEDsE4z9KAPNGHUUypZlxI4I5BxTMUAJ7UcYpccdaTsOKAE/PFNkBxzTz3zn8aZJ92gCCij8aKALifdFOFNQfKPWnjj8aACnDr7UgpQMmgDqvCke6N9shGTwuOtaPiZFM0HQsF+bPasfwlJGJ2Ehxg5zmtvxBN9ruEmKKI1GB23UAaHw0+e8uLcymNXBIYjpXfapHHd2TpYXxmgMZUgg5yK8r8JysPEEW18KzAbAa9imiTRrN7mSKKKDfyVOXyfQUAeNPExnaGUBQrc884roW1G3k0xBDC223G3zDwGrX8aaTY2ViuoW6Msl3z83X64ri9+bSO0SXLMckGgCO/tbS6iMoMo4yUzn8qxBOkEZVIQ6k8b66GeO3itHWaRhJjANYBtXMOwtvycjA6CgCzOkclpvhUiQDkdhUNjFdj/Vxsd3tWvp0aGAxXIBIGAwPWuy8K6fbXN3CjSJGyjhWON/tQB5vffaI32eXgEcn1rQ0lbSGFpL99sZH8C5INdZ4isAbqTbAsQVumawpbFJU/eIdi/ewcA0AYMs0U85jjAaDPy5FX7DTnZXuFZWVD8o9KmhtbaR23xeQVOFCrnNTRLDCOJmAz93PWgDU1TUJNQt7S3vJsxxpjaOPwFa/gbSbS7Mt5b+W32Q7ngmXqPauekEcyRKpBIPHeu3+FFtNENVk2N5rYVT2x9KAOx0+GxvWa+jV2SRNuzGFX8K86+JafYo47SN3aJjuXPQfT1r2WK3AiG/G/A4zjP4V4z8YbwzeJBbvGUECABaAOBhLNOmwYwcfNXQ61LLHprTkj5Y9oYDBrI0pFk1BRnkf3q3PFrv8A8I+FcAyEHoMbR70AeWMSxJPJPWmmnUnagBMcUUuKTHNACH3FMkHH1qXHaopOlAFeiiigC6n3RTx1pqfdGaeO9AAKUUoGR2FOUHOKANHQ0LXS7QG9vWux8QReVHZJOoU7ckVyGgSm31BHwDnjmu28RzG5gt5y/wC6CgbCvegDK0SOI65blm8uMOAXB6DPWvejBZXUQkguYL63TABB7+9fPmNv3AQHPB6V7d4K0/TNJ8P2bxXAC3eGmQHcd3bigDH+I1pPHp0U08YQFtqoDnA9RXnX2JP7RTY37sLksetet+NYbWK3ddWuJ7i6Zd1ssQwFHvXkjO+7bjqcDtQA7bHcSvHtLN2AFVtXubewSKKGP53+8xNXpoGh2iOXy5mHzOo6D0rn/EccbXFukQbgfMT3NAE15eM0JW1iyiDlgKsaHcXLXEUyozLGc431JpcG2xVWJ2Z5z1apG0lWd2iUqvoDg0AbmpSSNie6KhH5JZwcVR0OeC51uO2uFIs3boTgNVBNDneMMQ7AHOCCRir9zCptDsgYBVxu6YPtQAurWdn/AGhdJYXMjCM/NGOi/Q1lNb75QWXKjp61a0uFIbWZ2lMUx5G8ZL+1WJsywwtbvhwcvGy4zQBFpFtI1yAQGAYHC+le5eDdMMcE81tEjW7gH5DyGrx3S7lINQS4QbQCODyM/SvdPCWrTXNpIUg2bV3SRGPav4UAaMkMKxl7ySK3QjmaRsBPxr558e+VdeLLs212byLOBKp4b6GvZtV0661l3ttWCy6Hc/dt1O1g1eIa/pMejeJJrO3Yxwxt8ig5IFAFPS9kd8S8YCKAOTyPeuh+ISWo0WCWyZhG0PzSMuN5rH0uINdszRtNk/l71p/Eqd7fw7bW0zpNv5DL0UelAHkdJTqT+dACGk/nSikNAB/Ko5fu1JTJRhaAKv4UUtFAF5OgqQfWmxjPXiplXmgBoXvTwOSaUL64zViK2dwD0Q9zQA/TlH2lQ3IrutTtZYrK3VVaRWUMC3b6VxFpDiUHdgrXWQao8sQgQbnC4UE9KAKLxYdI2BJYjAzXu2g6PBb6HarFH+98sSOzE8GvIdC064n1GC2ZcySOM5GcCvom3ggtLaC2lG8KgGF6ED3oA5vVLG2t4LrUtYc+WISsauRknHavHWhiuJTuIgiXLDcecV6J41aW+1OOKaNxaRg+Umcge9efizkvL2QKn7oEgSsOAKAKkSy6hcqtmgk2jl/QCsbzVu9QlPyl4vlHua7SC50/TgLaJnmlAPmTJwPoK43TbQHX381Gj3EsobuM8UAXrSSWJgjRFZRy2eePat+wkivUKvNFAV534wTVW8sX1HDh/KnjGBs7isg2155u1XU7eMsOD9aAOlh1uWznkW0ljIZcAucg/TNYN/qdxeXDb7g714C44/SqsmnXczjznjY9RjjFPS1+x3qPDukYcsrDjNAFaK6m83y7hdm3sw/WuhgIe0jlUbmjPJxVK1vI5tRkS4CySsOcr936V2ulaGsVkdUtbuCe1VCJLfPzA+4oAr+HNNsmu7afVj5VpLIPnx8qntnFe9rCgERDKY9oAkQfKR26V4z4OurNIJdGurdI0n5iDn5CfT2r1rw5psel6YLdJJo7d+Ps8jbih9j6UAJLKsmtJptzYOZ2GUnUjYq/414n8ZNIbTPEyzy7ijfdkx1r3y90pr+dVklaGJVwJQ2D+dcb8Y/D0tx4RzbxNPNafMSTkle596APPPhvoNzfW15qUFv58UXyke5FeeeOheSXF3DfwsjwNlNwxgV3XgzxFr+nabJaeGbd5Y5fmuMLnb/hXM+Pr268QIbi7PlTp8jqRjOKAPLzQRx7VfFiZB8hHPFQyWkiAlhgZxQBVxSVIyEDpTcUANps33eetTBSf4T+VNmgkCZKMPqKAM+ij86KANqCBWVSG59PSrBtW343LnHrXvuheCfAOsaLaNJdeVfyAkiKUDIyeeabf/DDwxZqfM1tVg/hkYjcPr60AeG2OnyzzKioXZjgADNes6J8HdSm083l4fJkI3Rwv39z6V6Z8L/DPhfRLkyRz217eH/VSMQcD2FdL8Ur94PCGoPaTeRJgKNp55I6UAeJan4CtUihg06Lz9WfiQbwFT6VseHvhrb2TvJqyOwVNwEfVm9K9W8L6DYQ6NpzMo814VdmPLZI5JNbawqrFYowwXjJFAHm/gLwhDaJcXN8MTM5Kbhyieldlbwwxs0ZaNYMfK5Nas0YLMi8yr1x3rnPFcy2GhTzzwnaw2AHque4oA838QyrqHiG+Z2FtpcAKCded59q4PUZJpt1nYNi1GSxJwSPU1sLcXN7Mukacwntd2937+9dHZeF7a9BX7THbafGR5jkgyOfT6UAedWel3gtZWsyJEA5cDOPrWWJNrKZf3jjjf6e1ewanBpFp9pGkSLsRAp+bamff1ridca1cB7a1gilZcP5fIJ9RQA3SJLYqqwQTTS9WXOK6G3i0yYTS3lqsdsg+VYGyS/vXBrJNbyqic8c7CQfxprT3aRPGIGQNydpI3fhQBv6/cQROs/lRNKRwM/dHbpWTa6hc38mwW0Yc/KjJ3PvVaGC5mKhlZlPzOT/AA/WtCwtmEv2lYt0CsNwjHI9+KAK2r6Rf6epku7Z7W4b+8Oorb8EsYi0N6kmJRgNGM5PvXQ3Orl5UtvEAEtlMgWGQj5k96dFo15pl3Hb2Epuo2IdDjhh6Z7UATaxoAS1Se0lMluzDfnhoz7V6F4Dvpri4NteTKxiQBCx5YfWuN8Z3clhDBLDAysoC3Vvn5WyOuak+H99H5+2Fd9rI2VMjEmM+maAPa7nT4r2DyJh+6PLZOAfoaytKuHubzULG801oLWECOK4LblmX0FaWl3LSjyGKPH6HnFasdnEuURSuOTjpQB4LrWi3XgDxb9ttoJJNCvT8yJ/Ax9a5abwLrXirVrqQgQROxdHcYBHbFfU8tgkwBnQSRkcq3Oakg022VBsjAx09qAPkjVvg5qenWD37bW8rkrGecetIfhteap4dttX06LzlB2SxfxKfWvq7UUtZJGgnCGJ1wQwOM15TcSX/wANH1G5Etvc6RM+6CFmw24/wigDwa/+HOtopnOh3bxr/GF4NR6Z8P8AVbli7aTPFDnHzIck+wr7C8L3Ouajo0N5dx2sIuEDxwjnywfU+tben6Yltl5W86VuSzDjPtQB8jaZ8K/Et6W8jSlgjVus+Fp3ij4O61pmhS3t/e2ifOBsXnt619VeKLiw0/T3utQkWCBerM+0GvnD4heNYtQ0u6g0eK+lgMuSzglO/Q0AfL9wfLnkQ9VYg4+tFF0N9zM2QNzk4/GigD2jwno2manCltaar9j1d8hILpdsbc9N3rXTv8N/FbxqjmwQKcB5pgq1neJNH02Xwppdw7ImpOxw0RycZ6t6V67b6dpOv+EdNj8Ri7ultYQd0TsPMwPbrQBwnhzw5aaP4hto9R16G41NHB+zWJ3oPq1dz8ZjM/gmU6fG5BZfM2rzj1rGsfGPgLw6ZIdG0aZSPvM0e2TPuTzXaeH/ABbpviq3/wBBtJUgX5SJRyaAOT+H3jqCXSNN03U4HhuQBD9r6hvTPpXqSTxRAK7BvU57ViWXhXS4pZ5RAnlyHlWHAPtWxJb2NjEHllSKBVwGkOKALPnQvlohgN909zXlnxf1KKONLa3D3GpSjaoQ5EYPcitPxx43tNLh+weH4mutUkX5HTlEz3JryS5vtVs7po2cXeq3XLMvzEE9qAH27r4StZXuMDUZkwAWzjNbHgZby8vGvi4jtIl3yeeuQ30rNsPDsWmSG68UyIJXXcsbfNtNQ654imvlh02yOyAcDyxgyfWgDR1+90y6lmn09N7yt80Trx9ao2+mNqslnbrHDGzDJZm25HtWxrMdhoHha3juhGNWZc4UZYZ9a81ivJYnSYSyI2/PzH7tAG3qel3WlXLQ3Cqo3HyyTj9aLKaJ2MtzG1y8fCqjcZpdY1SbUxDcXkSTRxAKGVsMfqKbJ4iFjFCNOsIAijJTGWJ9TQBNeytdvGIbOaPtJs6GoLaU6TqEpjDSbeDGGx+dVI9avp2E7stvjkjOP0qjf6s97Pvlj25P3l/i9zQB2unTf2zbol9GGjjJbcOWUVPFpt/pqfbPD+oveRO+1Yz98e2K5WGSO2sC0c0qO3U9sVoaRd3Ee1o5GWTOQc4BHqD60AdPd+I5nlNh4stZLRiOC0e3P+NWbfQzbKuteH5BqNkhHnWURw4Hc0+w8XR36NbavDHqdmON1wo3J+NaEfhC6WVdb8Haolmg5FszcN7D1oA73wVrdhqVuzRSGLbwI3GHQ+hr0C0lM6oisUK/e4+8K8RtvEMEskcGtwf2HqYb/j6VPklP1rs7fxZq2iyxC/skvdMlxtvbT5sD1YCgD0nkABR/gKRSHyAc4OGqnper2WpQJLaTrIG9OOauSERIzhGY9cDvQBS1K4062X/iY3VvDEB92SQL/OvJvjxp2nav4f0yWyvbbyYJc/JID1HWrVj4Mj8e6pqt74u0y9tdk5S3VpSAUHcAVrn4P+GYrJraC3lO85y8hbp256UAS/C/xRY/8I3YadeX8L38S+WAH5YdsV21xqccEyRmOVixxkLwK5zSfhv4Z0x7WSLT0eW1kEsMjklkYdDmtrVr/wCwT2oaIN5rYMhGAooA8j/aPSe8t9NBlJ05Hy0Q43t9a5fxv4y8PJ8M7WxsoI7acMi/ZU5YYHJJr2jxh/wjeo6ZcRalPA8eMk7uE968V1PwVp934fudRsbHZpyyBYp5875Dg8gHtQB8o3i77ud1GFZ2I+maKL4GK9uI852yMvHTg0UAfRfwq8Lf2nojX9pqHlX67lEdxHuQHPvXU+FvB/iC+upItY1a4tLGJyw+znBc/wCz7V2Xw7hD+GrJbeOPB3j7g9T+ddZOosol83DKvBDD5h9MUAcVr/w+s57d7iF/Ou0XOZV5bHqayPC3xJ0jTCLPUNJWwER8syIMjI713Wt6rZaBbx3V1JI6SHkk5Iz7V5X4y0zQNZFzqWiNJ5v3pgM7Py9aAPSvGfikWHhWPUNASO/NwwCtu+VPc15/etdePpoLMaixeGHfclWxHGfTHeuM0uS8msH0qzmMWnyfPJ5g6H61f0HStRvJ44tBikt41yJr4nCbe5NAHR+HbzRW0qXR5901zHIVBiHL47bq6O0GnaJbzXVro6QXgT78nJH0NeU2es6R4X8RXSB11W0IKvcrlcN3K/jXYeGtfPi+1nsoryCSMA7YJG2SsPY96APPPEF9c6vqcstw5bLH+LirngvS5Hvpbwj/AESxXzHlJ4z2FXrvwjNJqQhZntmd9ojlX5gPXjtXo58FrbeHo9D0S7FzbzSB7kyNjcfb0oA8X8Y6lc6jr9ks7tI8xyAwxgZq/wCINBeN4raVAshUHJOKXxPp8mm/EIloXmjsmVQgGQAMV2V5qd14lM1tJZYdAGhli6Y9DQB503h+6jIAljby+pV+gqCaKCBiVdjKOAavXP2iGeZXQogOHzxWbK9uTlCSPzNAFeS2dnZymT161ZtrQzFWCqpUcAnAqa3nUxN8jMQMbvSmho2nU+cQo4xt5NAG94Xjto5blNXhWa1ePDbzgL7ity9+HWtLpenXum4uNHuz5kMsjbBAhyd8hP3V2jOemKqeCtIXW9XhtJ7lYbF/mu5pWCiOFeWJJ6Z6A+pFe4eMfiF4btNLGkWluuqpcxm3+zxfLGExjk+mOmB+NAHh2q6zYyRRaXo9u3kQtuE5Tb9sfGDIR1C9Qq9h15Jrovh5caguoh4FjuYANrRk8R++K6mD4e6XqfhKzk1C5awEAJS5BClB6N60vhbwHLpt4L+LVLcQRfOJAcLIvq1AHZyWiX1oBf20TQ9djRhs1zl1p9tpc5k0q/lsYz1hU7oz7bT0ropPHnhDSkAvtfs3mPBVDux+VNj8Y+Cr4ACWG4YnI2Rkk0Aclp0+q6fKt1Dhomfcdhwcf7ter6Lqj30ETgCQMOSBjFcpcJ4f1KUQWmpxxO3BiZeV9uajS08QaHdxRWLWtxZqeDvKnHvQB3sV6kl/Na4IeNQ2exqZ3jJ2s659M1y0V1qyzmX7BFlvvEy8n9Kimu9TLNImjNIAcHDdPegDrZX2xvJuBRFJOO+K+b/iD471PVdWkt5ZWs9MicqFXq4r2a21aRongfTdRTPBOzg1Uax8P3V5C19p0TTRHKLMgBzQBxfg3wfa6pFb301vdNasAVVidp9yK7L4oIbfwKyRxKqpIgAHAA57V0h1bSrGJPMuoLRTwFZgBXLfFDVLWbwdO0N1bTASJgI4560AfnxrBB1a9K/dM74/76NFLrTb9Yvn4+aeQ8f7xooA+2fCfiLStK8FWbXF5EJdzhUQ5c/N0Aqjf6nrN2r3VvNIlrKcqpj+dRXB+A/DIvdKstQWERKjOTcSt79hXoIvbC1CWljPNc3ZG44G5SKANPQ9Ohe0d47X55Rl5LhzIT+fAragstKitHtxbxg4+fAADf41hWT6wlrJ9mtQkA+YQ5+Zq43xh/wlWqTBbW0eyWPkRq2HPvQBe1XTtHsZJne9aaMElrXhdg9x1NcPr/iqaa2ksNAma109uHiTguO4NV/7DvgGutduJIm3fvNwJdqjmW1u71bXTbAea2PLDH52oA5K/kDnywEt0IwyY61h+dLY3SiJzE8bbldCR9Oa+ovDfgJLLT0caVBPqMqbmlul3LH7V4T8XNNvLTXmlu7dId3GI1wh+lAHs/wZ8Rf8JHpjX2otHPq9oPLdmGXaPsa5DX/HpXxbPFZYgtxJtwoxznrWf+ztc2q6hqlvJu+1z27CLDY55ry/xBLcR63crcArLHMc569aAPbfENpqcFvLqmnEt9pAE0jryRXNXGsXcU8X2SQwuFCnYMDNNn8R3N/pthDHcStbRwgSKTjJFY0l06YcuVcH7uOooA6DxdpzrpdrfTzm5lk6lTxn0Irl4VZZQYw4z1XFdf4a8Ww6fJJBqFoLmxlGDGFztJ7isjUoxHeyvG5lhY7k7YB7UAUbZ2G4uyxY4y1MMKxXDSTpvP8Asnr9KbLbSKVaVgInPDVRklD3T7XYsnAUHqKAL1mGluo7iVWmQN8qntXfw2cE9l/akGIJ4D88knKj8K47TrsJp8tuYwGbkMeCDU9jLe6hpF/a2zNJGF/fIPQd6APevDdvD4p8Fg38guIGB3+Wdqtivn34o+OL29vl0q1b7LploTGkERwGA4ySOteq/DSC31DwDHp99cyW0UUjAYbaziuC8Q/DhdRvLiXw/cLNIrEeSx5x9aAPL7b7RqE7GGDIH3nxwgrutIubTRo4pbRriaXbh5V4Cn2osfDd5pELy69NHZ2ydYRwZMdq5zW/GIacppVvHDCo2hccYoA9AuPGk0Wkedf2sV1AHwRkq5H1HNbHgnxLbX08tvJq11bW0pBjjMhJT2zXhl7r9zeWawThQqHcNvelsdXSB1ZtyOO69KAPq+40DUIytxZeKLmHeP3fnNuStrwqniixuC1/r0N9CwwFMYAB9jXz94f+IN/eWSWhnRo4yAPMXOK9S8G+ObS4trq2vpoY7qLAhRv4/pQB3ureKtZszNDHaxyMBkS9h+FeO+LvHGo6qTa3NvGG6howc5r2nTLlb+zBkEfmHGdvPFGr+GdP1URq6RqAeWRQCR6ZoA+ZxqCvbvHcyJLJnKlmLY9qwPFFyr2DmF5I5gw/dhvlx7V9Qat8M/CxgJGlLnbgsCRXjHxV8I+FdC0ZpUluhdFwEh3dqAPm6T/WP9TRRPkTyBCdoY4z6ZooA+sPh7BNL4XtZdUlWLT13/KM8jJzmuw8Oz6XLeldJij+zoMAjqPxryFvEkp8O2Wk2gICszEhuuT3rotB1+y8J2LrezLPcS/N5cXVaAPaI50McswOIkGAxGOleXa140uLi/ulIhR1OyKRTyB61w3iHx7fapKYbZ3t7Rz80LNya5rxFejTole4lR55Vyqxtkge9AHR674yCqy3DNM4bDueh+grmh4pt9K1hdVss/a4/mgB5wff2rhrq6knIaQsfrVfPNAHsOh/HjxTHrsU+t3KXWmHiS0jjCcex61l/GDxKniCeCeIMsMvzRI3VR3zXmYyTgVvMW1jT4VQfvLddv1oAp6NqF1Z3sL2szRSBhtcHGK2PHlm8F/FPMhE06CRnPRveuaXckw3jlGyR3r2Dxrbrr/gPRNTgQBIk8lwvzbSPU0AefaTcSy26K7ZUHAXpWwIyylpCxHTPpWHZRSaddbpE3W78MuePrmu4svDGoapIr6Q0M1uV3bt+Cg7g0AZNpBPvdoFZlUZZl5wKsG6j8sjexb+F88fSquva+NGhNnpUpMr5Wdh3rkBeXd9MI0fAPOB296AOuGpW25opyXPQKpzz61TgQrKzp+855OMFRVfTtOCAs5PmngN61cjuCk32d1+794d/rQBpLNBaDaipMTyJHPArY+H73WdVuo/kTy23FRwR9K5jWxhVS3xK8uFATpXT67OfAnhu3to54v7Qvof38QOWRT0z6UAKNUkuPCUkiOY5Y59qkcZHtXS/C7U7bSLkyS7p7m9YRmJznb75ryvwlNcauw0yFm8x33getdLr+i6noEC3txOsNln5ucOWHpQBS+OetR3niiSzgZTHb8MVPGfSvLnfnp0qzqF095eTXDklnbv1xVY4BPf60AIp796GOTz0PpTc9M0EYPXHpQBZtbh7OQPE/XjAPWtm38QzRyIYiqsP4jXN/U04dMntQB7t4J+JL2kZjuo3nbA2yK+MfUV6hD8Qw9oJo4wduDJHG24r718maHqcllcKFAKMRuyK9N8N3cN1qZlVxHA2FZM0AfTHhXxnaa9aMBkleGQjBrjPjb4dstb8MO9t+7ngkUjPf2rO0O7lsNR2QxbImUAEDgj1zXSeN08/wAISzo/JdOfWgD4Xv28u+uEUnCyMoyPQ0UzUtw1G6Eh+cSvu+uTRQB6/wCGomks/OgUMzEgZ/hFFzNDBPDM0Ujsj/OHOd1UdI1Eaf4fZY2OGJLBuh9q5e91GSd5MEqp6DPAoA1PE+oRTXWbfCzFt2VP3PauflYs26RizHqWOajGCCO/c0zIoAldgV4GCO2ab1GRgkdaYWyABSqeecCgBe3866Dwxe/ZVuCq75CPlXPWueAyBnp7VNa7xOgiJ3k4GKALmsQvFetJIMGX5sHtWh4d8U6joMc0NswltJ12yQS/Mjfh61ZGnvNpzNeuXAPEn92sCe0ljGVGUJ4IoA3oL2LVUkthGUl+8i54PtXV6Vrt/wCHfCV3HAyxF+A68uP/AK1ef+HzJFqUcigAg8kjit7xzfxM0cVsAmUG4DjJoA5OeZp5WkkOXc5JrX0a3KsCV+Y9D7VhryAAMYr0/wCH+iHV7tCR5ggj3v6YHrQBGkEloi9MOMrnmqb2bzXLTZjyBhtvUj3rpNQsWv7G71EXdtBdwyeWloOCy+orU+Dz6ReeKm0PxHaRyQaivlJIww0cw5Xaw5GckY6ElfSgDntHSPSZ5NWu4o5vs6Zt4zyN3qfpXn2o3s2qajPd3kxmmdixLn9BX0h8T/hNPofh+91DRL6OSxgBkkiuSFdU9AejH8ienJr5/ja3VyUhdiTjG3IBoA1Ph5DcQa9btDhJ3YEZ/hX1pvxR8SSaxrclqJd1tbnaMdGPc1f0yxubHRbrVbjIdVIVumPavOLiQzTPI3ViTQABwvUDFNAJYkYxUZzilLfKP6UANbr7Uqjvj5RSHrS5yDQAjH0HFHXFIKD1oAXJHetPS9TlsiSSWjPVe9ZZOTTkbaSaAPoX4U+LIbpRBfTRuyjEPmnp7V0PjPxA9jpVzaThRHJKrIOgI9q+Y7K9ktJ1kiYrg9uK7nxP4sbXdDtbd7hpJYQOW60AeVai3mahcvx80rH9TRRLzK555JooA6W+1Zry1hhChFHUDoapnAADNVeE7Rk8elTDMufmww9elAC5H8IAPv3ppGcE8Z7U+E5YBwcDptq7colrbhWKvI/O4HpQBQGeSME5o2HnkU9IiclmxgZBzUaqWLYYcfrQAA8cDj0q7pEixajDJKo2g1STjkjOOoNaGmgHULZiw27wSGoA9YsbCPUdLWGYCGBzuBRd2frXNeKvCktlM8lo7FQOhGBXoWoiaxhiubAxEGNR5EIz+fvWPem91CeKFWeST+6RyvtQB5pDFd2yGSddiqOcD71Y1z5k00khLH/eOSBXdePCLKxW1YEPu5I4/MVwc8zSkZxgdgKALuiWn2q5y0ZZUGSOxr1zwvbX+i6K91BA228G1sNgKteV+GWP9pRIJzEG5OeAa+kLTTMWkEuqIi27wAfuVyDxQB5BqNjO2oL5dsyM33fmJB981u6HoE1rLBqWrXEOmWsMgdbmV8HcDkYHWrXjLxDZ2EMcNlGCV+4ATlTXkGu6peardtPqE7ux6KWyBQB9OeLPjL4S1m1bSdVee6spNqyPaxn5T/z0HPODzj+vNcrrMPgzw8kSQJcNJdIJre8274Zoz/Ep/QjqCMEA14FbK5RipHAzg11nhjX4IdNbR/EIkn0Cd92YuZbGU8edFn8NydGHoQCAD0bxXpMOo/D+afw7qMN7CXBkiVgHU/TrXgs0TQylJUKleCp6ivQNW0g6BIsVxOssMyedbXsDHy7mI9HQ/mCDyDkHBrlr8fbFdCQZx8ysT94UAYZ9ccUgBbOOtT3EUluoWYDnng8ioMdwcj2oAQ4425zS7CxAVWJ9KVXC5AGc9KdFMFcM2cj0OKAImUo2GBU+lBU4yehqaZvMYs5BJ7iol9/yoAQg49aDkVMGTaFP1JqJsZJXj60AKgJ6EfjT45fJfLfdzyKjA55z9KbKflJNAGewJY8jrRSnrRQBfjO5R61JwGGBx3zUUX3RipecD0oAm3FCrjp2xSzSb4l6FgeTVfI69vQUgPscUAOyQcZzT8g8jj2FRj71KTwCOtAEocq2D+dOV9p+T7ynIqJRuz1pQCp+br0oA9XsJJ9R0GzubaeRZQu1m963bG11c2MVy65KnAcfeP1rmfh1LJqHhm809P8Aj4hkEkPOMn0Nek219LJbxHULSSCUAJ5cHRm9aAPPviDp7z6bHdSoVnZsEHk5rzCaMxybWUow6g19DwIdfvb/AEq6jdZI4y0bhct+NeMeKtA1DTLtvtdrKoJ++RwaAMfTbw2l1HIyK+09D0xX1HpPiB9V8DWD2SRH5NkpRuI8D3r5ROSgwMAcZ9a7f4Y69HpV/Il60klmV+aEN978KAK3i+R5rlpoAQVchh6+9cezbgzNwa9L1do9UvpGji8m3c5VMAHFcPf6XLFO5tkaSLPGO1AGbDJtcZyPcVJmQOycjPP1qAZjcZHzKec0PITx/KgDt/CGu28Fm+ia/vufD877gV5lspTx50Wfw3J0YDsQCI/FmjXPh7V9OWd4ri1kxLbXcPMVxETwyn+YPIOQea4+JsJtY4PrXRaTr14+lr4fdY7ixecToJV3tbuCMtGf4dwGCOhHbIBABl+JVB1OR0+WNu1Zsi7UXBznuK0fEkgOrTiM5UcYrLY8AHt2oAVtpQADnuadGq87iM449qj25PB4pMkjFADjkqG4wOKYacG4I7Gkz0z2oAUA7aVznAOKafT8aSgBcnOR1pkh+U08EbOh3etMk+5n1oApUUHrRQBdi5WpM8gjtTIBlBx0px+lAC55ySM0Hqc0g4o9+KAF70u70x70mMf4U4epXOaAAdiD+VS7gHDclqhBqRWCpwQf6UAem/BSWCXXJba543glTnHNd/PLPFqM9tq6N+8b/RmibJFeSfDKZbbxBHPOSLeIFnI616rpnjrSru7kgRYo5g3yM3SgDSvLVI57a8s55IdRjGGnj9P9oVR+JelXV74et2tppLyVjlig3fypPFFzeW+qrcWsmyGVADLxgn0qXT/Gf9l3UMU7xPbsmJEK859QaAPny+t3tLtoZkZSOzcUunyLFeRu4GFPNdD49ha41ea8i3GCRyVz9aq6DoM97PHlCdx+VMcn60AdlFHBqGnW5tkZZV646H8au2/gTVb6P7RZTok2M+Ux4xXTeEPD0VtZi0vWRZZGG0Z4HtXU22nXGnvMLVYgE+Xy9+Sw9qAPn/WtEk89ob63EF3GcF06N9a5u90q4gkbYheMDqK998WJpWmafJNqlqy+acsSw3D6V4jrOtxS3DDS4niiydrOctigDNtNMubkrhCqE4JPau18KaBm6KqS0h4WQjAJ9K4Z766cAPO5A5AzVuHXdSVMJckBRgUAdD4/8M/2deqYriKWdhmVEOdpriCCGIPUVba/uM/PIzHOSc9aSVoJGBBAY9TQBWyeD6Uw+3FWisRU7cHH86atvvxtYKO5Y0AQHJPNIc9OlSyfJhdwYe3So3bc2QB9BQAlHQg80lKeCOtADnkLAdPyqJ/unFPBOKZIfl/SgCmetFB60UAXIvu8ZqTnHSo4xhRUuTgAH6CgBBzzS8UnU80pA9Rj2oAOCTTlIGdxzjoKb27UDr0oAePZc+9JzjGaesbn5lGE96V0iCgpIS/8QI4/CgC/ply0NneKHCl1AznnFVrdxHKGRiGXkH0p0McMihUfDHg7qVY4RcNHKS2OBt7mgD1Dw1rkviTSmsZSjXcK/JJL6egpsnh67vJkie7t8Dk7mwVrhbR7nTMvDN5G7kYOTVb+3L6OczCctITyW70AeuL4QlubcBzFIkY5OcbvpXTeGdO0zw5Yia+m8p5gQBOQcfTFeGr431qP/V3G0YxjGQKyL7WL/UDm6uZHx0Uk4oA+hNV8deEo7QwSTsCpwDGvJ/GuBvfirJao9vpMf7sH5ZZBlh+NeWhiVGVH55qNmOc8Z9KANjxD4gvtcuWlvrh5AeozWKcZyo4p3X600emKAEPvSjHY8e9Jg+lA57flQAD2pB17UtIBk4oAmt4JpmxCjMfUDir66bKgle5kVY4xyfU+gq3pTPbqYYmOXGTkcVnatPK8zRNIGjU9V6ZoApShQfkOc9ab2pdpAPHHrTTigAPXikz24pcgjpSAZ4wM0AGfpTJOUPPNP/nSSfcJH0oApHrRQepooAuQ8qOamHp0qGHG0ZNSFvQ9OBQAp56fnSqFBH8VNzwMdqATjmgB/wAvUg7v0pYvmkGRn2prOWI9uKRWO4Ek9etAFi5uJHYoVCL02gVXAyK1WskuJB5UgVtuSWP3qoSwhMhWyw4IoAiHbHanByDkdfWm9MYzQOOvIoAsTXU08axyuGVeme1QAnrng0nBIABpxUrw3XrigBScYwBQGIBGetIuOMHA7mkYYOevvQAueRgdPWk69aF4IyR+VPSPzG4wDQA3GD8v51KLaRwWb5RjPzcVraPplzJdJsiDOeBuHSu9Xw7pGnqH8RXrxzsuVWIZBoA8mKOOqtj6UJuzhcgnvXbasNOjkMkBnWBRg5HBrm7y9gwyQxrgjqKAM47VZTksfQ1ctruKOcPJaxmMfwjvWefpSj1AzQBdur4Tk7IhCP4dpqjnqBQCeAelOI3McdBQAxhSZxVgopUEgLntUDAA8UAJzSYBPcUuTR39hQAuR6Zpkh4INPHtmmy4APNAFIk5NFBHNFAFuIHaKnAUDrz3BqK3fAwQCKlAyo457UAHy7uePTFJtOM44oAOeeCKsFo/usDj3oAr4H40AYqbCkkZUHtxTprOSKESuy7GOBg5oAebwG3EKxgN/f70kVpczShBCxdugPFVgMDI5/pVy1v50cFmZwBjPoKALU3h+/htxO0aGPvz0rNaGVTnb19K7uzSXUNI8u3vYZC5xsY4PP1rNi062sp5Ip5tsyj7p5BNAHKmJowDIhAPQ0FQPvcH6c1q3VxbPKY5Ufg9U6U1bmwWJx9lmZuzEjmgDNjj3kKFc5PUCrz6bPFD5jQtjrgjkCr0WvJbQr9is41ZcEs5yTRe+J9Rv3dmWNHYYPlr1/CgCPT9Emux5g2hGH8VdFoGg6U1wsepahFbMD1IzXHi6u5MRvMVx26YpDK0s4BkJdRwR3oA+lLHQdI0XT0u4Db3DhcrISBvrznXbhNWvZJpdqBT/qyQSPpXmtxqmouqxyXU2xeAu4gCoRfXPmfNIxbpnNAHXajaQ3MKm2Z3ZTySeB+Fc3e2Tgs6gMOhXHP4U7T5QzGKWZ4jn1xk1pXml3KxRzRyGQMei/w0AP0vQrW7EKyFkJHCscGtLxN4Xi0vTkdRHucZyjZx9aba201zChDAOn9081qXGn6heLCJsG2xhsnp9aAPM9sY4ZfxzUgt8kLC28EZI6Vu6/otlZMTHPtbPKnkfhXPRyiN8H5lB4NADOhzx8vHNNzycmnFk80vsymemaSQqXzEMD0oAZgHPpTSO9XNrSKS5WN17EYzVRgQ3XPvQA7dwOOaZKQQcDFODbTSMNynHB9KAKJ6milbO40UAWo+mAKtQSqisrpuBGAe4NQQr8gYDI6GpFG6QDBwT2oAVfldW+/jmhizMzH7rc1LJEYZGH8P9KiBBQKM7gc+xFACHJwAMmreftECQorMVyailChVkiyuaIzLC8bsrFTyMUARum1QAwYnqB2ojD/MUzwOafMUZmyG3E5pgbaMKxwRyBQBbtJViWOaNmWWNs4B4PtVrUn+1kTpHL5h5bPasuFgjDceD2xXSeH9UhW9CTplHGxh2+tAGDOZFO2VSGI6461ApZBxuGep9a2fEMEovCTzEPuFewrHlYEBQTgdRQAeZkYwp9yKRGIb7zDPpxSMMcKcgUoG7q/agCymHnAuCeejCrsCJZ38azlVRv8AlpnOBWSX4HUHvUixzlRKq71Hf0+tAF3WUjhuSIm3RtyDnOaoF8D5CNp6eoqR7oyf65egxgcZqBlGfagCeBJZG3IC7gZ9a39KuZWQFS/mD7wPQ1iWNz9lIIU5Jx7GupkjiexSSParnB4OCKAOghvLW9t0dbUW8sa7W2H73vWbqSX+mX9pO5lazn54YEVnWkqwObmOXcy8GLPUV2UiwXFray2M6SwyY3wOf9W31oA5nW7NdUd5SDAB0GAM/hXJ3VpsUrKNgHCsAOfxrv8Ax1Y3NpYrcwvHyoX5GyPwrj7OeOTS3ivZkeNjxkcqaAMBIZGJROW/ujmmMpQlGBDZ5zV6/tnsJ1aIOIjyr54P41DcwzSQC72kxE4znoaAGBkfC3JY4GFK9qUGLySuSX7e1QhQULZ59KQNyvA4oAdsCoCx4PtSMWhG/GQRgUsrFjtJDY6VC7vtKknae1AFVj8xz6+lFIep4ooA09OtnuSVQHpk+9XIbGZ8S2vVeq9xVzw5EwtpGLALnoetXIrb7LIJ43J3/eWgDGWBt4E5B3cc9RTJrF42YnGxe+eta180dv8AMwAuGORnkYqEpcXsy7UD8ZG3gYoAyGjbOATyOBQWcKctwOMCtySx+0T5jAXaMEHtVB9OeS4kjX7y8lh0oAzlYg85p8hXaMKBjv3NJJHsODz61LBB5oyTgDvQBBksAD17VLavslXc20Z6+lRyDZKQO1ITuJ7UAddNdC9i8uMA7EwzHoa5iaPaTsGeelS6fcNHIAfmQ8Ee1aSxWqtI5dSmMbO9AGEDt5xwaackkkflVm4tjGx2n5G5GardqAAVMsmyMhWYBuo9aiH3uDSZ980APTBfB6UhwuQQeelJ1b5aCc8NnI70AORsMu4kqDmr8d9JuJlkYkfdHas09PalVwM7lDfWgCyszi7DAbsnpnrXdWbfZ9OQREnfyYyOn41wdmdt1GQcZPXFdxGJHhxnYMcmgA1XUoXtVtjucDjb6Vzq2rJfvAULWkgyTjpVq+hlDHyW+U9G7VYCE6WdxJkUcsKAKN4ZnjSCArJGvygHsKjsdO8x3S5lZYx1QUlu7GNlk3GM9xwRV+1kgcxtl2UHG4UAYWt2AsLkBN3lsMqSOtUmKyZO0KcV6Pe6ab6wcqFkiC4VW+8D7V5vcRPDM0cgIdDgigBpYk9BuFMkBC81IrYIYD5hSSsWUknpQBRJ5NFB6nrRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A coronal T1-weighted section through a mediastinal goiter (long arrow) shows it to be contiguous with the left lobe of the thyroid (short arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_32_22031=[""].join("\n");
var outline_f21_32_22031=null;
